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1. INTRODUCTION 
1.1. Cancer  
Cancer, of which there are more than numerous divergent forms, is 
foremost cause of death in humans second only to cardiovascular diseases and 
more than 70% of all cancer deaths occur in under-developed and developing 
countries.1 
Cancer is a disease concerning abnormal cell proliferation through the 
potential to spread or occupy to the other parts of the cell or tissues. It remains a 
main cause of death, despite of great developments made in understanding the 
cellular and molecular base of cancer, the process in the mortality and morbidity is 
still elevated. According to world Health Organization (WHO), In 2005 cancer 
estimated for 7.6 million (13%) of all deaths globally. Moreover, these numerals 
are anticipated to continue increasing to achieve 11.4 million in 2030 cancer 
related mortality. It is also estimated that cancer rates could rise from 10 million 
new cases worldwide in 2000 to 15 million latest cases in 2020. While some 
aspects may well contribute to this accounted quick raise in new cases, the 
globally slowly ageing population is identified as principal factor.Approximately 
about 40% of the entire cancer cases assessed occur in high-resource countries 
(Japan,North America, Europe,Australia, Russia, New Zealand) and the remaining 
60% will be low andaverage earning countries. Moreover, global statistics showed 
that 11% rise in the new cancer occurrence and 80% rise in the figure of all cancer 
mortality in fewer developed areas by 2025.  
The most general types of cancer arebrain, lung, nasopharynx,larynx, 
oesophagus, urinary bladder, ovary, lymphoma, thyroid, stomach,colon and 
rectum. In that, colon, rectal, stomach,prostate and liver cancers are the majority 
general malignant neoplasm more familiar in male, while breast, colorectal, 
cervical, lung and stomach are the most common malignant neoplasm among 
female.  
A coherent approach in identify the universal burden of neoplasms is to 
assess the loss in disability-adjusted life-years (DALYs). This marker estimate the 
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years of life with disability and includes them to the years lost because of 
premature mortality.  
Chinacontributed to 25% of DALYs lost because of colorectal,lung, liver, 
breast, stomach, cervical and esophageal cancers.Europe and Asia for 73% of 
DALYs lost because of cancer. The trouble and burben of cancer is still rise 
universally despite advances for diagnosis and therapy. Epidemiological studies 
have reported that several malignant neoplasms may be avoidable. It is broadly 
held that 80–90% of human malignant neoplasm may be attributable to lifestyle 
and ecological factors such as dietary habits, alcohol and tobacco. The prevention 
of cancer contains primary, secondary and prevention techniques. Primary 
prevention includes to avoiding cancer-causing substances like carcinogens in the 
dietary elements or environment related with increased risk  factor; dietary 
elements with putative defensive agents. Secondary prevention goals at early 
identification and removal of benign cancer of oral, colon, cervical and breast 
cancers. It was anticipated that in the year 2020, worldwide over 10 million new 
cases of cancer happened (approximately 4.7 million women and 5.3 million men) 
and over 6 million people died from cancers. Lung, breast, colon, rectum, stomach 
and liver are most frequently affected organs. 
 
Figure1.01: Age adjusted incidence rates of all cancers in India 
Industrialization, urbanization modifiesthepopulation growth, lifestyles, 
and ageing all has contributed for epidemiological changes in the country. The 
rapidly increased absolute number of new cancer cases, due to enlargement in size 
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of the population, and rise in the proportion of aged people as a result of enhanced 
life expectancy following control of communicable diseases.2 
Colorectal cancer is the one of the most commonly diagnosed cancer in the 
worldwide and second most well-known cause of cancer death in western 
countries.3According to the American cancer society,In 2011-  141,210 new cases 
and 49,380 deaths estimated. About 28% in the rectal cancer and 72% cases 
increase in the colon cancer.4 In united states (2013),  National cancer institutes of 
health, 50,830(colon and rectal combined) deaths and  102,480 (colon) ,40,340 
(rectal) new cases estimated.5 
1.2.Treatments and Demerits 
Cancer is a serious health problem in as well as emergent and urbanized 
countries and its therapy with anticancer agents.6 The clinical achievement of 
related platinum based agents such as cisplatin , as anticancer agents comprises 
the most incredible contribution to the application of metals in medicine.However 
most essential problems related with these mettalo-agents comprise severe toxicity 
and side-effects, and major trouble associated with resistant. The subsequently 
major used classes of chemotherapeutic drugs in cancer treatment include 
molecule that interfere with DNA, like intercalators or DNA alkylating 
agents,groove binders,. However, the properties of diverse anticanceragents is 
anchored in intercalation, but target could be increased by addition of definite 
moiety or substituent‟s on the intercalative aromatic core.7  
Folate metabolism is considered as an important target for the 
development of new anticancer drugs because of its dependability in the 
nucleicacid precursors biosynthesis. The inhibition or supression of 
thymidylatesynthase like folate-dependent enzymes,which catalyzes the process of 
reductive methylation of deoxyuridylate [dUMP] to thymidylate [dTMP] hasalso 
been renowned as an important target for drug development and discovery. 
Conventional anticancerdrugs thatavoid this pathway have a demerit that they 
require an active transport mechanism to enter or penetrate thecells, which can 
cause cancer resistance if damaged. Also, most recent preclinical studies on 
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human liver carcinoma cell lines reported that at superior doses of antifolate a not 
a success of thymidylate synthase suppression or inhibition occurs and cytotoxic 
effects are protected. So new potent, efficient and selective anti-cancer agents are 
required.8 
1.3. Benzimidazole 
Benzimidazole is a aromatic heterocyclic organic compound. Benzimidazole 
is bicyclic in nature which is fusion of benzene and imidazole nucleus.9The 
benzimidazole comprises a relatively large, growing, important pharmacophore 
and privileged structure in modern drug discovery.10 Nowadays is a moiety of 
choice which have numerous pharmacological properties. Substituted 
benzimidazole derivatives have found applications in diverse therapeutical areas 
includingantimicrobial10,11,12, antioxidant13, 
antiviral14,antialergic15,antihypertensive16,analgesic17, antiinflammatory18, anti-
ulcer agents19,20.  
N
H
N
BENZIMIDAZOLE  
Furtheremore, various substituted benzimidazole derivatives have been 
found to possess potential anticancer properties21.Bis and ter – benzimidazole 
derivatives were extraordinarily active compounds intrusive with DNA 
topoisomerase I 22-23 and were also reported to their cytotoxity against the human 
lympholast cell line 24, breast adenocarcinoma and skin epidermoid carcinoma 25. 
3-methylthiazolo(3,2-a)benzimidazole derivatives were also reported significant 
antitumor activity against the colon cancer and lower toxicity against normal 
fibroblast .26 
 A rational approach for design the next generation inhibitors, 
benzimidazole derivatives, for example, Albendazole, a benzimidazole derivative 
clinically used as an anthemintic agent, can also prove in both invitro and invivo 
experimental condition    inhibit the hepatocellular carcinoma proliferation27. 
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Cyclic amine containing benzimidazole carboxamide 2-(1-propylpiperidin-4-yl)-
1H- benzimidazole-4- carboxamide 28 were vastly more potent as poly(ADP-
ribose) polymerase inhibitor and also (4-hydroxyphenyl)benzimidazole-4-
carboxamide 2-(4-oxadiazolyphenyl) derivatives were showed that enhance effect 
in chemotherapy and radiation therapy in-vitro29 and in-vivo30.Tricyclic 
benzimidazole derivative [AG14361],which is high –potency PARP-1 inhibitor31, 
has been developed and used in-vivo at non-toxic dose to enhance the effect of 
chemotherapy and radiation therapy in human cancer cell cultures and 
xenografts32,33. Based on all these findings these compounds may possess potent 
anticancer activity. 
1.4. NanoTechnology In Cancer Therapeutics 
Nanotechnology is one of the most vital technology in cancer therapy, which 
are being engineered for the targeted delivery of anticancer agents. 
Nanoconstructs furnish as customizable, targeted drug delivery vehiclesable to 
transporting high doses of chemotherapeutic drugs or therapeutic target genes into 
cancer or malignant cells while sparing normal cells. Like a „smart‟ 
multifunctional nano constructed deviceshold out the possibility of severely 
modifying the oncologypractice, permitting simple recognition and then fo llowed 
by efficient targeted therapy at the initial stages ofthe disease. 
1.5. BiologicalAnd Physiological Characteristics Of Nanoparticles 
In chemotherapeutics, pharmacologically efficient cancer agents reach the 
cancer tissue with poor selectivity and doselimitingtoxicities. Traditional drug 
delivery system contains intravenousand oral routes. There are numerous demeits 
to these systems; for example, oral administration of tablets or capsules could 
result in disorderly pharmacokinetics due to the contact of these drugs to the 
metabolicpathway process of the body. This can report in higher thannecessary 
doses being administered, which can furthercause rise the toxicities. The 
conventional intravenous routes areoften even more trouble. The selectivity of few 
traditional intravenousagents is low, resulting in detrimental effectsto normal 
tissues. 
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Nanoparticle drug delivery system, using polymers of biodegradable, furnish 
a more efficient, less harmful solution to overcome some of these troubles. It was 
in 1975 that Ringdorf projected a polymer-drug conjugate system that could 
increase the delivery of an anti-cancer system. He proposed that the 
pharmacological characters of a polymer-drug conjugate system could be 
manipulated by changing the physiological and chemical characters of the 
polymer. For example, Introducing solubilizing moieties into the polymer, an 
insoluble agent can be made water-soluble by thereby enhancing its and 
bioavailability and biodegradability. The delivery of the agent to reach the target 
cell can be achieved.34 
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2. AIM AND OBJECTIVES 
The introduction and literature review part of present study revealed that 
benzimidazole and its derivatives has a diverse pharmacological activity. 
Traditional anticancer agents have a drawback that they require an active transport 
mechanism to penetrate or enter into the cells.  
This is a major drawback to achieve adequate concentration of drug inside the 
cells. Also, current preclinical studies on human liver carcinoma cell lines 
revealed that at higher doses of antifolate a failure of thymidylate synthase 
inhibition occurs. There by it becomes interest and aim of present study is to 
synthesizenovel benzimidazole derivatives that incorporated which different 
heterocycles of anticancer activity such as differentcompounds with the backbone 
of chalconeswith Pyrimidine, pyrazolines and the synthesised benzimidazole 
derivatives are formulate as nanoparticles to  the target  to develop a novel 
anticancer agent that could beselective and good target for drug discovery and 
development.   
The prime objectives of the study are envisaged as follows: 
 To synthesize novel series of benzimidazole derivatives. 
 Charcterzation of  synthesized novel series of benzimidazole derivatives. 
 In-vitro anti-cancer studies (MTT - assay) for synthesised novel 
benzimidazole derivatives by using CaCo-2 colon cancer cell line and MCF-7 
breast cancer cell line. 
 Conversion of  lead benzimidazole derivatives into nanoparticles  using natural 
polymers 
 Characterization of  benzimidazole nanoparticles. 
 In-vitro anti-cancer studies (MTT - assay) for synthesised novel formulated 
benzimidazole derivative nanoparticle by using CaCo-2 colon cancer cell line. 
 Acute toxicity studies synthesised novel formulated benzimidazole derivative 
nanoparticle and fixing of dose. 
 In-vivo studies of Anti-cancer for synthesised novel formulated benzimidazole 
derivative nanoparticle  by DMH induced colon cancer.  
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3. REVIEW OF LITERATURES 
3.1. Cancer  
Mostafa M.,et.al.35 
 Reported the cancer continues to be a serious health problem in developing 
as well as urbanized countries.  
 Reported cancer has become the number one health problem and killer due 
to dissimilar worldwide factors. This enormous incidence of cancer has 
amplified the urgency of the investigate for the secure, latest and efficient 
anticancer drugs, goal at the prevention or heal of this diseases.  
M. Greenwell.,et.al.36 
 Reported the cancer is a continuous battle worldwide with a several 
development in preventative and cure therapy.  
 The cancer is characterized by cells in the human body continually rapid 
proliferation with the incapability to be prohibited or blocked. therefore, 
form the tumor of malignant cells through the potential to be metastatic. 
 There is a steady require for novel therapies to treat and prevent this life-
threatening illness.  
Mohamed Jawed Ahsan.,et.al.37 
 Reported the cancer is one of the foremost cause of death in globallly. 
Predictable that the novel cancer diseases will increase to 22 million 
within the next 2 decades.  
Salahuddin.,et.al.38 
 Reported the cancer is a medically known as malignant neoplasm and  
collection of several diseases, relating uncontrolled cell development and 
growth. cancer is a most important health hazards in developing as well as 
undeveloped countries.  
 The incidence of this disease globally rise the research for novel, efficient 
and safe anticancer drugs 
 In research laboratories are still concerned severely for the research of 
novel anticancer agents.  
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 Anticancer agents development involves application of existing agents to 
meet the therapeutic requirement in addition to the discovery of novel 
agents. 
Chih- Hsiung WU.,et.al.3 
 Reported cancer, of which there are more than 100 dissimilar forms, is 
foremost reason of death. 
 In worldwide colorectal cancer is the one of the most generally diagnosed 
cancer and western countries colorectal cancer is a second most common 
cause of cancer death. 
 In 2011, according to the American cancer society, estimated 1,41,210 
new cases and 49,380 deaths. About 72% cases arise in the colon and 
about 28% in the rectum. 
 In 2013 united states  - National cancer institute, estimated1,02,480 
(colon) ,40,340 (rectal) new cases and 50,830(colon and rectal combined) 
deaths.  
3.2. Cancer Therapy and Demerits 
Azmat ali khan.,et.al.39 
 Reported anticancer agents are recurrently allied with various toxicity and 
some side effects. Considering diverse difficult issue like widespread 
systemic delivery of an administered drug and its quick elimination, it is 
desirable to opt for appropriate substitutes for the currently existing 
anticancer agents. 
James SE.,et.al.40 
 Reported various chemotherapy agents are known to cause important 
clinical neurotoxicity, which can effect in the early cessation of treatment.  
 To recognize and develop more efficient means of neuro safety it is 
significant to understand the toxicity of these agents at the cellular and 
molecular levels.  
 In the present study, They estimate the effects of taxol (paclitaxel), 
methotrexate and cisplatin on principal rat neurons including hippocampal, 
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dorsal horn/dorsal root ganglion and cortical neuronal cultures. Their 
report revealed that all of these anti-cancer agents proved neutrite 
degeneration by induction of substantial neurotoxicity.  
Balram soni.,et.al.7 
 Reported major difficulties linked with these mettalo-agents include severe 
toxicities and further side-effects, and the most important problem by 
resistant. 
 The clinical accomplishment of cisplatin and related with platinum based 
agents, as anti-cancer agents includes the most impressive involvement to 
the utilization of metals in medicine.  
Magdy i. El-zahar.,et.al.8 
 Reported the traditional anticancer drugs have a  demerits that they require 
an active transport mechanism to enter inside the cells. 
 This is a major disadvantage to reach require concentration of agent inside 
the cells. Also, current preclinical trials on human liver carcinoma cell 
lines showed that at superior doses of antifolate a defeat of thymidylate 
synthase inhibition take places. 
N. S. Hari Narayana Moorthy.,et.al.41 
 Reported cancer is silent life-threatening illness and the second leading 
reason of death in the worldwide.  
 The successful management and treatment of cancer remains a challenging 
target because of its poor pharmacokinetic profiles ,non selectivity and 
toxicity profile.  
 The improvement of new, selective target, less side-effect and toxic 
chemotherapeutic drugs for cancer management and treatment is having an 
impact on current research. 
T. G. Nithya.,et.al.42 
 Reported the cancer is diseases one of the 5 leading reason for the death 
amongst both male and female and the single biggest reason of death 
globally. 
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 Cancer is a collection of diseases promoted by defeat of cell cycle control. 
 Cancer is connected with abnormal uncontrolled and rapid proliferation of 
cell growth . Cancer is caused by both internal factors (immune conditions, 
hormones inherited mutations and mutations that occur from metabolism) 
and external factors (infectious organisms tobacco, radiation and 
chemicals). 
 Certainly, the struggle to combat cancer is one of the supreme challenges 
of mankind. 
 This growing tendency shows efficiency in the present cancer therapies 
which contain chemotherapy, radiotherapy and surgical operation.  
 Since the average survival rates have remained effectively unchanged 
despite of such aggressive treatments, there is a critical need for anticancer 
drugs with superior effective and less toxic ,side effects that can be 
obtained at an reasonable cost. 
Mi Hee Park., et.al.43 
 Colon cancer is the 3rd most generally identified cancers in the worldwide, 
In 2013 USA identified 140,000 new cases , over 50,830 deaths and over 
1.2 million new cases and 600,000 deaths globally.  
 The chemotherapy, radiotherapy and Surgery are commonly used for 
treating colon cancer patients.  
 Those treatments are not enough because of resistance against 
chemotherapy effects.  
 Therefore, it is vital to build up new anti-cancer   drugs with less side 
effects to satisfy the unfulfilled therapeutic burden of patients. 
3.3. Benzimidazole as a potential anticancer scaffold  
Hanan M.Refaat.,et.al.21 
 Reported benzimidazole is a aromatic heterocyclic organic compound. 
Benzimidazole is bicyclic in nature which is fusion of benzene and 
imidazole nucleus. 
 The benzimidazole comprises a relatively large, growing, important 
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pharmacophore and privileged structure in modern drug discovery. 
N
H
N CN
R
 
 In an attempt to launch novel candidates with better anticancer property 
with the synthesis of several series of 2-substituted benzimidazoles 
derivative  2- [(4-oxothiazolidin-2-ylidene) methyl and (4-amino-2-
thioxothiazol-5-yl) benzimidazoles (2 & 3 correspondingly); 2-[(4-
fluorobenzylidene and cycloalkylidene) cyanomethyl] benzimidazoles (4 
and 5, respectively), jointly with the synthesis of various of 2-[(4- or 5-
oxothiazolidin-2-ylidene, 4-substituted thiazolyl-2-ylidene and 
[1,3]thiazin-2-ylidene) cyanomethyl]benzimidazole (6, 8, 7 & 9 
respectively). various of the synthesized products were subjected to in 
vitro anticancer studies showed that all the tested compounds exhibited 
anticancer activity with IC50 < 10 mg/ml against human breast 
adenocarcinoma (MCF7), human hepatocellular carcinoma (HEPG2) and 
human colon carcinoma (HCT 116) cell lines. 
Sabitha Alper.,et.al.22 
 Reported In 1971 wong discovered DNA topoisomerase I and II are vital 
enzymes for both antimicrobial and anticancer activity.  
 DNA topoisomerase enzyme catalyzes relax of negative supercoiled DNA 
in the lack of an energy cofactor. It was suggested that this enzyme also 
catalyzes transitory nicking of the DNA double helix and possesses both  
ligase and DNAse activity in 1 polypeptide  
 The discovery of E. coli topoisomerase I, researchers has isolated several 
other DNA topoisomerases from both eukaryotes and prokaryotes. 
 The vital role of mammalian DNA topoisomerase as molecular targets for 
anticancer agents was not identified until 1984. The researchers have since 
carried out wide studies of the topoisomerase targeting drugs and their 
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mechanism of action.  
 Since the recognization of topoisomerase I as the main molecular target, 
various novel topoisomerase I poisons have been showed which more of 
them are DNA minor groove binding form. 
 Hoechst 33258 and 33342 are Some of these DNA minor groove binders, , 
which are topoisomerase I poisons, contain benzimidazole ring systems. 
These agents emerge to disrupt the breakage-gathering cycle of 
topoisomerase I by stabilizing a topoisomerase I reversible and cleavable 
complex. 
N
H
N
N
N
H
N
OH
N
H3C
 
Hoechst 33258
N
H
N
N
N
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N
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Hoechst 33342 
 The detection of DNA topoisomerases has added a novel aspect to the 
study of anticancer drugs. In the last years detailed stduy of bi- and ter-
benzimidazole derivatives showed that these compounds are a novel class 
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of topoisomerase I inhibitors that poisons mammalian topoisomerase I. In 
this background survey about cytotoxicity and topoisomerase I poisoning 
activity of bi and ter-benzimidazoles is given. Moreover some current 
report about new derivatives, some comparison of activity of various 
functional groups and structure activity relationships (SAR) are reported. 
A.Selcen Alpan .,et.al.23 
 Reported 1 H- Benzimidazole derivatives are mammalian DNA 
topoisomerase I inhibitors. 
 Various benzimidazole derivatives are also active as inhibitors of type 
DNA topoisomerases I. Topoisomerases are omnipresent enzymes, found 
in eukaryotes, prokaryotes, and viruses, organelles, such as chloroplast and 
mitochondria. These enzymes regulate conformational modification in 
topology of DNA  by catalyzing determined rupture and rejoining of DNA 
strands during more geneticprocesses, together with DNA replication, 
transcription,recombination and transposition.  
 
Figure 3.01: DNA Topoisomerase  
 Based on the reaction mechanism Topoisomerases are classified; type I 
topoisomerases make a single-stranded rupture or break in a DNA duplex, 
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mediate passage of the intact strand through the rupture or break, and then 
reseal it.  
 On the other hand, Type II topoisomerases  create transient rupture in both 
strands of a duplex, pass an intact DNA section through the break and then 
reseal the cleavage site.  
 Over the past years, topoisomerase poisoning has been identified as an 
efficient approach for the improvement of chemotherapeutics, as these 
enzymes are molecular and cellular targets for an ever-rising no of 
anticancer and antibacterial agents. 
 
Figure 3.02: DNA Topoisomerase I & II 
 Benzimidazole is one of the most vital heterocyclic groups manifesting 
diverse biological activity like antifungal, antibacterial, antimicrobial, 
antihelmintic and antiprotozoal properties. Numerous benzimidazole 
derivatives are active as inhibitors of DNA topoisomerases type I. In this 
research mention  the three derivative of 1H-benzimidazole with dissimilar 
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electronic characteristics at position 5 specifically 5-chloro-4-(1H-
benzimidazole-2-yl)phenol (Cpd 1), 5-methyl-4-(1H-benzimidazole-2-
yl)phenol (Cpd 2) and 4-(1H-benzimidazole-2-yl)phenol (Cpd 3), were 
synthesized and screened for their effectiness on mammalian DNA 
topoisomerase type I property by using quantitative in vitro plasmid 
supercoil relax assays. For the structure elaboration of the compounds, mp, 
IR, UV, 1H NMR, 13C NMR, mass spectral data and elemental analyses 
were also interpreted. Among all these compounds, 5-methyl-4-(1H-
benzimidazole-2-yl)phenol (Cpd 2) manifested moderately potent 
topoisomerase I inhibition 
Christine Le Sann.,et.al. 24 
 Reported Bis and ter – benzimidazole derivatives were amazingly active 
compounds interfering with DNA topoisomerase I. 
 
 Described novel methodology for the synthesis of symmetric bis-
benzimidazoles having 2-aryl core moities, together with 2-[4-(3′-
aminopropoxy) phenyl] and 2-[4-(3′-aminopropanamido) phenyl] 
substituents, including the synthesis of new fusion molecules comprising 
bis-benzimidazoles in ester and amide mixture with the N-mustard 
chlorambucil.  
 The in vitro y studies of these compounds against 5 cancer cell lines are 
also reported. 
Junk sun kim, .,et.al.25 
 Reported cytotoxity against the human lympholast cell line with 
benzimidazole derivatives.  
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 Numerous 2-aryl -5-substituted-2,5-bi- 1H-benzimidazole derivatives were 
synthesized and screened as topoisomerase I poisons and evaluated  
cytotoxicity against the human lymphoblast cell line (RPMI 8402). This 
study revealed that, 2,5- bi-1H-benzimidazole derivatives which having 
either a 5-cyano, a 5-(4-methylpiperazinyl) or a 5-(aminocarbonyl),  group. 
Among these bi-benzimidazoles the pharmacological property of 2-phenyl 
derivatives and the effect of the different positional isomers of either a a 2-
naphthyl  or 2-tolyl group or core moiety on topoisomerase I inhibitory 
activity and cytotoxicity were estimated. 
A.Selcen Alpan .,et.al.26 
 Reported the cytotoxity studies against the skin epidermoid carcinoma and 
breast adenocarcinoma of bis and ter benzimidazole derivatives. 
 The detection of DNA topoisomerases has added a novel dimension to the 
study of anticancer agents.  
 In the past years detailed investigation reports showed of bi- and ter-
benzimidazole derivatives reported that these compounds are a new class 
of topoisomerase I inhibitors. 
 In this context a survey and review about topoisomerase I poisoning 
property and cytotoxicity activity of bi and ter-benzimidazoles is reported. 
Moreover many current reports about novel derivatives, some structure 
activity relationships of diverse functional groups were discussed. 
N
H
N
X
R
R1
N
N
R
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 Benzimidazoles of both synthetic and natural sources are the key 
components of various bio-active compounds. various reports have shown 
antifungal, antiviral, H2 receptor blocker and antitumor activities for 
benzimidazoles and their derivatives. In this study, we synthesized twelve 
bis-benzimidazole derivatives by selecting di(1H-benzo[d ]imidazol-2-
yl)methane as the main compound. The numbers of carbons at 2 positions 
of bis-benzimidazole derivatives were changed from 1 to 4, and 
derivatives were synthesized with methyl substitutions at 5- and/or 6- 
positions. The compounds were screened via in vitro plasmid superciol 
relaxation assays using mammalian DNA topoisomerase I and cytostatic 
assays were carried out against HeLa (cervix adenocarcinoma), MCF7 
(breast adenocarcinoma) and A431 (skin epidermoid carcinoma) cells for 
selected derivatives.  
 Results propose that the malonic acid derivatives of bis-benzimidazoles, 
namely, bis(5-methyl-1H-benzo[d ]imidazol-2- yl)methane and bis(5,6-
dimethyl-1H-benzo[d]imidazol-2-yl)methane, were remarkably active 
compounds in interfering with DNA topoisomerase I and the former 
compound was also found to be cytotoxic against A431 cells and MCF7. 
The inhibitory effects obtained with these derivatives are significant as 
these compounds can be potential sources of anticancer agents. 
Hatem A, .,et.al.27 
 The 3-methylthiazolo-benzimidazole derivatives were reported significant 
anticancer property towards the colon cancer and lower toxicity towards 
normal fibroblast.   
M.H.Pourgholami.,et.al.,28 
 Reported benzimidazole derivatives are rational approach for drug design 
the next generation inhibitors, for example- Albendazole, is a 
benzimidazole derivative clinically reported as an anthemintic drug, can 
also show in both invitro and invivo experimental studies condition inhibit 
the hepatocellular carcinoma developement. 
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H
N
NH
S
O
O
 
Albendazole 
 A major target of drug molecules is tubulin protein, and consequently, 
tubulin inhibitors have attracted enormous attention as antimitotic 
anticancer drug as for chemotherapeutic treatment.  
 It has been reported that, the benzimidazole carbamate moiety of 
antiparasitics together with albendazole act by inhibiting polymerization of 
tubulin. In this research, albendazole was screened in cell culture against a 
range of rat, human and mice hepatocellular carcinoma [HCC] cells line 
and in vivo test against human SKHEP-1 tumor growth in nude mice. 
Albendazole stimulated a dose-dependent inhibition of thymidine 
inclusion in every cell lines observed and a remarkable decline in cell 
numbers in SKHEP-1 cells observed.  
 In 100 nM concentration found inhibitory effect of albendazole  and 
proliferation in all cell lines  at 1000 nM, observed was inhibited by more 
than 80%, while, compared to control proliferation of HepG2, Hep3B and 
SKHEP-1 were inhibited by more than 90%. Cell cycle analysis and 
reported that, dose-depending employed, albendazole can inhibit or arrest 
SKHEP-1 cells at both G0–G1 (250 nM) and G2-M (1000 nM) phases of 
the cell cycle.  
 The nude mice treated with albendazole 300 mg/kg per day oral for 20 
days inoculated subcutaneously with SKHEP-1, led to profound inhibition 
of tumor growth. Immuno histochemical analysis test of these tumors 
showed that compared to control, those treated with albendazole have 
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lower growth fractions. These results demonstrate that albendazole 
powerfully suppresses both in vitro and in vivo proliferation of HCC cells. 
Y.Tong Thomas D.Penning.,et.al.,30 
 Developed the benzimidazole carboxamide poly(ADP-ribose) polymerase 
(PARP) inhibitors with excellent PARP enzyme potency as well as single-
digit nanomolar cellular potency with a series of phenylpyrrolidine & 
phenylpiperidine-substituted derivatives. These research efforts led to the 
recognition of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl) phenyl)- 1H-
benzimidazole-4-carboxamide (22b - A-966492).  
 Compound - 22b showed significant potency against the PARP-1 enzyme 
with a Ki of 1 nM and an EC50 of 1 nMin a whole cell assay test. In 
addition, 22b is orally bioavailable across multiple species, appears to 
distribute into tumor tissue and crosses the blood-brain barrier. In a 
B16F10 subcutaneous murine melanoma model combination with 
temozolomide showed good in vivo potency and also MX-1 breast cancer 
xenograft model both as a single agent and in combination with 
carboplatin. 
N
H
N
N
H
F
O NH2
 
(S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-
carboxamide (22b, A-966492) 
Y.Tong.,et.al.,33 
 Reported the small molecule inhibitors of PARP-1 have been followed by 
a variety of organizations as potential therapeutic agents either capable of 
acting as stand-alone agents to combat cancer or sensitizing cytotoxic 
treatments . As one of the approach to develop our portfolio of PARP-1 
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inhibitors, They pursued unsaturated heterocycles to replace or substitute 
the saturated cyclic amine derivatives added to the benzimidazole nucleus. 
Not only did a diversity of these novel production compounds preserve 
high enzymatic efficacy, many of them also showed vigorous cellular 
activity.  
N
H
N
O NH2
O
N
N
 
Compounds 24 
 The enzymatic IC50 value and cellular EC50  were as low as 1 nM or 
below. Compounds 24 (EC50 = 3.7 nM) and 44 (EC50 = 7.8 nM), featuring 
an oxadiazole and a pyridine core, correspondingly, showed balanced 
potency and PK profiles. In addition, temozolomide in a B16F10 murine 
melanoma model, these two molecules showed potent oral in vivo efficacy 
in potentiating the cytotoxic agent. B16F10. 
3.4. In-Vitro Cytotoxicities studies  
Juan C .,et.al.,34 
 Reported MTT is generally used to test the cytotoxicity and cell viability. 
 It is a colorimetric assay  for estimate the cell metabolic activity. NADPH-
dependent cellular oxidoreductase enzymes may, under definite 
conditions, reveal the number of viable cells present. oxidoreductase 
enzymes are competent of reducing the tetrazolium dye MTT – 3- (4,5-
dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide to 
insoluble formazan. 
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Figure 3.03: Chemical structures of yellow MTT and Purple 
Formazan product in living cell 
 A yellow tetrazoleofMTT, is reduced to purple formazan in living cells. A 
solubility of  solution usually either dimethy sulfoxide, an acidified 
ethanol solution, or a solution of the derergent sodium dodecyl sulfate in 
diluted hydrochloric acid is added to dissolve the insoluble 
purple formazan product into a colored solution. The absorbance of this 
colored solution can be estimated by measuring at a 
certain wavelength usually between 500 and 600 nm by 
a spectrophotometer. The depends on the solvent degree of light 
absorption will vary. 
C. Awortwe.,et.al.,35 
 Reported the investigations to detect the likely gastrointestinal 
permeability of drugs in Caco-2 model is engaged in pre-clinical because it 
states characteristics of transporters, microvilli, cytochrome P450 
enzymes,  and enterocytes of similar that of the small intestine of human.  
 The FDA suggest this model as integral constituent of the 
biopharmaceutics classification system [BCS].  
 Caco-2 cell line  is mostly used in many dedicated researchers or 
laboratories to screen novel chemical moieties through forecast of its 
bioavailability, solubility and the opportunity of drug-drug interactions in 
the gut lumen. However, challenges in the inborn properties of Caco-2 cell 
and also reported the inter- laboratory protocol generation & variations of 
irreproducible data. 
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Tor Lea.,et.al.,36 
 Reported the human epithelial cell line Caco-2 has been generally used as 
a model of the intestinal epithelial barrier. From a colon carcinoma the 
Caco-2 cell line is originally derived. However, one of its most beneficial 
characteristics is its capable to impulsively distinguish into a monolayer of 
cells with many characteristics typical of absorptive enterocytes with brush 
border layer as found in the small intestine.  
 The Caco-2 cell line is heterogeneous and includes cells with slightly 
diverse characteristics. Thus, cultivation conditions can be anticipated to 
choose for the growth of sub populations of cells concluding in a cellular 
model system with characteristics that may vary from the original cell line. 
Tamer S.,et.al.,37 
 Reported the use of Gold‟s reagent core precursor E- 3-(N,N-
dimethylamino)-1-(3-methylthiazolo[3,2-a]benzimidazole derivative 4 was  
synthesized in excellent yield. The reaction of enamin-one 4 with 5-amino-
3-aryl-1 –phenylpyrazole derivatives  5a, b in refluxing acetic acid in the 
presence of H2SO4, yielded pyrazolo[3,4-b]pyridines 7a, b. Similarly, 
pyrazolo[1,5-a]pyrimidine derivatives  10a, b & 14a–f were prepared by 
reaction of enaminone 4 with 5-amino-1H-pyrazoles 8a, b & 12a–f, 
correspondingly. The structure of pyrazolo[1,5-a]pyrimidine 10b was 
determined by X-ray diffraction. The synthesized compounds were 
screened for their in-vitro anticancer activity towards the colon cancer cell 
line CaCo-2; their cytotoxicity against the normal BHK (fibroblast cell 
line) was investigated as well. Some of the tested compounds showed cell 
growth inhibitory activity. The significant anticancer activity of 
compound 14f against the CaCo-2 cell line (IC50  0.5 μg/mL) was paired 
with a lower toxicity against BHK (IC50  2.3 μg/mL). 
Mansour S.,et.al.,38 
 Reported  In the studies of tumor biology and hormone mechanism of 
action MCF-7 human breast cancer cells are used broadly.  
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 Range of new 1,2-dihydropyridines 10 to 17, thiophenes 18 to 21 and 
thiazole 22 having a biologically active sulfone entitiy were acquired via 
the reaction of 2-cyano-N0-[1-(4-(piperidin-1-ylsulfonyl) 
 phenyl) ethylidene] acetohydrazide derivative 3 with a several of reagents. 
The structures of the newly synthesized compounds were proved by 
elemental analysis, spectral data.  
 All the newly synthesized compounds were assessed for their in-vitro 
antitumor activity against human breast cancer cell line (MCF7). 
Compounds 15 and 11 with IC50 values (20.6, 25.5 mM) showed better 
activity than Doxorubicin as a standard drug with IC50 value (32.02 mM), 
while compound 14 is almost as active as Doxorubicin as positive control.  
Liesbeth E Jonges.,et.al.,39 
 Reported the apoptosis is an vital biologic process. As well as having a 
role in controlling cell number during early improvement, The removal of 
infected or genetically altered cells by apoptosis process. 
 Imperfections in the apoptotic process mechanism are often found in 
growth of neoplastic which is also the case in colorectal cancer.  
 Development of colorectal cancer progress through a sequence of genetic 
changes that result in the activation of oncogenes and loss of tumor 
inhibition genes.   
 Several techniques to examine apoptotic process frequencies in tumors 
have been detailed. In this research, they reported that biochemical 
recognition of enzymatic caspase-3 activity is a quantitative and simple 
technique to estimate the apoptosis in colorectal cancer cells. 
 The Caspases (cysteinyl aspartate-specific proteases) are a family of vital 
signaling molecules with several tasks depending on the organ and subtype 
involved. 
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Figure 3.04: Extrinsic & Intrinsic Apoptopic Pathway 
 The use of the active form of caspase-3 detailed the identification of 
apoptotic process. This protease has been concerned as an “effector” 
caspase connected with the beginning of the “death cascade” and is 
therefore an vital marker of the cell‟s access point into the apoptotic 
signaling pathway. Caspase-3 is activated through the upstream caspase-8 
& caspase-9, and since it provides as a junction point for dissimilar 
signaling pathways, it is fine selection as a read-out in an apoptosis assay. 
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3.4. Nano Technology in Cancer Therapy 
Rajini sinha.,et.al.,40 
 Discussed most recent anticancer drugs do not significantly differentiate 
between normal cells and cancerous, leading to systemic toxicity, side-
effects and adverse effects.  
 This significantly limits the greatest permissible dose of the drug. In 
addition, quick elimination and widespread delivery into targeted cell 
tissues and organs requires the administration of a drug in high quantities, 
which is not inexpensive and often results in                    unwanted 
toxicity.  
 Various plans have supported research on new nanodevices able of 
identifing cancer at its premalignant stage, presence cancerous tissue 
within the body, distribute antineoplastic agents to the cancer cells, and 
estimate if these cells are being killed by the agents. 
 Nanoparticles and other nano crystals have been receiving a more 
awareness newly and their use in cancer therapy is becoming a developing 
industry. 
 The current Food and Drug Administration consent of Abraxane (ABI-
007), an albumin- taxol nanoparticle for the therapy of breast cancer, has 
opened the doors for the improvement of other nanoscale drug delivery 
devices with the goal of landing more of a drug onto the target cell and 
less onto healthy cell . 
 Nanotechnology is a fast-expanding growing area of science. This 
technology of research is involved to lead to the development and 
discovery of novel, multifunctional applications, sophisticated which can 
identify cancer cells, deliver drugs to target cell, assist in reporting 
outcome of treatment, and give real-time evaluation of surgical efficacy 
therapeutic and most vitally, check intracellular modification to help avoid 
precancerous cells from becoming malignant. 
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Figure 3.05: Targeting of nano particle by enhancedPermeability and 
retention affect. 
 
Tebbutta N C.,et.al.,50 
 Reported the potency of present cancer chemotherapy is mainly limited by the 
side-effects, toxicity associated with the antitumor agents to normal cell or 
tissues. This restrictions result from the fact that antitumor agents currently 
used in chemotherapy lack capable selectivity towards cancer cells or tissues.  
 The improvement of a new nanoparticle drug delivery system to overcome 
these present barriers in convention drug treatment. Nanoparticles due to their 
tiny size and target exact localization property offer many merits contrast to 
conventional dosage forms which consist of reduced dose improved 
efficiency, reduced toxicity, patient compliance and convenience. 
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 Aiming of agents specially to colon is helpful for the theraphy of diseases 
associated with the colon such as Crohn‟s diseases, Amoebiasis, Ulcerative 
colitis  and colorectal cancer.  
 A nano drug delivery system is mainly often associated with particulate 
transporters such as liposomes, emulsion and nanoparticles which are planned 
to localize drugs at the target tissue site. 
Karanjit Kaur.,et.al.,51 
 Reported the chitosan is a natural copolymer of glucosamine and N-acetyl 
glycosamine and its hydrophilic in nature.  
 It is regard as a secure excipient due to its biodegradability, biocompatibility 
and lack of side-effect & toxicity, moreover it is cationic  nature and have 
muco adhesive character it will increase the cellular uptake through ionic 
interaction. 
 
Figure 3.06: Structure of Chitosan 
Sunil A.,et.al.,52 
 Reported the developing efficient and safe chitosan-based particular drug 
delivery systems.   
 The review revealed the chief novel findings on chitosan-based micro or 
nanoparticulate drug delivery systems and pharmaceutical use published 
over the last decade.  
 Methods and materials of their formulation, drug loading ability, release 
property, and uses are explained. Chemically changed chitosan or its 
derivatives used in drug delivery research are detailed critically to estimate 
the effectiveness of these systems in delivering the bioactive molecules. 
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From a literature survey, it is realized that research activities on chitosan 
micro or nanoparticulate systems containing severe drugs for dissimilar 
theraphy applications have amplified at the quick rate.  
 Chitosan is a polysaccharide, alike structure to cellulose. Both are made by 
linear- linked monosaccharides.  However, an vital disparity to cellulose is 
that chitosan is composed of 2- amino-2-deoxy- h-d-glucan united with 
glycosidic linkages.  
 The primary amine groups provide particular characters that make 
Chitosan extremely useful in pharmaceutical purpose. Compared to 
numerous other natural polymers, chitosan has a mucoadhesive property 
and positive charge. Therefore, it is used widespreadly in drug delivery 
applications. 
 Chitosan is biocompatible with living cell and tissues since it does not 
cause rejection and allergic reactions.  
 
Figure 3.07: Applications of Chitosan 
 It breaks down slowly to nontoxic products amino sugars, which are fully 
absorbed by the human body.  
 Under the action of ferments Chitosan degrades, it is nontoxic and easily 
detachable from the organism without causing simultaneous side reactions. 
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 It has antimicrobial activity and absorbs toxic metals such as hg, cd, pb, 
etc. In addition, it has excellent adhesion, coagulation capability, and 
immune stimulating property. 
Emmanuel N K.,et.al.,53 
 This research work reported details of pertaining to the formulation of 
chitosan nanoparticle that prepared by the ionic gelation method.  
 The molecular interfaces of the ionic cross- linking of chitosan with 
tripolyphosphate have been examined and explained by means of all-
electron density functional group theory. 
 
Figure 3.08:Ionic Gelation Method 
 They have recognized primary- interaction ionic cross- linking 
configurations that they define as T- link, M-link and H-link and solvent 
effects have been taken into account using implicit models. 
 They have quantified the respective interaction energies. H- links, which 
display greatest interaction energies and are also spatially largely 
accessible, are the most possible cross- linking configurations. At close 
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range, proton transfer has been recognized, with greatest interactio n 
energies ranging from 12.3 up to 68.3 kcal/mol depending on the relative 
coordination of chitosan with tripolyphosphate and the protonation of the 
tripolyphosphate polyanion.  
 On the basis of results for the linking types (interaction energies and 
torsion bias), we propose a simple mechanism for their impact on the 
chitosan/TPP nanoparticle formation process.  
 They establish the β ratio, which is obtained from the commonly used α 
ratio but is more essential since it moreover takes into account structural 
particulars of the oligomers.  
3.5. Pharmacological Screening 
Khairia M.,et.al.,54 
 Reported Synthesis and preclinical security estimation in mice and rats of 
Curcumin 1 and curcumin analogs 2 & 3 were done. Besides, the 
chemopreventive property in DMH-induced colon cancer in albino rats 
model were achieved.  
 Sections of mammary heart, gland, liver, kidney, spleen, and colon were 
done.  
 Administration of the prophylactic therapy for 4 weeks before the 
induction of carcinoma by DMH, reported that compound 3 is the most 
active.  
 Chemopreventive therapy with dissimilar forms of curcumin extracts for 
two and four weeks caused a suppression in the number of aberrant crypt 
foci (ACF) particularly compound 3. 
 Chemopreventive therapy with diverse forms of curcumin extracts for 2 
and 4 weeks caused a decrease in the number of cancer cells. 
I-Mei Siu.,et.al.,55 
 Reported Aberrant crypt foci (ACF) are grossly invisible putative 
premalignant lesions in the colon.  
 As dysplasia is considered an important precursor of colon carcinoma. 
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 Aberrant crypt foci (ACF) are clusters of abnormal tube- like glands in the 
lining of the colon and rectum. Aberrant crypt foci form before colorectal 
polyps and are one of the earliest changes seen in the colon that may lead 
to cancer.  
Michael J. Wargovich .,et.al.,56 
 Reported Aberrant crypt foci (ACF) are one of the initial histopathological 
appearances of colon cancer.  
 In this review work, they significantly present the cellular, molecular, 
histopathological, and chemopreventive proof that ACF are relevant 
biomarkers for colon cancer.  
 The clinical and laboratory proof are highly indicative that ACF are in the 
pathway most important to colon cancer, but not all ACF will do so. The 
likely fate and outcome of ACF in the progression towards colon cancer 
may be dependent on a number of characteristics that describe their 
predictive control for the progression or prevention  of tumor. 
 Aberrant crypt replication is fundamentally similar to that of normal crypts 
with the replication process starting at the base of the crypt approaching 
cells outwards and upward to form new colonic crypts in totaling to 
replenishing the cells in the original crypt.  
 This is a branching process and budding, known as crypt fission, which 
forms superior sized foci over time.  
 This process does, however, occur at an amplified rate in several disease 
states of the bowel. 
 Since ACF are regard as putative precursors for cancer, therapeutics  are 
targeted to change this stage or earlier in the disease growth to either halt 
disease development, prevent or reverse it,  ACF formation.  
 ACF formation accompanies modifies in the morphology of colonic crypts 
in both benign diseases of the colon cancer and bowel.  
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 Since ACF formation is presently the initial noted change visible with only 
a microscope.Aberrant crypt foci can be used as a biomarker for disease, 
include colon cancer. 
 
Figure 3.09:Aberrant crypt foci 
 
 
Figure 3.10:Types ofAberrant crypt foci 
 Three ACF types and possible pathways in colon carcinogenesis. The inset 
shows the speculated pattern of proliferation zone in the crypt of subtypes 
of ACF. Hypothetical scheme for the transition of crypts from normal to 
dysplastic ACF showing nuclear morphometry (dark blue is ACF; purple 
is stratified nucleus).  
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Three types of dysplastic ACF reported in the literature: 
 Mucin depleted foci (MDF, goblet cells in pink are lost and replaced by 
stratified nuclei in purple; Brown represent β-catenin which can 
accumulate in MDF), β-catenin accumulated crypts (BCAC, brown 
denoted nuclear β-catenin within the crypts) and flat-dysplastic ACF (flat 
ACF, brown is β-catenin within highly dysplastic and pleiomorphic 
crypts). 
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4. MATERIALS AND METHODS 
4.1 Experiment Envisaged  
4.1.1 Synthesis scheme 57-59. 
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4.1.1.1  Synthesis of benzimidazolyl chalcones (3a-e) 
N
N
H
C
CH3
O
N
N
H
C
C
H
O
CH
R1
KOH
Ethanol
R1-CHO
2-Acetyl benzimdazole
2 (a-e)
Chalcone derivative
3 (a-e)  
 Weighed 0.01 molar of  2-acteyl benzimidazole (1a) and 10m 30 % 
potassium hydroxide solution was taken in a round bottom fask to this add 
0.012 molar of various aromatic aldehyde (2a-e) namely, benzadehyde 
(2a) , pyridine aldehyde (2b) , 3-chloro-4-methoxy benzadehyde (2c), 3,4-
dimethoxy benzadehyde (2d), anthracene aldehyde (2e)  separately, with 
stirring then refux the mixture for 2 hours, cool to room temperature and 
pour in to a beaker containing ice cold water, with stirring to get a product.  
 The precipitated chacolnes was filtered with ice cold water, washed dried 
and recryataized from ethanol. The chemical names of above synthesized 
benzimidazoly chalcones as follows: (3a-e). 
 1-(1H-benzo[d]imidazole-2-yl)-3-phenylprop-2-en-1-one (3a) 
 1-(1H-benzo[d]imidazole-2-yl)-3-(pyridine-4-yl)prop-2-en-1-one (3b) 
 1-(1H-benzo[d]imidazole-2-yl)-3-(3-chloro-4-methoxyphenyl)prop-2-en-
1-one (3c) 
 1-(1H-benzo[d]imidazole-2-yl)-3-(3,4-dimethoxyphenyl)prop-2-en-1-one 
(3d) 
 3-(anthracen-10-yl)1-(1H-benzo[d]imidazole-2-yl)prop-2-en-1-one (3e) 
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4.1.1.2 Synthesis of 1-methyl-benzimidazolyl chalcones (3f-j) 
N
N
CH3
C
CH3
O
N
N
CH3
C
C
H
O
CH
R1
KOH
Ethanol
R1-CHO
1-methyl-2-acetyl benzimdazole
2 (a-e)
Chalcone derivative
3 (f-j)  
 Weighed 0.01 molar of 1-methyl-2-acteyl benzimidazole (1b) and 10m 30 
% potassium hydroxide solution was taken in a round bottom fask to this 
add 0.012 molar of various aromatic aldehyde (2a-e) namely, benzadehyde 
(2a) , pyridine aldehyde (2b) , 3-chloro-4-methoxy benzadehyde (2c), 3,4-
dimethoxy benzadehyde (2d), anthracene aldehyde (2e)  separately, with 
stirring then refux the mixture for 2 hours, cool to room temperature and 
pour in to a beaker containing ice cold water, with stirring to get a product.  
 The precipitated chacolnes was filtered with ice cold water, washed dried 
and recryataized from ethanol. The chemical names of above synthesized 
benzimidazoly chalcones as follows: (3f-j). 
 1-(1-methyl-1H-benzo[d]imidazole-2-yl)-3-phenylprop-2-en-1-one (3f) 
 1-(1-methyl-1H-benzo[d]imidazole-2-yl)-3-(pyridine-4-yl)prop-2-en-1-one 
(3g) 
 3-(3-chloro-4-methoxyphenyl) 1-(1-methyl-1H-benzo[d]imidazole-2-yl)-
prop-2-en-1-one (3h) 
 3-(3,4-dimethoxyphenyl)-1-(1-methyl-1H-benzo[d]imidazole-2-yl)-prop-
2-en-1-one (3i) 
 3-(anthracen-10-yl)1-(1-methyl-1H-benzo[d]imidazole-2-yl)prop-2-en-1-
one (3j) 
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4.1.1.3 Synthesis of benzo[d]imidazol-2-yl pyrimidine derivatives (4a-e) 
N
N
H
C
C
H
O
CH
R1
KOH
Chalcone derivative
3 (a-e)
C
O
H2N NH2 .HCl
Guanidine.HCl
N
N
H
N
N
R1
4 (a-e) NH2
C2H50H
 
 A mixture of compounds 3(a-e) (0.001mol) was condensed with 
guninidine hydrochloride (0.001 mol) in presences of potassium hydroxide 
(0.002 mol) in absolute ethanol (5ml) at refux on a water bath for 3 hours.  
 The reaction mixture was cooled at room temperature and poured in ice 
cold water. Solid product was filtered and washed with water, dried and 
recrystallized to give 4(a-e), respectively.  
 4-(1H-benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine (4a) 
 4-(1H-benzo[d]imidazol-2-yl)-6-(pyridin-4-yl)pyrimidin-2-amine (4b) 
 4-(1H-benzo[d]imidazol-2-yl)-6-(3-chloro-4-
methoxyphenyl)pyrimidin-2-amine (4c)  
 4-(1H-benzo[d]imidazol-2-yl)-6-(3,4-dimethoxyphenyl)pyrimidin-2-
amine(4c) 
 4-(anthracen-10-yl)-6-(1H-benzo[d]imidazol-2-yl)pyrimidin-2-amine 
(4e) 
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4.1.1.4  Synthesis of 1-methyl-benzo[d]imidazol-2-yl pyrimidinederivatives 
(4f-j) 
N
N
CH3
C
C
H
O
CH
R1
KOH
Chalcone derivative
3 (f-j)
C
O
H2N NH2 .HCl
Guanidine.HCl
N
N
CH3
N
N
R1
4 (f-j)
NH2
C2H50H
 
 A mixture of compounds 3(f-j) (0.001mol) was condensed with guninidine 
hydrochloride (0.001 mol) in presences of potassium hydroxide (0.002 mol) in 
absolute ethanol (5ml) at refux on a water bath for 3 hours.  
 The reaction mixture was cooled at room temperature and poured in ice cold 
water.  
 Solid product was filtered and washed with water, dried and recrystallized to 
give 4(f-j), respectively. 
 4-(1-methyl-1H-benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine (4f) 
 4-(1-methyl-1H-benzo[d]imidazol-2-yl)-6-(pyridin-4-yl)pyrimidin-2-amine 
(4g) 
 4-(3-chloro-4-methoxyphenyl)-6-(1-methyl-1H-benzo[d]imidazol-2-
yl)pyrimidin-2-amine (4h) 
 4-(3,4-dimethoxyphenyl)-6-(1-methyl-1H-benzo[d]imidazol-2-
yl)pyrimidin-2-amine (4i) 
 4-(anthracen-10-yl)-6-(1-methyl-1H-benzo[d]imidazol-2-yl)pyrimidin-2-
amine (4j) 
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4.1.1.5 Synthesis of (pyrazol-3-yl)-benzo[d]imidazole derivatives (5a-e) 
N
N
H
C
C
H
O
CH
R1
KOH
Chalcone derivative
3 (a-e) 5 (a-e)
N
N
H
N
N
C6H5NHNH2
C2H50H
R1
 
 A mixture of compounds 3(a-e) (0.001mol) was condensed with phenyl 
hydrazine (0.001 mol) in presences of potassium hydroxide (0.002 mol) in 
absolute ethanol (5ml) at refux on a water bath for 3 hours.  
 The reaction mixture was cooled at room temperature and poured in ice cold 
water.  
 Solid product was filtered and washed with water, dried and recrystallized to 
give 5(a-e), respectively.  
 2-(1,5-diphenyl-1H-pyrazol-3-yl)-1H-benzo[d]imidazole (5a) 
 2-(1-phenyl-5-(pyridin-4-yl)-1H-pyrazol-3-yl)-1H-benzo[d]imidazole (5b) 
 2-(5-(3-chloro-4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-1H-
benzo[d]imidazole (5c) 
 2-(5-(3,4-dimethoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-1H-
benzo[d]imidazole (5d) 
 2-(5-(anthracen-10-yl)-1-phenyl-1H-pyrazol-3-yl)-1H-benzo[d]imidazole 
(5e) 
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4.1.1.6 Synthesis of (pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazolederivatives 
(5f-j) 
N
N
CH3
C
C
H
O
CH
R1
KOH
Chalcone derivative
3 (f-j) 5 (f-j)
N
N
CH3
N
N
C6H5NHNH2
C2H50H
R1
 
 A mixture of compounds 3(f-j) (0.001mol) was condensed with phenyl 
hydrazine (0.001 mol) in presences of potassium hydroxide (0.002 mol) in 
absolute ethanol (5ml) at refux on a water bath for 3 hours.  
 The reaction mixture was cooled at room temperature and poured in ice cold 
water. Solid product was filtered and washed with water, dried and 
recrystallized to give 5(f-j), respectively.   
 2-(1,5-diphenyl-1H-pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole (5f) 
 1-methyl-2-(1-phenyl-5-(pyridin-4-yl)-1H-pyrazol-3-yl)-1H-
benzo[d]imidazole(5g) 
 2-(5-(3-chloro-4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-1-methyl-1H-
benzo[d]imidazole (5h) 
 2-(5-(3,4-dimethoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-1-methyl-1H-
benzo[d]imidazole (5i) 
 2-(5-(anthracen-10-yl)-1-phenyl-1H-pyrazol-3-yl)-1-methyl-1H-
benzo[d]imidazole (5j) 
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4.2 In-Vitro Cytotoxicities studies  60 
 In-vitro anti-cancer studies (MTT - assay) for synthesized novel 
benzimidazole derivatives by using CaCo-2 colon cancer cell line and 
MCF-7 breast cancer cell line. 
4.2.1 In-vitro cytotoxic evaluation against MCF-7 and CaCo-2 cell line61 
4.2.1.1 Cell culture 
 MCF-7 (Human breast cancer cell line) and CaCo-2 (Human colon cancer 
cell line) were obtained from NCCS Pune. 
 It was maintained in Roswell Park Memorial Institute (RPMI) 
supplemented with 10% fetal bovine serum (FBS), 2mM glutamine, 
amphotericin (3 g/ml), gentamycin (400 g/ml), streptomycin (250 
g/ml), penicillin (250 units/ml) and 1mg/ml insulin in  the incubator at 
5% CO2, 37°C was obtained from NCCS Pune. 
4.2.1.2 Preparation of media and other reagents required for cell culture  
4.2.1.3  RPMI medium 
 Roswell Park Memorial Institute (RPMI) medium was prepared as follows:  
The powdered media was dissolved in 900 ml of sterile glass  distilled or 
Millipore water in an autoclaved glass conical flask under sterile 
conditions.  
 The antibiotics were added in the concentration as mentioned above and 
stirred well. 3.7 g of Sodium bicarbonate was added into the flask and 
stirred until it gets dissolved completely. 10% FBS was added and mixed 
well.  
 The liquid was slowly poured into the upper portion of a media 
sterilisation unit and filtered through a 0.2 filter under negative pressure.  
 The medium was immediately stored at 4oC. 
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4.2.1.4 Saline: Trypsin: Versene (STV) 
 10X Saline A: 8g NaCl, 0.4g KCl, 1.0g D-Glucose and 0.35 g NaHCO3 
(Tissue Culture Grade) were dissolved in 100 ml water and stored at 4oC. 
Versene: 1g EDTA (Tissue Culture grade) was added into 90 ml distilled 
water. Then 5N NaOH was added drop wise until it gets dissolved.  
 The solution was filter sterilizes and stored at 4oC. 100 ml of STV was 
prepared by adding 25 mg of trypsin in a mixture of 10 ml of 10X Saline A 
and 2.5 ml of Versene Double distilled water was added to make upto 100 
ml, sterile filtered, liquated, and frozen at –20oC to –70oC. 
4.2.1.5 Maintaining and storage of cell lines  
 MCF-7 and CaCo-2 cells show a steady growth rate with a doubling time 
approximately 33 hours. The cells reached confluency in 3 to 4 days and 
these cells were passaged to get the cells for the experiments and also to 
store in liquid nitrogen. 
 The culture medium was removed from the T25 culture flask by decanting 
into a clean container inside the laminar airflow chamber, and cells were 
rinsed with medium without serum, to remove traces of serum, which may 
inhibit action of trypsin. 2 ml of STV solution was added to the flask 
containing cells and incubated at 37oC for a few minutes. As soon as cells 
started dislocating from the surface, flask was rinsed with 5ml of serum-
containing medium to arrest the trypsinisation.  
 The suspension of cells was collected in a sterile 15 ml centrifuge tube and 
the cells were pelleted at 1500 rpm for 5 minutes.  
 The cell pellet was resuspended in fresh medium with serum and a part of 
the cells were seeded back into the flask.  
 The remaining cells were used for experiment or pelleted as earlier and 
resuspended in cryopreservative medium (syntha freeze) in a cryovial and 
frozen at -70oC for a day then transferred to liquid nitrogen. 
 
 
 
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles Page 44 
 
4.2.1.6 Drug Preparation 
 All the compounds were dissolved in DMSO to give a stock concentration 
of 50μg/μl.  
 The stock solution was then serially diluted with culture medium.  
 The test concentration were 0.1,0.3,1,3,10,30 μM.  
 The concentration of DMSO never exceeded 1%  in any of the 96 wells. 
4.2.1.7MTT assay 
 Cell lines were maintained in RPMI supplemented with 10% FBS, 2mM 
glutamine, amphotericin (3 g/ml), gentamycin (400 g/ml), streptomycin  
(250 g/ml) and penicillin (250 units/ml) in a carbon dioxide incubator at 
5% CO2.  
 Approximately 2 X 104 cells/well were seeded in 96 well plate using 
culture medium,the viability was tested using trypan blue dye with help of 
haemocytometer and 95% of viability was confirmed.After 24hrs, the fresh 
medium with the extracts were added at respective wells and kept 
incubation for 72 hrs. After incubation the following assays were 
performed. 
 After 72hrs of the drug treatment the fresh medium was changed again for 
all groups and 10 μl of MTT (5 mg/ml stock solution) was added and the 
plates were incubated for an additional 4 h. The medium was discarded 
and the formazan blue, which was formed in the cells, was dissolved with 
100μl of DMSO.  
 The optical density was measured at 570nm.  
 The percentage toxicity was calculated by using following formula. Graph 
pad prism software was used to calculated IC50 of the extracts. 
% Toxicity = 1- treated cells/untreated cells x 100 
4.2.1.8 Apoptosis Studies   
 Apoptosis studies were performed with a staining method utilizing 
acridine orange (AO) and ethidium bromide (EB).  
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 CaCo-2 cells were incubated in the absence or presence of the test 
compound at 37°C and 5% CO2 for 48 h. After 48 h, cells were stained 
with AO/EB solution (100 μg/mL AO, 100 μg/mL EB).  
 The cells were observed under a fluorescence microscope. 
4.3  Formulation and characterization of nanoparticle62,63 
 Formulation of  lead benzimidazole derivatives into nanoparticles using 
natural polymers 
 Characterization of benzimidazole nanoparticles. 
 In-vitro anti-cancer studies (MTT - assay) for synthesised novel 
formulated benzimidazole derivative nanoparticle by using CaCo-2 colon 
cancer cell line. 
4.3.1 Preparation of novel benzimidazole derivative [4-(1H-
benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine (4a)] loaded chitosan 
nanoaprticles (BZI nano)64 
 Synthesised novel benzimidazole derivative [4-(1H-benzo[d]imidazol-2-
yl)-6-phenylpyrimidin-2-amine (4a)] loaded chitosan nanoparticles were 
prepared using ionic gelation method. 
 Determinate weight of chitosan was dissolved in glacial acetic acid. 
 1% [v/v], 5mg of synthesized novel benzimidazole derivatives [4-(1H-
benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine (4a)]  was added to 
the above solution and under constant magnetic stirring followed by 
addition of aqueous Triphenyl phosphate (TPP) solution in a drop wise 
manner, then the solution was kept on constant magnetic stirring for 30 
mins and sonicator [vibrasonics].  
 The nanoparticle suspension was centrifuged at 13,000 rpm and 40C for 30 
minutes using Eppendr of Ultracentrifuge to remove excessive amounts of 
TPP and unencapsulated novel benzimidazole derivative [4-(1H-
benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine (4a)]  .   
 The pellets were dispersed in deionised water.  
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 Finally, nanoparticles were lyophilized for 24 hrs using freeze dryer 
[lyodel] for storage in powdered form. 
 Optimization of benzimidazole derivative Nanoparticles of (CS-NP) on the 
basis of CS/ TPP ratio done. 
4.3.2 Conditions for formation synthesised novel benzimidazole derivative                                                                                        
[4-(1H-benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine (4a)]loaded 
chitosan nanoparticles (BZI nano)65 
 Chitosan Nanoparticles were prepared by simple scale up ionotropic 
gelation method similar to the method developed.  
 Chitosan is a cationic polyelectrolyte the nanoparticles were formed by 
inducing the gelation by controlling its interaction with polyanion TPP 
which leads to reduce the aqueous solubility of CS this system based on 
inter and intramolecular linkages created between TPP and positive charge 
of charged amino groups of CS which are responsible for the successful 
formation of the nanoparticles.  
 The particle size, PDI, drug encapsulation and zeta potential were 
analyzed. 
4.3.2.1 Effect of Chitosan Concentration 
 The role of chitosan concentration (0.2, 0.4 and 0.6%) on formation of 
nanoparticles and its influence on particle size was evaluated.  
4.3.2.2 Effect of Triphenyl phosphate (TPP) concentration 
 The role of TPP (0.2, 0.4 and 0.6%) concentration on particle size 
formation was studied.  
 The sonication time in the formation of CS-NP played a crucial role in the 
formation of smaller size nanoparticles.  
 Effect of sonification on particle size was studied. 
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4.3.3 Physicochemical characterization of nanoparticles66 
4.3.3.1  Particle size and Zeta potential using photon correlation 
Spectroscopy 
 The average hydrodynamic diameter and polydispersity index (PDI) of the 
formulated nanoparticles were determined by dynamic light scattering 
(DLS) analysis using Zetasizer Nano ZS90 (Malvern Instruments limited, 
UK) 1ml of sample of nanoparticles dispersion was placed in disposable 
cuvettes for particle size measurements.  
 Each experiment was conducted in triplicate. The electrophoretic mobility 
(zeta potential) measurements were made using the Malvern Zetasizer 
(Nano ZS90, Malvern Instruments) at 25ºC. Samples were diluted with 
double distilled water. 
4.3.3.2 Transmission electron microscopy TEM images of synthesised novel 
benzimidazole derivative (BZI  nano) 
 Transmission electron microscopy (TEM) is a microscopy technique in 
which a beam of electrons is transmitted through an ultra-thin specimen, 
interacting with the specimen as it passes through it. 
 The surface morphology of the prepared NPs was determined for by using 
transmission electron microscopy (HRTEM).  
 A drop of Nanosuspension was placed on a carbon film coated copper grid 
for TEM. Studies were performed at 80 kv using JOEL JEM 2100.The 
copper grip was fixed in to sample holder and placed in a vacuum chamber 
of the transmission electron microscope and observed under low vacuum 
and TEM images were recorded. 
4.3.3.3Encapsulation efficiency 
 Nanoparticles were separated from aqueous phase by ultracentrifugation 
(Eppendr of) at 13000 rpm and 4°C for 45 minutes. The supernatants were 
collected and evaluated for novel benzimidazole derivative  residues by 
UV.  
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 The encapsulation efficiency (EE) was determined indirectly by 
measurement of the amount of free novel benzimidazole derivative in the 
supernatant after ultracentrifugation and was calculated according to the 
following equation: 
EE =   Amount of total drug - Amount of free drug in supernant X 100 
Amount of total drug 
4.3.4.4In vitro Release67 
 A modified dialysis method was used to evaluate the invitro release of 
novel benzimidazole derivative [4-(1H-benzo[d]imidazol-2-yl)-6-
phenylpyrimidin-2-amine (4a) ] loaded chitosan NPs.Two millilitres of 
nanoparticles suspension (corresponding to 2 mg of novel benzimidazole 
derivatives ) was placed in a dialysis bag (cellophane membrane, 
molecular weight cut off 10,000–12,000, Hi-Media, India) which was tied 
and placed into 20 ml of phosphate buffer (0.1M, pH 7.4) maintained at 
37ºC with continuous magnetic stirring.  
 At selected time intervals, aliquots were withdrawn from the release 
medium and replaced with the same amount of phosphate buffer. The 
sample was assayed spectrophotometrically for novel benzimidazole 
derivative at 235 nm  
4.4In vitro cytotoxicity of nanoparticles68 
4.4.1 Cell culture 
 MCF-7 (Human breast cancer cell line) and CaCo-2 (Human colon cancer 
cell line) were obtained from NCCS Pune. 
4.4.2 Drug Preparation 
 The synthesized novel benzimidazole derivative (BZI 3 nano) were 
dissolved in DMSO to give a stock concentration of 50μg/μl.  
 The stock solution was then serially diluted with culture medium.  
 The test concentration were 0.1,0.3,1,3,10,30 μM.  
 The concentration of DMSO never exceeded 1%  in any of the 96 wells. 
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4.4.3MTT assay 
 Cell lines were maintained in RPMI supplemented with 10% FBS, 2mM 
glutamine, amphotericin (3 g/ml), gentamycin (400 g/ml), streptomycin  
(250 g/ml) and penicillin (250 units/ml) in a carbon dioxide incubator at 
5% CO2.  
 Approximately 2 X 104 cells/well were seeded in 96 well plate using 
culture medium,the viability was tested using trypan blue dye with help of 
haemocytometer and 95% of viability was confirmed.After 24hrs, the fresh 
medium with the extracts were added at respective wells and kept 
incubation for 72 hrs. After incubation the following assays were 
performed. 
 After 72hrs of the drug treatment the fresh medium was changed again for 
all groups and 10 μl of MTT (5 mg/ml stock solution) was added and the 
plates were incubated for an additional 4 h. The medium was discarded 
and the formazan blue, which was formed in the cells, was dissolved with 
100μl of DMSO.  
 The optical density was measured at 570nm.  
 The percentage toxicity was calculated by using following formula. Graph 
pad prism software was used to calculated IC50 of the extracts. 
% Toxicity = 1- treated cells/untreated cells x 100 
4.5 Acute Toxicity Study69,70 
 Acute toxicity studies and fixing of dose for the newlyl formulated 
benzimidazole derivative nanoparticle.  
 Acute oral toxicity test was carried out according to the OECD guideline 
No. 423.Male Wistar Albino Rats were kept for overnight fasting prior to 
drug administration. 
 The sighting study of the compound was carried out on the group (3 
numbers) of albino rats of wistar strain of male sex following fixed dose 
method. 
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 Only one animal among the group of three was tested with initial dose 
5mg/kg via orally administration and observe once in 30 min for the first 4 
h and periodically during the first 24 h for event toxicity or mortality. 
Since there was no such toxicity or mortality, the other animals in the 
group were testes with initial test dose 5mg/kg and observed for 14 days, 
the test compound did not produce any signs of toxicity or mortality. 
Figure 4.01: Acute Toxicity Study 
 The procedure of sighting study was repeated at a higher dose of 25mg/kg 
and observed for 14 days, and the test compounds did not produce any 
signs of toxicity or mortality.  
 At 50mg/kg sighting study, the compound produced mortality in more than 
40% of the population with tremors and convulsion.  
4.6 Pharmacological Screening71,72 
 In-vivo studies of Anti-cancer for synthesized novel formulated 
benzimidazole derivative nanoparticle (BZI 3 nano) by DMH induced 
colon cancer.  
4.6.1  Animals:73,74 
 In this study, A total of 24 Male Wistar albino rats (150-180 gm) were 
selected and procured from RVS College Of Pharmaceutical Sciences,  
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Tamilnadu, India.All animals were maintained under environmentally 
controlled conditions of  25±2° C, relative humidity of 45 to 55 % and 12 
hr light-12 hr dark cycle.  
 The animals were acclimatized to laboratory conditions at least one week 
before starting the experiment and they had free access to food and water 
ad labitum. The study protocol was approved by Institutional Animal 
Ethics Committee (IAE1012/c/16/CPCSEA – Corres - 2013). 
4.6.1.2     Chemicals  
 DMH were purchased from Sigma Chemicals private limited, Bangalore, 
Methylene blue from Sisco Research Laboratories private limited, 
Mumbai, Haematoxylin from Merck Specialities private limited, Mumbai. 
All other chemicals and reagents used were of analytical grade. 
4.6.1.3 Preparation of DMH 
 DMH was dissolved in 1 mM EDTA just prior to use and the pH adjusted 
to 6.5 with 1 mM NaOH to ensure the stability of the carcinogen.  
4.5.1.4    Induction of colon cancer 
 The rats were given subcutaneous injections of DMH twice a week for 2 
weeks at a dose of 30 mg/kg body weight (Ilan Aroch et al., 2010). 
4.6.1.5 Preparation of standard drug (5-Fluorouracil)  
 The 5-Fluorouracil was dissolved in normal saline 
4.6.1.6   Preparation of test drug (BZI 3 nano)  
 BZI 3 nano was suspended in 5% gum acacia and each rat received a daily 
1 ml as suspension at a dose of 5 mg/kg body weight orally by oral gavage 
throughout the experimental period.  
4.6.2 Experimental Design & Treatment Schedule75 
 Group I served as normal control, which received vehicle (gum acacia 
suspension), Group II rats served as disease control were given 
subcutaneous injections of DMH twice a week for 2 consecutive weeks at 
30 mg/kg b.w., in addition to this Group III rats were given standard (5-
Fluorouracil) at a dose of 20 mg/kg body weight daily by i.p  and Group 
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IV rats were given formulated novel benzimidazole derivative nanoparticle 
(BZI 3 nano) at a dose of 5 mg/kg body weight daily for total 30 days of 
study period by oral route. 
 Group I : Vehicle control: received 1ml of normal saline ( p.o) 
 Group II : Disease control (DMH: 30 mg/Kg, s.c) 
 Group III : Disease + 5-Fluorouracil (5-FU: 20 mg/kg, i.p) 
 Group IV : Disease + BZI 3 nano (5 mg/kg, p.o) 
4.6.2.1    In vivo Methods76 
 Body weight was recorded every week, and at the starting and end of 
experimental period blood samples were taken and various blood 
parameters were recorded. At the end of the study period all the rats were 
sacrificed under ether anaesthesia and cervical dislocation. Following in 
vivo parameters were studied. 
4.6.2.2   Body Weight Changes77 
 The body weight changes of the Control, DMH, 5-FU and BZI 3 nano 
treated rats were measured throughout the study.  
 The rats were weighed at the beginning of the experiment and then 
subsequently once a week and final before sacrifice. 
4.6.2.3    Determination of Aberrant Crypt Foci (ACF)75 
 At the end of the study, rat colons were removed and flushed with 
Potassium Phosphate buffered saline (0.1M, pH 7.2) and colons were split 
open longitudinally and placed on strips of filter paper with their luminal 
surfaces open and exposed. Another strip of filter paper was placed on top 
of the luminal surface.  
 The colons were then secured and fixed in a tray containing 10% buffered 
formalin for overnight.  
 Each of the fixed colons was cut into proximal and distal portions of equal 
lengths and portion was further cut into 2cm long segments. 
 Each segment was placed in a Petri dish and stained with 0.2% methylene 
blue solution for 2min. 
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 The segment was examined using a light microscope at low magnification 
to score the total number of ACF as well as the number of crypts per focus.  
 ACF were distinguished from normal crypts by their thicker, darker-
stained, raised walls with elongated slit- like lumens and significantly 
increased distance from the lamina to basal surface off cells. 
4.6.2.4    Apoptosis Measurement in Colonic Mucosa78 
 Apoptosis evaluation was carried out in paraffin-embedded section of 
normal colonic mucosa and tumours stained with haematoxylin. At least 
20 full longitudinal crypt sections of normal mucosa of rat were scored at 
the microscope, determainining the presence of cells in each crypt with the 
following characteristics of apoptosis: cell shrinkage, loss of norma l 
contact with the adjacent cell, chromatin condensation or formation of 
round or oval nuclear fragments.  
 When clusters of more than one apoptotic fragments. When clusters of 
more than one apoptotic body were seen within the diameter of one cell, 
these bodies were considered as fragments of one apoptotic cell.  
 Tumour apoptosis was determined by scoring at least 1000 cells/rat for the 
presence of apoptotic cells that were coded as described. In tumours and 
colon mucosa, apoptosis was scored by a single observer on coded samples 
and quantified as apoptotic index (AI). 
AI=number of apoptotic cells/cells scored×100. 
4.6.2.5    Haematological Evaluation79 
 Before the initiation of the study and immediately before necropsy, blood 
samples were collected for haematological analysis in EDTA tubes with 
1.5%EDTA and differentially quantified through a coulter T890 for the 
following: leukocyte, erythrocyte, platelet counts and haemoglobin 
determination. 
 
 
 
 
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles Page 54 
 
4.5.2.6  Individual Organs Weights79 
 At the end of the study animals were sacrified and remove the all visceral 
organs like liver, kidney, colon, spleen, heart, pancreas, stomach, lungs 
were removed, weighed and relative weight of organs were calculated. 
4.6.2.7      Histopathology of Colon80,81 
 The colon were excised, flushed with saline, cut open longitudinally along 
the main axis and then again washed with saline. These colonic sections 
fixed in 10% buffered formalin for at least 24 hrs and after fixation, the 
specimens were dehydrated in ascending grades of ethanol, cleared in 
benzene and embedded in paraffin wax.  
 Blocks were made and 5µm thick sections were cut from the distal colon. 
The paraffin embedded colonic tissue sections were deparaffinised using 
xylene and ethanol.  
 These sections stained with haematoxylin and eosin and were observed 
under light microscope at 10X and 40X magnifications to investigate the 
histo architecture of colonic mucosa. 
4.6.2.8      Statistical Analysis: 
 Results were given as means ± SD of each group. Data were analyzed by 
one-way analysis of variance and any significant difference among 
treatment groups was evaluated by Dunnet‟s Test. The results were 
considered statistically significant at P < 0.05.  
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5. RESULTS AND ANALYSIS 
5.1Experiment Envisaged  
5.1.1 Benzo[d]imidazol-2-yl pyrimidine derivatives (4a-e) 
5.1.1.1   4-(1H-benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine (4a) 
The physical, chromatographic and spectral characterization of the 
synthesized compound 4-(1H-benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine 
(4a) are presented in the Table 5.01.  
The IR spectrum of compound (4a)(Figure 5.01) , the presence of 3378 
cm-1 and 3523 cm-1 bands indicate NH2 Stretching , NH Stretching , 3201 cm
-1 , 
1453 cm-1  1589 cm-1 , 1303 cm-1 and 988 cm-1band confirms the presence of 
Aromatic CH Stretching  , Aromatic C=C Stretching  , Aromatic C=N Stretching , 
Aromatic C-N Stretching and Aromatic C-H Stretching .The 1H NMR spectrum of 
the compound4-(1H-benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine (4a) 
(Figure 5.02), benzo[d]imidazol-2-yl pyrimidine derivatives  accounts for four 
protons of benzimidazole moiety resonated as multiplet between δ7.48 – 8.20ppm. 
The multipletbetweenδ7.21 – 7.47ppm was assigned to five protons of aromatic 
moiety. A chemical signal at δ5.13ppm was attributed to the –N H function of 
benzimidazole. The chemical signal at δ7.36ppm can be attributed to the 2-
pyrimidine moiety. The  13C NMR spectrum of compound 4-(1H-
benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine (4a)(Figure 5.03),the 
chemical signal at δ154.79 and 124.02 ppm can be attributed to the C2 and C6 of 
the benzimidazole moiety. A chemical signal at δ133.02 ppm was attributed to the 
C1of the benzenemoiety. The chemical signal at δ163.79 and 95.45 ppm can be 
attributed to the C2 and C5 of the Pyrimidine moiety. The mass spectrum of the 
compound 4-(1H-benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine (4a) (Figure 
5.04), exhibit an ion peak at 287.32m/z value which can be designated as the M+ 
ion peak of the compound (4a)and indicated formation of the molecule. 
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Table 5.01: Physical,chromatographic and spectral characterization of the 4-
(1H-benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine (4a) 
Compound 
code 
Compound Spectral 
Characterization 
Figure 
 
4a 
 
 
4-(1H-benzo[d]imidazol-2-
yl)-6-phenylpyrimidin-2-
amine 
Mol.Formula:C17H13N5 
Mol. Wt:287.32 
Yield: 85 % 
Mp: 146 – 149 0C 
Rf : 0.75 
NN
NH2
HN
N
 
 
IR (KBr) cm-1 : 3378 cm-
1 (NH2 Stretching ), 3523 
cm-1(NH Stretching ), 
3201 cm-1 (Aromatic CH 
Stretching ) , 1453 cm-1  
(Aromatic C=C 
Stretching ) , 1589 cm-1 
(Aromatic C=N 
Stretching ), 988 cm-1  
(Aromatic C-H Stretching 
), 1303 cm-1 (Aromatic C-
N Stretching ).  
 
 
 
Figure 
5.01 
  
1H NMR (500 MHz, 
DMSO) δ (ppm) : 7.48 – 
8.20 (m, 4H, 
Benzimidazole), 7.21 – 
7.47 (m, 5H, Ar-H ), 4.17, 
5.13 (s, 1H).  
 
Figure  
5.02 
 
13C-NMR (400 MHz, 
DMSO-d6) δ (ppm) : δ 
154.79 (Benzimidazole-
C), 124.02 
(Benzimidazole - CH), 
126.87 (Benzene - CH), 
133.02 (Benzene - C ), 
163.79 (Pyrimidine - C), 
95.45 (Pyrimidine – CH ). 
 
 
Figure  
5.03 
  
Mass : m/z: 287.32. Figure  
5.04 
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Figure 5.01: IR spectrum of the 4-(1H-benzo[d]imidazol-2-yl)-6-
phenylpyrimidin-2-amine (4a) 
 
Figure 5.02: 1H NMR spectrum of the 4-(1H-benzo[d]imidazol-2-yl)-6-
phenylpyrimidin-2-amine (4a) 
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Figure 5.03: 13C-NMR spectrum of the 4-(1H-benzo[d]imidazol-2-yl)-6-
phenylpyrimidin-2-amine (4a) 
 
Figure 5.04: Mass spectrum of the 4-(1H-benzo[d]imidazol-2-yl)-6-
phenylpyrimidin-2-amine (4a) 
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5.1.1.2   4-(1H-benzo[d]imidazol-2-yl)-6-(pyridin-4-yl)pyrimidin-2-amine (4b) 
The physical, chromatographic and spectral characterization of the 
synthesized compound 4-(1H-benzo[d]imidazol-2-yl)-6-(pyridin-4-yl)pyrimidin-
2-amine (4b)  are presented in the Table 5.02.  
The IR spectrum of compound (4b)(Figure 5.05) , bands at3412 cm-1, 3556 
cm-1confirms the presence of NH2 Stretching , NH Stretching .3140 cm
-1,1439 cm-
1 , 1589 cm-1, 915 cm-1 and 1290 cm-1 band confirms the presence of Aromatic CH 
Stretching  , Aromatic C=C Stretching  , Aromatic C=N Stretching , Aromatic C-
H Stretching , Aromatic C-N Stretching. 
The 1H NMR spectrum of the compound4-(1H-benzo[d]imidazol-2-yl)-6-
(pyridin-4-yl)pyrimidin-2-amine (4b) (Figure 5.06), benzo[d]imidazol-2-yl 
pyrimidine derivatives  accounts for four protons of benzimidazole moiety 
resonated as multiplet between δ7.71 – 8.16 ppm. The multipletbetweenδ7.08 – 
7.11 ppm was assigned to five protons of aromatic moiety. A chemical signal at 
δ5.17 ppm was attributed to the –N H function of benzimidazole. The chemical 
signal at δ4.27 ppm can be attributed to the 2-pyridine moiety.  The  13C NMR 
spectrum of compound 4-(1H-benzo[d]imidazol-2-yl)-6-(pyridin-4-yl)pyrimidin-
2-amine (4b)(Figure 5.07),the chemical signal at δ154.95 and 121.81 ppm can be 
attributed to the C2 and C6 of the benzimidazole moiety. A chemical signal at 
δ133.02 ppm was attributed to the C1of the benzenemoiety. The chemical signal at 
δ126.87, 163.79 and 95.45 ppm can be attributed to the C2 and C5 of the 
Pyrimidine moiety ,The chemical signal at δ146.04, 121.81 (Pyridine-C), 
(Pyridine-CH).  
 The mass spectrum of the compound 4-(1H-benzo[d]imidazol-2-yl)-6-
(pyridin-4-yl)pyrimidin-2-amine (4b)(Figure 5.08), exhibit an ion peak at 
288.31m/z value which can be designated as the M+ ion peak of the compound 
(4b) and indicated formation of the molecule. 
 
 
 
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles Page 60 
 
Table 5.02: Physical,chromatographic and spectral characterization of the 4-
(1H-benzo[d]imidazol-2-yl)-6-(pyridin-4-yl)pyrimidin-2-amine (4b) 
Compound 
code 
Compound Spectral 
Characterization 
Figure 
 
4b 
 
 
4-(1H-benzo[d]imidazol-2-
yl)-6-(pyridin-4-yl)pyrimidin-
2-amine 
Mol.Formula:C16H12N6 
Mol. Wt:288.31 
Yield:70 % 
Mp:152 - 156 0C 
Rf :0.65 
 
NN
NH2
N HN
N
 
IR (KBr) cm-1 : 3412 cm-
1 (NH2 Stretching ), 3556 
cm-1(NH Stretching ), 
3140 cm-1 (Aromatic CH 
Stretching ) , 1439 cm-1  
(Aromatic C=C 
Stretching ) , 1589 cm-1 
(Aromatic C=N 
Stretching ), 915 cm-1 
(Aromatic C-H Stretching 
), 1290 cm-1 (Aromatic C-
N Stretching ).  
 
 
 
Figure 
5.05 
  
1H NMR (500 MHz, 
DMSO)δ (ppm) :7.71 – 
8.16 (m, 4H, 
Benzimidazole), 7.08 – 
7.11 (m, 5H, Ar-H ), 4.27 
(s, 2H, Amino pyridine), 
5.17 (s, 1H).  
 
Figure  
5.06 
13C-NMR (400 MHz, 
DMSO-d6)δ (ppm) :δ 
154.95 (Benzimidazole-
C), 121.81 
(Benzimidazole - CH), 
126.87, 163.79 
(Pyrimidine - C), 95.45 
(Pyrimidine – CH ), 
146.04 (Pyridine-C), 
121.81(Pyridine-CH).  
 
 
Figure  
5.07 
Mass : m/z: 288.31.  
 Figure  
5.08 
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Figure 5.05: IR spectrum of the 4-(1H-benzo[d]imidazol-2-yl)-6-(pyridin-4-
yl)pyrimidin-2-amine (4b) 
 
 
Figure 5.06: 1H NMR spectrum of the 4-(1H-benzo[d]imidazol-2-yl)-6-
(pyridin-4-yl)pyrimidin-2-amine (4b) 
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Figure 5.07: 13C-NMR spectrum of the 44-(1H-benzo[d]imidazol-2-yl)-6-
(pyridin-4-yl)pyrimidin-2-amine (4b) 
 
Figure 5.08: Mass spectrum of the 4-(1H-benzo[d]imidazol-2-yl)-6-(pyridin-4-
yl)pyrimidin-2-amine (4b) 
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5.1.1.34-(1H-benzo[d]imidazol-2-yl)-6-(3-chloro-4-methoxyphenyl)pyrimidin-
2-amine (4c)  
The physical, chromatographic and spectral characterizat ion of the 
synthesized compound 4-(1H-benzo[d]imidazol-2-yl)-6-(3-chloro-4-
methoxyphenyl)pyrimidin-2-  amine(4c)  are presented in the Table 5.03.  
The IR spectrum of compound (4c)(Figure 5.09) , bands at3378 cm-1,3523 
cm-1,3201 cm-1, 1418 cm-1  confirms the presence of NH2 Stretching  , NH 
Stretching , Aromatic CH stretching,  Aromatic C= C Stretching. 1589 cm-1,875 
cm-1,1303 cm-1band confirms the presence of Aromatic C= N Stretching, 
Aromatic C-H Bending, Aromatic C-N Stretching. 1118 cm-1band confirms the 
presence of C-Cl Stretching.  
The 1H NMR spectrum of the compound4-(1H-benzo[d]imidazol-2-yl)-6-
(3-chloro-4-methoxyphenyl)pyrimidin-2-  amine (4c)  (Figure 5.10), 
benzo[d]imidazol-2-yl pyrimidine derivatives  accounts for four protons of 
benzimidazole moiety resonated as multiplet between δ7.48 – 8.26 ppm. The 
multipletbetweenδ6.94 – 7.40 ppm was assigned to five protons of aromatic 
moiety. A chemical signal at δ5.13ppm was attributed to the –N H function of 
benzimidazole. The chemical signal at δ4.09 ppm can be attributed to the amino 
pyridine moiety.  The multipletbetweenδ3.46- 3.62  ppm was assigned to six 
protons of 2 –OCH3 moiety. The  
13C NMR spectrum of compound (4c) (Figure 
5.11),the chemical signal at δ154.04 and 124.02 ppm can be attributed to the C2 
and C6 of the benzimidazole moiety. A chemical signal at δ126.87 ppm was 
attributed to the C1of the benzenemoiety. The chemical signal at δ163.95and 
93.45 ppm can be attributed to the C2 and C5 of the Pyrimidine moiety. The mass 
spectrum of the compound 4-(1H-benzo[d]imidazol-2-yl)-6-(3-chloro-4-
methoxyphenyl)pyrimidin-2-  amine(4c)(Figure 5.12), exhibit an ion peak at 
351.79m/z value which can be designated as the M+ ion peak of the compound 4c 
and indicated formation of the molecule. 
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Table 5.03: Physical,chromatographic and spectral characterization of the 4-
(1H-benzo[d]imidazol-2-yl)-6-(3-chloro-4-methoxyphenyl)pyrimidin-2-  
amine (4c) 
Compound 
code 
Compound Spectral Characterization Figure 
 
4c 
 
 
4-(1H-benzo[d]imidazol-2-yl)-6-
(3-chloro-4-
methoxyphenyl)pyrimidin-2-
amine 
Mol.Formula:C18H14ClN5O 
Mol. Wt:351.79 
Yield: 80% 
Mp: 213- 216 0C 
Rf :0.40 
NN
NH2
O
Cl
HN
N
 
 
 
 
 
IR (KBr) cm-1: 3378 cm-1 
(NH2 Stretching ) , 3523 cm
-
1 (NH Stretching) , 3201 cm-
1 (Aromatic CH stretching),  
1418 cm-1   (Aromatic C= C 
Stretching) , 1589 cm-1 
(Aromatic C= N 
Stretching), 875 cm-1 
(Aromatic C-H Bending), 
1303 cm-1 (Aromatic C-N 
Stretching), 1118 cm-1  (C-
Cl Stretching).  
 
 
 
Figure 
5.09 
1H NMR (500 MHz, 
DMSO) δ (ppm): 7.48 – 
8.26 (m, 4H , 
Benzimidazole ), 6.94 – 
7.40 (m, 4H , Ar-H ),  4.09 
(s, 2H, Amino pyridine ), 
5.13 (s, 1H, ), 3.46- 3.62 (m, 
6H, 2 –OCH3).  
 
Figure  
5.10 
  
13C-NMR (400 MHz, 
DMSO-d6) δ  in ppm : δ 
154.04 (Benzimidazole – C 
) , 124.02 (Benzimidazole – 
CH ), 126.87 (Benzene – 
CH ), 133.02 (Benzene – C 
) , 163.95 (Pyrimidine–
C),93.45 (Pyrimidine–CH)  
 
 
Figure  
5.11 
Mass: m/z: 351.79 
 
Figure  
5.12 
 
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles Page 65 
 
 
Figure 5.09: IR spectrum of the 4-(1H-benzo[d]imidazol-2-yl)-6-(3-chloro-4-
methoxyphenyl)pyrimidin-2-amine (4c) 
 
Figure 5.10: 1H NMR spectrum of the 4-(1H-benzo[d]imidazol-2-yl)-6-(3-
chloro-4-methoxyphenyl)pyrimidin-2-amine (4c) 
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Figure 5.11: 13C-NMR spectrum of the 4-(1H-benzo[d]imidazol-2-yl)-6-(3-
chloro-4-methoxyphenyl)pyrimidin-2-amine (4c) 
 
Figure 5.12: Mass spectrum of the 4-(1H-benzo[d]imidazol-2-yl)-6-(3-chloro-
4-methoxyphenyl)pyrimidin-2-amine (4c) 
 
5.1.1.44-(1H-benzo[d]imidazol-2-yl)-6-(3,4-dimethoxyphenyl)pyrimidin-2-
amine(4d) 
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The physical, chromatographic and spectral characterization of the 
synthesized compound 4-(1H-benzo[d]imidazol-2-yl)-6-(3,4-
dimethoxyphenyl)pyrimidin-2-amine(4d)  are presented in the Table 5.04.  
The IR spectrum of compound (4d)(Figure 5.13) , bands at3484 cm-1 ,3398 
cm-1, 3284 cm-1confirms the presence of NH2 Stretching  , NH Stretching , 
Aromatic CH stretching.1585 cm-1   , 1589 cm-1, 879 cm-1, 1383 cm-1band 
confirms the presence ofAromatic C= C Stretching, Aromatic C= N Stretching , 
Aromatic C-H Bending, Aromatic C-N Stretching. 
The 1H NMR spectrum of the compound4-(1H-benzo[d]imidazol-2-yl)-6-
(3,4-dimethoxyphenyl)pyrimidin-2-amine (4d) (Figure 5.14), benzo[d]imidazol-2-
yl pyrimidine derivatives  accounts for four protons of benzimidazole moiety 
resonated as multiplet between δ7.21 – 7.47 ppm. The multipletbetweenδ7.48 – 
8.20 ppm was assigned to five protons of aromatic moiety. A chemical signal at 
δ5.13ppm was attributed to the –N H function of benzimidazole. The chemical 
signal at δ4.17 ppm can be attributed to the aminopyridine moiety.  
The13C NMR spectrum of compound 4-(1H-benzo[d]imidazol-2-yl)-6-
(3,4-dimethoxyphenyl)pyrimidin-2-amine (4d)(Figure 5.15),the chemical signal at 
δ154.81and 115.27ppm can be attributed to the C2 and C6 of the benzimidazole 
moiety. A chemical signal at δ133.02 ppm was attributed to the C1of the 
benzenemoiety. The chemical signal at δ163.81and 95.62ppm can be attributed to 
the C2 and C5 of the Pyrimidine moiety. 
The mass spectrum of the compound 4-(1H-benzo[d]imidazol-2-yl)-6-
(3,4-dimethoxyphenyl)pyrimidin-2-amine (4d)(Figure 5.16), exhibit an ion peak 
at 347.37m/z value which can be designated as the M+ ion peak of the compound 
4d and indicated formation of the molecule. 
 
 
Table 5.04: Physical,chromatographic and spectral characterization of the 4-
(1H-benzo[d]imidazol-2-yl)-6-(3,4-dimethoxyphenyl)pyrimidin-2-amine(4d) 
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Compound 
code 
Compound Spectral Characterization Figure 
 
4d 
 
 
4-(1H-benzo[d]imidazol-2-yl)-6-
(3,4-
dimethoxyphenyl)pyrimidin-2-
amine 
Mol.Formula:C19H17N5O2 
Mol. Wt:347.37 
Yield: 66% 
Mp: 138 -140 0C 
Rf :0.80 
 
NN
NH2
O
O
HN
N
 
 
IR (KBr) cm-1: 3484 cm-1 
(NH2 Stretching ) , 3398 cm
-1  
(NH Stretching) , 3284 cm-1 
(Aromatic CH stretching),  
1585 cm-1  (Aromatic C= C 
Stretching) , 1589 cm-1 
(Aromatic C= N Stretching), 
879 cm-1 (Aromatic C-H 
Bending), 1383 cm-1 
(Aromatic C-N Stretching). 
 
 
 
Figure 
5.13 
  
1H NMR (500 MHz, DMSO) 
δ (ppm): 7.21 – 7.47 (m, 4H , 
Benzimidazole ), 7.48 – 8.20 
(m, 5H , Ar-H ),  4.17 (s, 2H, 
Amino pyridine ), 5.13 (s, 1H, 
). 
 
Figure 
5.14 
 
13C-NMR (400 MHz, 
DMSO-d6) δ  in ppm : δ 
154.81 (Benzimidazole – C ) , 
115.27 (Benzimidazole – CH 
), 163.81 (Pyrimidine–
C),95.62 (Pyrimidine–CH) 
 
 
 
Figure 
5.15 
Mass: m/z: 347.37.  
 Figure 
5.16 
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Figure 5.13: IR spectrum of the 4-(1H-benzo[d]imidazol-2-yl)-6-(3,4-
dimethoxyphenyl)pyrimidin-2-amine (4d)
 
Figure 5.14: 1H NMR spectrum of the 4-(1H-benzo[d]imidazol-2-yl)-6-(3,4-
dimethoxyphenyl)pyrimidin-2-amine (4d) 
 
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles Page 70 
 
 
Figure 5.15: 13C-NMR spectrum of the 4-(1H-benzo[d]imidazol-2-yl)-6-(3,4-
dimethoxyphenyl)pyrimidin-2-amine (4d) 
 
Figure 5.16: Mass spectrum of the 4-(1H-benzo[d]imidazol-2-yl)-6-(3,4-
dimethoxyphenyl)pyrimidin-2-amine (4d) 
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5.1.1.54-(anthracen-10-yl)-6-(1H-benzo[d]imidazol-2-yl)pyrimidin-2-amine 
(4e) 
The physical, chromatographic and spectral characterization of the 
synthesized compound 4-(anthracen-10-yl)-6-(1H-benzo[d]imidazol-2-
yl)pyrimidin-2-amine (4e)  are presented in the Table 5.05.  
The IR spectrum of compound (4e)(Figure 5.17) , bands at 3313 cm-1, 
3370 cm-1, 3100 cm-1confirms the presence of NH2 Stretching  , NH Stretching , 
Aromatic CH stretching. 1428 cm-1  , 1534  cm-1, 860 cm-1, 1370 cm-1band 
confirms the presence of Aromatic C= C Stretching, Aromatic C= N Stretching , 
Aromatic C-H Bending, Aromatic C-N Stretching. 1118 cm-1The band confirms 
the presence of C-Cl Stretching. 
The 1H NMR spectrum of the compound4-(anthracen-10-yl)-6-(1H-
benzo[d]imidazol-2-yl)pyrimidin-2-amine (4e) (Figure 5.18), benzo[d]imidazol-2-
yl pyrimidine derivatives  accounts for four protons of benzimidazole moiety 
resonated as multiplet between δ7.46 – 7.87ppm. The multiplet between  δ7.25 – 
7.49 ppm was assigned to ten protons of aromatic moiety. A chemical signal at 
δ5.10ppm was attributed to the –N H function of benzimidazole. The chemical 
signal at δ4.17ppm can be attributed to the aminopyridine moiety.  
 The  13C NMR spectrum of compound 4-(anthracen-10-yl)-6-(1H-
benzo[d]imidazol-2-yl)pyrimidin-2-amine (4e)(Figure 5.19),the chemical signal at 
δ154.44and 123.02 ppm can be attributed to the C2 and C6 of the benzimidazole 
moiety. A chemical signal at δ133.02 ppm was attributed to the C1of the 
benzenemoiety. The chemical signal at δ163.32and 95.70ppm can be attributed to 
the C2 and C5 of the Pyrimidine moiety. 
 The mass spectrum of the compound 4-(anthracen-10-yl)-6-(1H-
benzo[d]imidazol-2-yl)pyrimidin-2-amine (4e)(Figure 5.20), exhibit an ion peak 
at 387.15m/z value which can be designated as the M+ ion peak of the compound 
4e and indicated formation of the molecule. 
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Table 5.05: Physical,chromatographic and spectral characterization of the 4-
(anthracen-10-yl)-6-(1H-benzo[d]imidazol-2-yl)pyrimidin-2-amine (4e) 
Compound 
code 
Compound Spectral Characterization Figure 
 
4e 
 
 
4-(anthracen-10-yl)-6-(1H-
benzo[d]imidazol-2-
yl)pyrimidin-2-amine 
Mol.Formula:C25H17N5 
Mol. Wt:387.15 
Yield: 70%  
Mp: 188-190 0C 
Rf : 0.70 
N
N
H2N
N
H
N
 
 
IR (KBr) cm-1: 3313 cm-1 
(NH2 Stretching ) , 3370 cm
-1  
(NH Stretching) , 3100 cm-1 
(Aromatic CH stretching),  
1428 cm-1  (Aromatic C= C 
Stretching) , 1534  cm-1  
(Aromatic C= N Stretching), 
860 cm-1 (Aromatic C-H 
Bending), 1370 cm-1 
(Aromatic C-N Stretching), 
1118 cm-1  (C-Cl Stretching). 
 
 
 
Figure 
5.17 
1H NMR (500 MHz, DMSO) 
δ (ppm): 7.46 – 7.87  (m, 4H , 
Benzimidazole ), 7.25 – 7.49  
(m, 10H , Ar-H ),  4.17 (s, 2H, 
Amino pyridine ), 5.10 (s, 1H, 
). 
 
Figure 
5.18 
 
13C-NMR (400 MHz, 
DMSO-d6) δ  in ppm : δ 
154.44 (Benzimidazole – C ) , 
123.02 (Benzimidazole – CH 
), 163.32 (Pyrimidine–
C),95.70 (Pyrimidine–CH).  
 
 
Figure 
5.19 
 
Mass: m/z: 387.15 
 
 
Figure 
5.20 
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Figure 5.17: IR spectrum of the 4-(anthracen-10-yl)-6-(1H-benzo[d]imidazol-
2-yl)pyrimidin-2-amine (4e) 
 
Figure 5.18: 1H NMR spectrum of the 4-(anthracen-10-yl)-6-(1H-
benzo[d]imidazol-2-yl)pyrimidin-2-amine (4e) 
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Figure 5.19: 13C-NMR spectrum of the 4-(anthracen-10-yl)-6-(1H-
benzo[d]imidazol-2-yl)pyrimidin-2-amine (4e) 
 
Figure 5.20: Mass spectrum of the 4-(anthracen-10-yl)-6-(1H-
benzo[d]imidazol-2-yl)pyrimidin-2-amine (4e) 
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5.1.2  Synthesis of 1-methyl-benzo[d]imidazol-2-yl pyrimidine derivatives 
(4f-j) 
5.1.2.1    4-(1-methyl-1H-benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine 
(4f) 
The physical, chromatographic and spectral characterization of the 
synthesized compound 4-(1-methyl-1H-benzo[d]imidazol-2-yl)-6-
phenylpyrimidin-2-amine (4f) are presented in the Table 5.06.  
The IR spectrum of compound (4f)(Figure 5.22), bands at 3378 cm-1, 3523 
cm-1  , 3201 cm-1confirms the presence of NH2 Stretching  , NH Stretching , 
Aromatic CH stretching. 1453 cm-1 , 1589  cm-1, 988 cm-1, 1303 cm-1band 
confirms the presence of Aromatic C= C Stretching, Aromatic C= N Stretching , 
Aromatic C-H Bending, Aromatic C-N Stretching.  
The 1H NMR spectrum of the compound4-(1-methyl-1H-
benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine (4f) (Figure 5.22), 
benzo[d]imidazol-2-yl pyrimidine derivatives  accounts for four protons of 
benzimidazole moiety resonated as multiplet between δ7.48 – 8.21 ppm. The 
multiplet between  δ7.19 – 7.47 ppm was assigned to five protons of aromatic 
moiety. The chemical signal at δ 4.17 ppm can be attributed to the aminopyridine 
moiety.  The  13C NMR spectrum of compound 4-(1-methyl-1H-
benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine (4f)(Figure 5.23),the 
chemical signal at δ154.79 and 123.02 ppm can be attributed to the C2 and C6 of 
the benzimidazole moiety. A chemical signal at δ133.02 ppm was attributed to the 
C1of the benzenemoiety. The chemical signal at δ163.79and 95.17ppm can be 
attributed to the C2 and C5 of the Pyrimidine moiety. 
The mass spectrum of the compound 4-(1-methyl-1H-benzo[d]imidazol-2-
yl)-6-phenylpyrimidin-2-amine (4f)(Figure 5.24), exhibit an ion peak at 
301.13m/z value which can be designated as the M+ ion peak of the compound 4f 
and indicated formation of the molecule. 
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Table 5.06: Physical,chromatographic and spectral characterization of the 4-
(1-methyl-1H-benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine (4f) 
Compound 
code 
Compound Spectral Characterization Figure 
 
4f 
 
 
4-(1-methyl-1H-
benzo[d]imidazol-2-yl)-6-
phenylpyrimidin-2-amine 
Mol.Formula: C18H15N5 
Mol. Wt: 301.13 
Yield: 68% 
Mp: 149-152 0C 
Rf : 0.75 
 
NN
NH2
N
N
 
 
IR (KBr) cm-1: 3378 cm-1  
(NH2 Stretching ) , 3523 
cm-1 (NH Stretching) , 3201 
cm-1 (Aromatic CH 
stretching) , 1453 cm-1  
(Aromatic C= C Stretching) 
, 1589  cm-1 (Aromatic C= 
N Stretching), 988 cm-1 
(Aromatic C-H Bending), 
1303 cm-1 (Aromatic C-N 
Stretching).  
 
 
 
Figure 
5.21 
1H NMR (500 MHz, 
DMSO) δ (ppm):  7.48 –  
8.21  (m, 4H , 
Benzimidazole ), 7.19 –  
7.47  (m, 5H , Ar-H ),  4.17 
(s, 2H, Amino pyridine ), 
4.90 (s, 1H, ).  
 
 
 
Figure  
5.22 
13C-NMR(400 MHz, 
DMSO-d6) δ  in ppm : δ 
154.79 (Benzimidazole – C 
) , 123.02 (Benzimidazole –  
CH ), 119.87(Benzene – CH 
), 133.02 (Benzene – C ) , 
163.79 (Pyrimidine–
C),95.17 (Pyrimidine–CH), 
32.04 (Aliphatic –CH3) 
78.89 (Aliphatic –CH). 
 
 
 
Figure  
   5.23 
Mass: m/z: 301.13 
 
Figure  
5.24 
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Figure 5.21: IR spectrum of the 4-(1-methyl-1H-benzo[d]imidazol-2-yl)-6-
phenylpyrimidin-2-amine (4f) 
 
Figure 5.22: 1H NMR spectrum of the 4-(1-methyl-1H-benzo[d]imidazol-2-
yl)-6-phenylpyrimidin-2-amine (4f) 
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Figure 5.23: 13C-NMR spectrum of the 4-(1-methyl-1H-benzo[d]imidazol-2-
yl)-6-phenylpyrimidin-2-amine (4f) 
 
Figure 5.24: Mass spectrum of the 4-(1-methyl-1H-benzo[d]imidazol-2-yl)-6-
phenylpyrimidin-2-amine (4f) 
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5.1.2.2 4-(1-methyl-1H-benzo[d]imidazol-2-yl)-6-(pyridin-4-yl)pyrimidin-2-
amine (4g) 
 The physical, chromatographic and spectral characterization of the 
synthesized compound 4-(1-methyl-1H-benzo[d]imidazol-2-yl)-6-
phenylpyrimidin-2-amine(4g)are presented in the Table 5.07.  
The IR spectrum of compound (4g)(Figure 5.26), bands at 3410 cm-1, 3556 
cm-1  , 3140 cm-1confirms the presence of NH2 Stretching  , NH Stretching , 
Aromatic CH stretching. 1439  cm-1  , 1589 cm-1, 915 cm-1, 1290 cm-1band 
confirms the presence of Aromatic C= C Stretching, Aromatic C= N Stretching , 
Aromatic C-H Bending, Aromatic C-N Stretching.  
The 1H NMR spectrum of the compound4-(1-methyl-1H-
benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine(4g) (Figure 5.26), 
benzo[d]imidazol-2-yl pyrimidine derivatives  accounts for four protons of 
benzimidazole moiety resonated as multiplet between δ7.66 – 7.71 ppm. The 
multiplet between  δ7.08 – 7.11 ppm was assigned to five protons of aromatic 
moiety. The chemical signal at δ 4.27 ppm can be attributed to the aminopyridine 
moiety. The  13C NMR spectrum of compound 4-(1-methyl-1H-
benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine(4g)(Figure 5.27),the chemical 
signal at δ154.90 and 123.71ppm can be attributed to the C2 and C6 of the 
benzimidazole moiety. A chemical signal at δ133.02 ppm was attributed to the 
C1of the benzenemoiety. The chemical signal at δ163.36and 95.17ppm can be 
attributed to the C2 and C5 of the Pyrimidine moiety.The chemical signal at δ31.04 
ppm can be attributed to Aliphatic –CH3.The mass spectrum of the compound 4-
(1-methyl-1H-benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine(4g)(Figure 
5.28), exhibit an ion peak at 302.13m/z value which can be designated as the M+ 
ion peak of the compound 4g and indicated formation of the molecule. 
Table 5.07: Physical,chromatographic and spectral characterization of the 4-
(1-methyl-1H-benzo[d]imidazol-2-yl)-6-(pyridin-4-yl)pyrimidin-2-amine (4g) 
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Compound 
code 
Compound Spectral 
Characterization 
Figure 
 
4g 
 
 
4-(1-methyl-1H-
benzo[d]imidazol-2-yl)-6-
(pyridin-4-yl)pyrimidin-2-amine 
Mol.Formula:C17H14N6 
Mol. Wt:302.13 
Yield: 75% 
Mp: 152-154 0C 
Rf : 0.65 
NN
NH2
N N
N
 
 
IR (KBr) cm-1: 3410 cm-1 
(NH2 Stretching ) , 3556 
cm-1 (NH Stretching) , 
3140 cm-1 (Aromatic CH 
stretching), 1439  cm-1 
(Aromatic C= C 
Stretching) , 1589 cm-1 
(Aromatic C= N 
Stretching), 915 cm-1 
(Aromatic C-H Bending), 
1290 cm-1 (Aromatic C-N 
Stretching).  
 
 
 
Figure 
5.25 
 
1H NMR (500 MHz, 
DMSO) δ (ppm): 7.66 – 
7.71 (m, 4H , 
Benzimidazole ), 7.08 – 
7.11 (m, 5H , Ar-H ),  
4.27 (s, 2H, Amino 
pyridine ), 5.17 (s, 1H, ).  
 
 
Figure  
5.26 
 
13C-NMR(400 MHz, 
DMSO-d6) δ  in ppm : δ 
154.90 (Benzimidazole – 
C ) , 123.71 
(Benzimidazole – CH ), 
163.36 (Pyrimidine–
C),95.17 (Pyrimidine–
CH) 31.04 (Aliphatic –
CH3).Mass: m/z: 302.13
 
 
 
Figure  
5.27 
Mass: m/z: 302.13 
 
Figure  
5.28 
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Figure 5.25: IR spectrum of the 4-(1-methyl-1H-benzo[d]imidazol-2-yl)-6-
(pyridin-4-yl)pyrimidin-2-amine (4g) 
 
Figure 5.26: 1H NMR spectrum of the 4-(1-methyl-1H-benzo[d]imidazol-2-
yl)-6-(pyridin-4-yl)pyrimidin-2-amine (4g) 
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Figure 5.27: 13C-NMR spectrum of the 4-(1-methyl-1H-benzo[d]imidazol-2-
yl)-6-(pyridin-4-yl)pyrimidin-2-amine (4g) 
 
Figure 5.28: Mass spectrum of the 4-(1-methyl-1H-benzo[d]imidazol-2-yl)-6-
(pyridin-4-yl)pyrimidin-2-amine (4g) 
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5.1.2.3  4-(3-chloro-4-methoxyphenyl)-6-(1-methyl-1H-
benzo[d]imidazol-2-yl)pyrimidin-2-amine (4h) 
The physical, chromatographic and spectral characterization of the 
synthesized compound 4-(3-chloro-4-methoxyphenyl)-6-(1-methyl-1H-
benzo[d]imidazol-2-yl)pyrimidin-2-amine(4h)are presented in the Table 5.08.  
The IR spectrum of compound (4h)(Figure 5.29), bands at 3484 cm-1  , 
3398 cm-1, 3284 cm-1, confirms the presence of NH2 Stretching  , NH Stretching , 
Aromatic CH stretching. 1585 cm-1   , 1589 cm-1 , 879 cm-1, 1383 cm-1band 
confirms the presence of Aromatic C= C Stretching, Aromatic C= N Stretching , 
Aromatic C-H Bending, Aromatic C-N Stretching. The 1H NMR spectrum of the 
compound4-(3-chloro-4-methoxyphenyl)-6-(1-methyl-1H-benzo[d]imidazol-2-
yl)pyrimidin-2-amine(4h)  (Figure 5.30), benzo[d]imidazol-2-yl pyrimidine 
derivatives  accounts for four protons of benzimidazole moiety resonated as 
multiplet between δ7.47- 8.20 ppm. The multiplet between  δ 7.48 – 8.26  ppm 
was assigned to five protons of aromatic moiety. The chemical signal at δ 4.76 
ppm can be attributed to the aminopyridine moiety.The  13C NMR spectrum of 
compound 4-(3-chloro-4-methoxyphenyl)-6-(1-methyl-1H-benzo[d]imidazol-2-
yl)pyrimidin-2-amine(4h)  (Figure 5.31),the chemical signal at δ154.04 and 
124.02ppm can be attributed to the C2 and C6 of the benzimidazole moiety. A 
chemical signal at δ133.02 ppm was attributed to the C1of the benzenemoiety. The 
chemical signal at δ163.95and 93.45ppm can be attributed to the C2 and C5 of the 
Pyrimidine moiety.The chemical signal at δ31.89 ppm can be attributed to 
Aliphatic –CH3.The mass spectrum of the compound 4-(3-chloro-4-
methoxyphenyl)-6-(1-methyl-1H-benzo[d]imidazol-2-yl)pyrimidin-2-
amine(4h)(Figure 5.32), exhibit an ion peak at 365.15m/z value which can be 
designated as the M+ ion peak of the compound 4h and indicated formation of the 
molecule. 
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Table 5.08: Physical,chromatographic and spectral characterization of the 4-
(3-chloro-4-methoxyphenyl)-6-(1-methyl-1H-benzo[d]imidazol-2-
yl)pyrimidin-2-amine (4h) 
Compound 
code 
Compound Spectral Characterization Figure 
 
4h 
 
4-(3-chloro-4-methoxyphenyl)-
6-(1-methyl-1H-
benzo[d]imidazol-2-
yl)pyrimidin-2-amine 
Mol.Formula: C19H16ClN5O 
Mol. Wt: 365.1 
Yield: 80% 
Mp: 202-204 0C 
Rf : 0.82 
 
NN
NH2
N
N
O
Cl
 
IR (KBr) cm-1: 3484 cm-1  
(NH2 Stretching ) , 3398 
cm-1 (NH Stretching) , 3284 
cm-1 (Aromatic CH 
stretching),  1585 cm-1  
(Aromatic C= C Stretching) 
, 1589 cm-1 (Aromatic C= N 
Stretching), 879 cm-1 
(Aromatic C-H Bending), 
1383 cm-1 (Aromatic C-N 
Stretching).  
 
 
 
Figure 
5.29 
1H NMR (500 MHz, 
DMSO) δ (ppm): 7.47- 
8.20 (m, 4H , 
Benzimidazole ), 7.48 –  
8.26 (m, 5H , Ar-H ),  4.76 
(s, 2H, Amino pyridine ), 
5.13 (s, 1H,). 
Figure  
5.30 
 
13C-NMR(400 MHz, 
DMSO-d6) δ  in ppm : δ 
154.04 (Benzimidazole – C 
) , 124.02 (Benzimidazole – 
CH ), 126.87 (Benzene –  
CH ), 133.02 (Benzene – C 
) , 163.95 (Pyrimidine–
C),93.45 (Pyrimidine–CH), 
55.71 (Aliphatic –CH3).  
31.89 (Aliphatic –CH3). 
 
 
Figure  
5.31 
Mass: m/z: 365.15. 
 
Figure  
5.32 
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Figure 5.29: IR spectrum of the 4-(3-chloro-4-methoxyphenyl)-6-(1-methyl-
1H-benzo[d]imidazol-2-yl)pyrimidin-2-amine (4h) 
 
Figure 5.30: 1H NMR spectrum of the 4-(3-chloro-4-methoxyphenyl)-6-(1-
methyl-1H-benzo[d]imidazol-2-yl)pyrimidin-2-amine (4h) 
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Figure 5.31: 13C-NMR spectrum of the 4-(3-chloro-4-methoxyphenyl)-6-(1-
methyl-1H-benzo[d]imidazol-2-yl)pyrimidin-2-amine (4h) 
 
Figure 5.32: Mass spectrum of the 4-(3-chloro-4-methoxyphenyl)-6-(1-
methyl-1H-benzo[d]imidazol-2-yl)pyrimidin-2-amine (4h) 
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5.1.2.4   4-(3,4-dimethoxyphenyl)-6-(1-methyl-1H-benzo[d]imidazol-2-
yl)pyrimidin-2-amine (4i) 
The physical, chromatographic and spectral characterization of the 
synthesized compound 4-(3,4-dimethoxyphenyl)-6-(1-methyl-1H-
benzo[d]imidazol-2-yl)pyrimidin-2-amine(4i)are presented in the Table 5.09.  
The IR spectrum of compound (4i)(Figure 5.33), bands at 3378 cm-1, 3523 
cm-1, 3201 cm-1confirms the presence of NH2 Stretching  , NH Stretching , 
Aromatic CH stretching. 1418 cm-1   , 1589 cm-1, 875 cm-1, 1303 cm-1band 
confirms the presence of Aromatic C= C Stretching, Aromatic C= N Stretching , 
Aromatic C-H Bending, Aromatic C-N Stretching. The 1H NMR spectrum of the 
compound4-(3,4-dimethoxyphenyl)-6-(1-methyl-1H-benzo[d]imidazol-2-
yl)pyrimidin-2-amine(4i) (Figure 5.34), benzo[d]imidazol-2-yl pyrimidine 
derivatives  accounts for four protons of benzimidazole moiety resonated as 
multiplet between δ 7.65 – 8.19  ppm. The multiplet between  δ 7.39 – 7.54 ppm 
was assigned to five protons of aromatic moiety. The chemical signal at δ 4.46 
ppm can be attributed to the aminopyridine moiety. The multiplet between  δ 3.63- 
3.72 ppm was assigned to six protons of methoxy (2 –OCH3 )moiety.The  
13C 
NMR spectrum of compound 4-(3,4-dimethoxyphenyl)-6-(1-methyl-1H-
benzo[d]imidazol-2-yl)pyrimidin-2-amine(4i)   (Figure 5.35),the chemical signal 
at δ154.81 and 115.27ppm can be attributed to the C2 and C6 of the benzimidazole 
moiety. The chemical signal at δ163.81and 93.62ppm can be attributed to the C2 
and C5 of the Pyrimidine moiety.A chemical signal at δ56.71ppm was attributed to 
the C1of the Aliphatic –CH3moiety.The chemical signal at δ31.89 ppm can be 
attributed to Aliphatic –CH3.The mass spectrum of the compound 4-(3,4-
dimethoxyphenyl)-6-(1-methyl-1H-benzo[d]imidazol-2-yl)pyrimidin-2-amine(4i) 
(Figure 5.36), exhibit an ion peak at 361.15m/z value which can be designated as 
the M+ ion peak of the compound 4i and indicated formation of the molecule. 
 
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles Page 88 
 
Table 5.09: Physical,chromatographic and spectral characterization of the 4-
(3,4-dimethoxyphenyl)-6-(1-methyl-1H-benzo[d]imidazol-2-yl)pyrimidin-2-
amine (4i) 
Compound 
code 
Compound Spectral 
Characterization 
Figure 
 
4i 
 
4-(3,4-dimethoxyphenyl)-6-(1-
methyl-1H-benzo[d]imidazol-2-
yl)pyrimidin-2-amine 
Mol.Formula: C20H19N5O2 
Mol. Wt: 361.15 
Yield: 70% 
Mp: 200-202 0C 
Rf : 0.68 
NN
NH2
N
N
O
O
 
IR (KBr) cm-1: 3378 cm-1  
(NH2 Stretching ) , 3523 
cm-1 (NH Stretching) , 
3201 cm-1 (Aromatic CH 
stretching),  1418 cm-1  
(Aromatic C= C 
Stretching) , 1589 cm-1 
(Aromatic C= N 
Stretching), 875 cm-1 
(Aromatic C-H Bending), 
1303 cm-1 (Aromatic C-N 
Stretching), 1118 cm-1  
(C-Cl Stretching).  
 
 
 
Figure 
5.33 
1H NMR (500 MHz, 
DMSO) δ (ppm): 7.65 –  
8.19 (m, 4H , 
Benzimidazole ), 7.39 – 
7.54 (m, 4H , Ar-H ), 4.46 
(s, 2H, Amino pyridine ), 
5.10 (s, 1H, ), 3.63- 3.72 
(m, 6H, 2 –OCH3). 
 
 
Figure  
5.34 
13C-NMR(400 MHz, 
DMSO-d6) δ  in ppm : δ 
154.81 (Benzimidazole – 
C ) , 115.27 
(Benzimidazole – CH ), 
163.81 (Pyrimidine–
C),95.62 (Pyrimidine–
CH), 56.71 (Aliphatic –
CH3). 31.89 (Aliphatic –
CH3). 
 
 
 
Figure  
5.35 
Mass: m/z: 361.15 
 
Figure  
5.36 
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Figure 5.33: IR spectrum of the 4-(3,4-dimethoxyphenyl)-6-(1-methyl-1H-
benzo[d]imidazol-2-yl)pyrimidin-2-amine (4i) 
 
Figure 5.34: 1H NMR spectrum of the 4-(3,4-dimethoxyphenyl)-6-(1-methyl-
1H-benzo[d]imidazol-2-yl)pyrimidin-2-amine (4i) 
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Figure 5.35: 13C-NMR spectrum of the 4-(3,4-dimethoxyphenyl)-6-(1-methyl-
1H-benzo[d]imidazol-2-yl)pyrimidin-2-amine (4i) 
 
Figure 5.36: Mass spectrum of the 4-(3,4-dimethoxyphenyl)-6-(1-methyl-1H-
benzo[d]imidazol-2-yl)pyrimidin-2-amine (4i) 
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5.1.2.5  4-(anthracen-10-yl)-6-(1-methyl-1H-benzo[d]imidazol-2-
yl)pyrimidin-2-amine (4j) 
The physical, chromatographic and spectral characterization of the 
synthesized compound 4-(anthracen-10-yl)-6-(1-methyl-1H-benzo[d]imidazol-2-
yl)pyrimidin-2-amine (4j)are presented in the Table 5.10.  
The IR spectrum of compound (4j)(Figure 5.37), bands at 3313 cm-1, 3375 
cm-1, 3099 cm-1confirms the presence of NH2 Stretching  , NH Stretching , 
Aromatic CH stretching. 1428 cm-1   , 1534  cm-1, 860 cm-1, 1370 cm-1band 
confirms the presence of Aromatic C= C Stretching, Aromatic C= N Stretching , 
Aromatic C-H Bending, Aromatic C-N Stretching. The IR spectrum of 
synthesized compound (4i) was shown in (Figure 5.37).The 1H NMR spectrum of 
the compound4-(anthracen-10-yl)-6-(1-methyl-1H-benzo[d]imidazol-2-
yl)pyrimidin-2-amine (4j) (Figure 5.38), benzo[d]imidazol-2-yl pyrimidine 
derivatives  accounts for four protons of benzimidazole moiety resonated as 
multiplet between δ 7.46 – 7.87  ppm. The multiplet between  δ 7.25 – 7.49 ppm 
was assigned to ten protons of aromatic moiety. The chemical signal at δ 4.1ppm 
can be attributed to the aminopyridine moiety. The  13C NMR spectrum of 
compound 4-(anthracen-10-yl)-6-(1-methyl-1H-benzo[d]imidazol-2-yl)pyrimidin-
2-amine (4j) (Figure 5.39),the chemical signal at δ154.44 and 123.02ppm can be 
attributed to the C2 and C6 of the benzimidazole moiety. The chemical signal at 
δ163.32and 95.70ppm can be attributed to the C2 and C5 of the Pyrimidine 
moiety.The chemical signal at δ31.90 ppm can be attributed to Aliphatic –CH3. 
The mass spectrum of the compound 4-(anthracen-10-yl)-6-(1-methyl-1H-
benzo[d]imidazol-2-yl)pyrimidin-2-amine (4j) (Figure 5.40), exhibit an ion peak 
at 401.46m/z value which can be designated as the M+ ion peak of the compound 
4j and indicated formation of the molecule. 
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Table 5.10: Physical,chromatographic and spectral characterization of the 4-
(anthracen-10-yl)-6-(1-methyl-1H-benzo[d]imidazol-2-yl)pyrimidin-2-amine 
(4j) 
Compound 
code 
Compound Spectral Characterization Figure 
 
4j 
 
4-(anthracen-10-yl)-6-(1-
methyl-1H-benzo[d]imidazol-
2-yl)pyrimidin-2-amine 
Mol.Formula:C26H19N5 
Mol. Wt: 401.46 
Yield: 70% 
Mp: 205- 208 0C 
Rf : 0.60 
N N
NH2
N
N
 
IR (KBr) cm-1: 3313 cm-1  
(NH2 Stretching ) , 3375 
cm-1 (NH Stretching) , 3099 
cm-1 (Aromatic CH 
stretching),  1428 cm-1  
(Aromatic C= C Stretching) 
, 1534  cm-1 (Aromatic C= 
N Stretching), 860 cm-1 
(Aromatic C-H Bending), 
1370 cm-1 (Aromatic C-N 
Stretching), 1118 cm-1  (C-
Cl Stretching).. 
 
 
 
Figure 
5.37 
1H NMR (500 MHz, 
DMSO) δ (ppm): 7.46 –  
7.87  (m, 4H , 
Benzimidazole ), 7.25 –  
7.49  (m, 10H , Ar-H ),  
4.17 (s, 2H, Amino pyridine 
), 5.10 (s, 1H, ).  
 
 
Figure  
5.38 
13C-NMR(400 MHz, 
DMSO-d6) δ  in ppm : δ 
154.44 (Benzimidazole – C 
) , 123.02 (Benzimidazole – 
CH ), 163.32 (Pyrimidine–
C),95.70 (Pyrimidine–CH), 
31.90 (Aliphatic –CH3) 
 
 
 
Figure  
5.39 
  
.Mass: m/z: 401.46 
 
Figure  
5.40 
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Figure 5.37: IR spectrum of the 4-(anthracen-10-yl)-6-(1-methyl-1H-
benzo[d]imidazol-2-yl)pyrimidin-2-amine (4j) 
 
Figure 5.38: 1H NMR spectrum of the 4-(anthracen-10-yl)-6-(1-methyl-1H-
benzo[d]imidazol-2-yl)pyrimidin-2-amine (4j) 
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Figure 5.39: 13C-NMR spectrum of the 4-(anthracen-10-yl)-6-(1-methyl-1H-
benzo[d]imidazol-2-yl)pyrimidin-2-amine (4j) 
 
Figure 5.40: Mass spectrum of the 4-(anthracen-10-yl)-6-(1-methyl-1H-
benzo[d]imidazol-2-yl)pyrimidin-2-amine (4j) 
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5.1.3 Benzo[d]imidazole pyrazole derivatives (5a-e) 
5.1.3.1       2-(1,5-diphenyl-1H-pyrazol-3-yl)-1H-benzo[d]imidazole (5a) 
The physical, chromatographic and spectral characterization of the 
synthesized compound 2-(1,5-diphenyl-1H-pyrazol-3-yl)-1H-benzo[d]imidazole 
(5a)are presented in the Table 5.11.  
The IR spectrum of compound (5a)(Figure 5.41), bands at 3520 cm-1 -, 
3100 cm-1  cm-1confirms the presence of NH Stretching , Aromatic CH stretching. 
1505 cm-1   , 1534  cm-1, 880 cm-1, 1303 cm-1 band confirms the presence of 
Aromatic C= C Stretching, Aromatic C= N Stretching , Aromatic C-H Bending, 
Aromatic C-N Stretching. 1168 cm-1band confirms the presence of C-O-C 
Stretching. 
The 1H NMR spectrum of the compound2-(1,5-diphenyl-1H-pyrazol-3-yl)-
1H-benzo[d]imidazole (5a) (Figure 5.42), benzo[d]imidazole pyrazole 
derivativesaccounts for four protons of benzimidazole moiety resonated as 
multiplet between δ7.75 – 7.77   ppm. The multiplet between  δ 6.96– 7.51 ppm 
was assigned to ten protons of aromatic moiety. The chemical signal at δ 5.22 
ppm can be attributed to the moiety. 
The  13C NMR spectrum of compound 2-(1,5-diphenyl-1H-pyrazol-3-yl)-
1H-benzo[d]imidazole (5a) (Figure 5.43),the chemical signal at δ138.37 and 
123.01ppm can be attributed to the C2 and C6 of the benzimidazole moiety. The 
chemical signal at δ143.38and 107.98ppm can be attributed to the C2 and C4 of the 
Pyrazole moiety. 
The mass spectrum of the compound 2-(1,5-diphenyl-1H-pyrazol-3-yl)-
1H-benzo[d]imidazole (5a) (Figure 5.44), exhibit an ion peak at 336.14m/z value 
which can be designated as the M+ ion peak of the compound 5a and indicated 
formation of the molecule. 
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Table 5.11: Physical,chromatographic and spectral characterization of the 2-
(1,5-diphenyl-1H-pyrazol-3-yl)-1H-benzo[d]imidazole (5a) 
Compound 
code 
Compound Spectral 
Characterization 
Figure 
 
5a 
 
2-(1,5-diphenyl-1H-pyrazol-3-
yl)-1H-benzo[d]imidazole 
Mol.Formula: C22H16N4 
Mol. Wt: 336.14 
Yield: 70% 
Mp: 165- 1680C 
Rf : 0.7 
H
N
N
N
N
 
IR (KBr) cm-1: 3520 cm-1  
(NH Stretching) , 3100 
cm-1 (Aromatic CH 
stretching),  1505 cm-1  
(Aromatic C= C 
Stretching) , 1534  cm-1 
(Aromatic C= N 
Stretching), 880 cm-1 
(Aromatic C-H Bending), 
1303 cm-1 (Aromatic C-N 
Stretching), 1168 cm-1  
(C-O-C Stretching). 
 
 
 
Figure 
5.41 
1H NMR (500 MHz, 
DMSO) δ (ppm): 7.75 –  
7.77 (m, 4H , 
Benzimidazole ), 6.96–  
7.51 (m, 10H , Ar-H ),  
5.22 (s, 1H, ), 4.02- 4.06 
(m, 6H, 2 –OCH3). 
 
 
Figure  
5.42 
13C-NMR(400 MHz, 
DMSO-d6) δ  in ppm : δ 
138.37 (Benzimidazole – 
C ) ,123.01 
(Benzimidazole – CH 
),143.38 (Pyrazole – C ), 
107.98 (Pyrazole – CH ),  
126.87(Benzene – CH ), 
133.02 (Benzene – C ) , 
163.79 (Pyrimidine–
C),95.45 (Pyrimidine–
CH).  
 
 
Figure  
5.43 
Mass: m/z: 336.14. 
 
Figure  
5.44 
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Figure 5.41: IR spectrum of the 2-(1,5-diphenyl-1H-pyrazol-3-yl)-1H-
benzo[d]imidazole (5a) 
 
Figure 5.42: 1H NMR spectrum of the 2-(1,5-diphenyl-1H-pyrazol-3-yl)-1H-
benzo[d]imidazole (5a) 
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Figure 5.43: 13C-NMR spectrum of the 2-(1,5-diphenyl-1H-pyrazol-3-yl)-1H-
benzo[d]imidazole (5a) 
 
Figure 5.44: Mass spectrum of the 2-(1,5-diphenyl-1H-pyrazol-3-yl)-1H-
benzo[d]imidazole (5a) 
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5.1.3.22-(1-phenyl-5-(pyridin-4-yl)-1H-pyrazol-3-yl)-1H-benzo[d]imidazole 
(5b) 
The physical, chromatographic and spectral characterization of the 
synthesized compound 2-(1-phenyl-5-(pyridin-4-yl)-1H-pyrazol-3-yl)-1H-
benzo[d]imidazole (5b)are presented in the Table 5.12.  
The IR spectrum of compound (5b)(Figure 5.45), bands at 3523 cm-1 , 
3094 cm-1  cm-1confirms the presence of NH Stretching , Aromatic CH stretching. 
1505 cm-1   , 1534  cm-1, 880 cm-1 , 1303 cm-1 band confirms the presence of 
Aromatic C= C Stretching, Aromatic C= N Stretching , Aromatic C-H Bending, 
Aromatic C-N Stretching. 1168 cm-1band confirms the presence of C-O-C 
Stretching. 
The 1H NMR spectrum of the compound2-(1-phenyl-5-(pyridin-4-yl)-1H-
pyrazol-3-yl)-1H-benzo[d]imidazole (5b) (Figure 5.46), benzo[d]imidazole 
pyrazole derivativesaccounts for four protons of benzimidazole moiety resonated 
as multiplet between δ7.75 – 7.77    ppm. The multiplet between  δ 6.96– 7.51 
ppm was assigned to ten protons of aromatic moiety. The chemical signal at δ 
5.22 ppm can be attributed to the moiety. 
The  13C NMR spectrum of compound 2-(1-phenyl-5-(pyridin-4-yl)-1H-
pyrazol-3-yl)-1H-benzo[d]imidazole (5b) (Figure 5.47),the chemical signal at 
δ138.37 and 123.01ppm can be attributed to the C2 and C6 of the benzimidazole 
moiety. The chemical signal at δ126.38and 107.98ppm can be attributed to the C2 
and C4 of the Pyrazole moiety.The chemical signal at δ 149.79 and 121.45 ppm 
can be attributed to the (Pyridine–C), (Pyridine–CH) moiety. 
The mass spectrum of the compound 2-(1-phenyl-5-(pyridin-4-yl)-1H-
pyrazol-3-yl)-1H-benzo[d]imidazole (5b) (Figure 5.48), exhibit an ion peak at 
337.13m/z value which can be designated as the M+ ion peak of the compound 5b 
and indicated formation of the molecule. 
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Table 5.12: Physical,chromatographic and spectral characterization of the 2-
(1-phenyl-5-(pyridin-4-yl)-1H-pyrazol-3-yl)-1H-benzo[d]imidazole (5b) 
Compound 
code 
Compound Spectral 
Characterization 
Figure 
 
5b 
 
2-(1-phenyl-5-(pyridin-4-yl)-1H-
pyrazol-3-yl)-1H-
benzo[d]imidazole 
Mol.Formula: C21H15N5 
Mol. Wt: 337.13 
Yield: 75% 
Mp: 174- 176 0C 
Rf : 0.62 
N
H
N
N
N
N
 
IR (KBr) cm-1: 3523 cm-
1 (NH Stretching) , 3094 
cm-1 (Aromatic CH 
stretching),  1505 cm-1  
(Aromatic C= C 
Stretching) , 1534  cm-1 
(Aromatic C= N 
Stretching), 880 cm-1 
(Aromatic C-H Bending), 
1303 cm-1 (Aromatic C-N 
Stretching), 1168 cm-1  
(C-O-C Stretching). 
 
 
 
Figure 
5.45 
1H NMR (500 MHz, 
DMSO) δ (ppm): 7.75 – 
7.77 (m, 4H , 
Benzimidazole ), 6.96– 
7.51 (m, 10H , Ar-H ),  
5.22 (s, 1H, ), 4.02- 4.06 
(m, 6H, 2 –OCH3). 
 
 
Figure  
5.46 
13C-NMR(400 MHz, 
DMSO-d6) δ  in ppm : δ 
138.37 (Benzimidazole – 
C ) ,123.01 
(Benzimidazole – CH 
),126.38 (Pyrazole – C ), 
108.98 (Pyrazole – CH ),  
126.87(Benzene – CH ), 
139.02 (Benzene – C ) , 
149.79 (Pyridine–
C),121.45 (Pyridine–CH).  
 
 
Figure  
5.47 
Mass: m/z: 337.13. 
 
Figure  
5.48 
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Figure 5.45: IR spectrum of the 2-(1-phenyl-5-(pyridin-4-yl)-1H-pyrazol-3-
yl)-1H-benzo[d]imidazole (5b) 
 
Figure 5.46: 1H NMR spectrum of the 2-(1-phenyl-5-(pyridin-4-yl)-1H-
pyrazol-3-yl)-1H-benzo[d]imidazole (5b) 
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Figure 5.47: 13C-NMR spectrum of the 2-(1-phenyl-5-(pyridin-4-yl)-1H-
pyrazol-3-yl)-1H-benzo[d]imidazole (5b) 
 
Figure 5.48: Mass spectrum of the 2-(1-phenyl-5-(pyridin-4-yl)-1H-pyrazol-3-
yl)-1H-benzo[d]imidazole (5b) 
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5.1.3.32-(5-(3-chloro-4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-1H-
benzo[d]imidazole (5c) 
 The physical, chromatographic and spectral characterization of the 
synthesized compound 2-(5-(3-chloro-4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-
yl)-1H-benzo[d]imidazole (5c)are presented in the Table 5.13.  
The IR spectrum of compound (5c)(Figure 5.49), bands at 3484 cm-1  , 
3100 cm-1  , 3284 cm-1confirms the presence of NH2 Stretching,NH Stretching , 
Aromatic CH stretching. 1585 cm-1  , 1589 cm-1,879 cm-1, 1383 cm-1band confirms 
the presence of Aromatic C= C Stretching, Aromatic C= N Stretching , Aromatic 
C-H Bending, Aromatic C-N Stretching. 1168 cm-1band confirms the presence of 
C-O-C Stretching. 
The 1H NMR spectrum of the compound2-(5-(3-chloro-4-methoxyphenyl)-
1-phenyl-1H-pyrazol-3-yl)-1H-benzo[d]imidazole (5c)(Figure 5.50), 
benzo[d]imidazole pyrazole derivativesaccounts for four protons of benzimidazole 
moiety resonated as multiplet between δ7.21 – 7.47 ppm. The multiplet between  
δ7.48 – 8.20 ppm was assigned to five protons of aromatic moiety. The chemical 
signal at δ5.13ppm can be attributed to the moiety.The  13C NMR spectrum of 2-
(5-(3-chloro-4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-1H-benzo[d]imidazole 
(5c)(Figure 5.51),the chemical signal at δ154.01 and 123.37ppm can be attributed 
to the C2 and C6 of the benzimidazole moiety. The chemical signal at δ143.38and 
107.98ppm can be attributed to the C2 and C4 of the Pyrazole moiety.The 
chemical signal at δ55.40ppm can be attributed to the Aliphatic – CH3moiety.The 
mass spectrum of the compound 2-(5-(3-chloro-4-methoxyphenyl)-1-phenyl-1H-
pyrazol-3-yl)-1H-benzo[d]-imidazol(5c) (Figure 5.52), exhibit an ion peak at 
400.11m/z value which can be designated as the M+ ion peak of the compound 5c 
and indicated formation of the molecule. 
 
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles Page 104 
 
Table 5.13: Physical,chromatographic and spectral characterization of the 2-
(5-(3-chloro-4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-1H-
benzo[d]imidazole (5c) 
Compound 
code 
Compound Spectral 
Characterization 
Figure 
 
5c 
 
2-(5-(3-chloro-4-
methoxyphenyl)-1-phenyl-1H-
pyrazol-3-yl)-1H-
benzo[d]imidazole 
Mol.Formula: C23H17ClN4O 
Mol. Wt: 400.11 
Yield: 65% 
Mp: 190- 192 0C 
Rf : 0.55 
HN
N
N
N
O
Cl
 
IR (KBr) cm-1: 3484 cm-
1 (NH Stretching ) , 3100 
cm-1 (NH Stretching) , 
3284 cm-1 (Aromatic CH 
stretching),  1585 cm-1  
(Aromatic C= C 
Stretching) , 1589 cm-1 
(Aromatic C= N 
Stretching), 879 cm-1 
(Aromatic C-H Bending), 
1383 cm-1 (Aromatic C-
N Stretching). 
 
 
 
Figure 
5.49 
1H NMR (500 MHz, 
DMSO) δ (ppm): 7.21 – 
7.47 (m, 4H , 
Benzimidazole ), 7.48 – 
8.20 (m, 5H , Ar-H ),  
5.13 (s, 1H, ). 
 
 
Figure  
5.50 
13C-NMR(400 MHz, 
DMSO-d6) δ  in ppm : δ 
154.01 (Benzimidazole – 
C ) ,123.37 
(Benzimidazole – CH 
),143.38 (Pyrazole – C ), 
107.98 (Pyrazole – CH ),  
126.87(Benzene – CH ), 
133.02 (Benzene – C ) , 
55.40 (Aliphatic – CH3).  
 
 
Figure  
5.51 
Mass: m/z: 400.11. Figure  
5.52 
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Figure 5.49: IR spectrum of the 2-(5-(3-chloro-4-methoxyphenyl)-1-phenyl-
1H-pyrazol-3-yl)-1H-benzo[d]imidazole (5c) 
 
Figure 5.50: 1H NMR spectrum of the 2-(5-(3-chloro-4-methoxyphenyl)-1-
phenyl-1H-pyrazol-3-yl)-1H-benzo[d]imidazole (5c) 
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Figure 5.51: 13C-NMR spectrum of the 2-(5-(3-chloro-4-methoxyphenyl)-1-
phenyl-1H-pyrazol-3-yl)-1H-benzo[d]imidazole (5c) 
 
Figure 5.52: Mass spectrum of the 2-(5-(3-chloro-4-methoxyphenyl)-1-
phenyl-1H-pyrazol-3-yl)-1H-benzo[d]imidazole (5c) 
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5.1.3.42-(5-(3,4-dimethoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-1H-
benzo[d]imidazole (5d) 
The physical, chromatographic and spectral characterization of the 
synthesized compound 2-(5-(3,4-dimethoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-
1H-benzo[d]imidazole(5d)are presented in the Table 5.14.  
The IR spectrum of compound (5d)(Figure 5.53), bands at 3391 cm-1,  
3099 cm-1confirms the presence ofNH Stretching , Aromatic CH stretching. 1453 
cm-1   , 1623  cm-1, 759 cm-1, 1505 cm-1band confirms the presence of Aromatic 
C= C Stretching, Aromatic C= N Stretching , Aromatic C-H Bending, Aromatic 
C-N Stretching. 1168 cm-1band confirms the presence of C-O-C Stretching. 
The 1H NMR spectrum of the compound2-(5-(3,4-dimethoxyphenyl)-1-
phenyl-1H-pyrazol-3-yl)-1H-benzo[d]imidazole(5d) (Figure 5.54), 
benzo[d]imidazole pyrazole derivativesaccounts for four protons of benzimidazole 
moiety resonated as multiplet between δ7.11 – 7.33 ppm. The multiplet between  
δ7.34– 7.42 ppm was assigned to thirteen protons of aromatic moiety. The 
chemical signal at δ5.11 ppm can be attributed to the moiety.  
The  13C NMR spectrum of 2-(5-(3,4-dimethoxyphenyl)-1-phenyl-1H-
pyrazol-3-yl)-1H-benzo[d]imidazole(5d) (Figure 5.55),the chemical signal at 
δ154.01 and 123.37ppm can be attributed to the C2 and C6 of the benzimidazole 
moiety. The chemical signal at δ142.38and 107.98ppm can be attributed to the C2 
and C4 of the Pyrazole moiety.The chemical signal at δ56.24ppm can be attributed 
to the Aliphatic – CH3moiety. 
 The mass spectrum of the compound 2-(5-(3,4-dimethoxyphenyl)-1-
phenyl-1H-pyrazol-3-yl)-1H-benzo[d]imidazole(5d) (Figure 5.56), exhibit an ion 
peak at 396.16m/z value which can be designated as the M+ ion peak of the 
compound 5d and indicated formation of the molecule. 
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Table 5.14: Physical,chromatographic and spectral characterization of the 2-
(5-(3,4-dimethoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-1H-benzo[d]imidazole 
(5d) 
Compound 
code 
Compound Spectral Characterization Figure 
 
5d 
 
2-(5-(3,4-
dimethoxyphenyl)-1-
phenyl-1H-pyrazol-3-yl)-
1H-benzo[d]imidazole 
Mol.Formula: 
C24H20N4O2 
Mol. Wt: 396.16 
Yield: 80% 
Mp: 179- 182 0C 
Rf : 0.45 
 
IR (KBr) cm-1: 3391 cm-1 (NH 
Stretching) ,3099 cm-1 (Aromatic 
CH stretching),  1453 cm-1  
(Aromatic C= C Stretching) , 
1623  cm-1 (Aromatic C= N 
Stretching), 759 cm-1 (Aromatic 
C-H Bending), 1505 cm-1 
(Aromatic C-N Stretching). 
 
 
 
Figure 
5.53 
1
H NMR (500 MHz, DMSO) δ 
(ppm): 7.11 – 7.33 (m, 4H , 
Benzimidazole ), 7.34– 7.42 (m, 
13H , Ar-H ),  5.11 (s, 1H, ). 
 
 
Figure  
5.54 
13C-NMR(400 MHz, DMSO-d6) 
δ  in ppm : δ 154.01 
(Benzimidazole – C ) ,123.37 
(Benzimidazole – CH ),142.38 
(Pyrazole – C ), 107.98 (Pyrazole 
– CH ),  126.87(Benzene – CH ), 
133.02 (Benzene – C ) , 56.24 
(Aliphatic – CH3).  
 
 
Figure  
5.55 
Mass: m/z: 396.16 
 
Figure  
5.56 
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Figure 5.53: IR spectrum of the 2-(5-(3,4-dimethoxyphenyl)-1-phenyl-1H-
pyrazol-3-yl)-1H-benzo[d]imidazole (5d) 
 
Figure 5.54: 1H NMR spectrum of the 2-(5-(3,4-dimethoxyphenyl)-1-phenyl-
1H-pyrazol-3-yl)-1H-benzo[d]imidazole (5d) 
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Figure 5.55: 13C-NMR spectrum of the 2-(5-(3,4-dimethoxyphenyl)-1-phenyl-
1H-pyrazol-3-yl)-1H-benzo[d]imidazole (5d) 
 
Figure 5.56: Mass spectrum of the 2-(5-(3,4-dimethoxyphenyl)-1-phenyl-1H-
pyrazol-3-yl)-1H-benzo[d]imidazole (5d) 
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5.1.3.52-(5-(anthracen-10-yl)-1-phenyl-1H-pyrazol-3-yl)-1H-
benzo[d]imidazole (5e) 
The physical, chromatographic and spectral characterization of the 
synthesized compound 2-(5-(anthracen-10-yl)-1-phenyl-1H-pyrazol-3-yl)-1H-
benzo[d]imidazole(5e)are presented in the Table 5.15.  
The IR spectrum of compound (5e)(Figure 5.57), bands at 3370 cm-1  , 
3100 cm-1confirms the presence of NH Stretching , Aromatic CH stretching. 1428 
cm-1 ,1534  cm-1, 860 cm-1, 1370 cm-1band confirms the presence of Aromatic C= 
C Stretching, Aromatic C= N Stretching , Aromatic C-H Bending, Aromatic C-N 
Stretching. 1168 cm-1band confirms the presence of C-O-C Stretching. 
 The 1H NMR spectrum of the compound2-(5-(anthracen-10-yl)-1-phenyl-
1H-pyrazol-3-yl)-1H-benzo[d]imidazole(5e)(Figure 5.58), benzo[d]imidazole 
pyrazole derivativesaccounts for four protons of benzimidazole moiety resonated 
as multiplet between δ7.46 – 7.87  ppm. The multiplet between  δ7.25 – 7.49  ppm 
was assigned to ten protons of aromatic moiety. The chemical signal at δ5.10ppm 
can be attributed to the moiety. 
The  13C NMR spectrum of 2-(5-(anthracen-10-yl)-1-phenyl-1H-pyrazol-3-
yl)-1H-benzo[d]imidazole(5e)(Figure 5.59),the chemical signal at δ138.37 and 
123.01ppm can be attributed to the C2 and C6 of the benzimidazole moiety. The 
chemical signal at δ143.38and 107.98ppm can be attributed to the C2 and C4 of the 
Pyrazole moiety.The chemical signal at δ 126.87 ppm and 133.02 ppm can be 
attributed to the benzene – CH , benzene – Cmoiety. 
The mass spectrum of the compound 2-(5-(anthracen-10-yl)-1-phenyl-1H-
pyrazol-3-yl)-1H-benzo[d]imidazole(5e) (Figure 5.60), exhibit an ion peak at 
436.17m/z value which can be designated as the M+ ion peak of the compound 5e 
and indicated formation of the molecule. 
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Table 5.15: Physical,chromatographic and spectral characterization of the 2-
(5-(anthracen-10-yl)-1-phenyl-1H-pyrazol-3-yl)-1H-benzo[d]imidazole (5e) 
Compound 
code 
Compound Spectral 
Characterization 
Figure 
 
5e 
 
2-(5-(anthracen-10-yl)-1-phenyl-
1H-pyrazol-3-yl)-1H-
benzo[d]imidazole 
Mol.Formula: C30H20N4 
Mol. Wt: 436.17 
Yield: 65% 
Mp: 160- 162 0C 
Rf : 0.70 
NH
N
N
N
 
IR (KBr) cm-1: 3370 cm-
1 (NH Stretching) , 3100 
cm-1 (Aromatic CH 
stretching),  1428 cm-1  
(Aromatic C= C 
Stretching) , 1534  cm-1 
(Aromatic C= N 
Stretching), 860 cm-1 
(Aromatic C-H Bending), 
1370 cm-1 (Aromatic C-N 
Stretching), 1118 cm-1  
(C-Cl Stretching). 
 
 
 
Figure 
5.57 
1H NMR (500 MHz, 
DMSO) δ (ppm): 7.46 –  
7.87  (m, 4H , 
Benzimidazole ), 7.25 – 
7.49  (m, 10H , Ar-H ),  
5.10 (s, 1H, ). 
 
 
Figure  
5.58 
13C-NMR(400 MHz, 
DMSO-d6) δ  in ppm : δ 
138.37 (Benzimidazole – 
C ) ,123.01 
(Benzimidazole – CH 
),143.38 (Pyrazole – C ), 
107.98 (Pyrazole – CH ),  
126.87(Benzene – CH ), 
133.02 (Benzene – C ).  
 
 
Figure  
5.59 
Mass: m/z: 436.17. 
 
Figure  
5.60 
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Figure 5.57: IR spectrum of the 2-(5-(anthracen-10-yl)-1-phenyl-1H-pyrazol-
3-yl)-1H-benzo[d]imidazole (5e) 
 
Figure 5.58: 1H NMR spectrum of the 2-(5-(anthracen-10-yl)-1-phenyl-1H-
pyrazol-3-yl)-1H-benzo[d]imidazole (5e) 
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Figure 5.59: 13C-NMR spectrum of the 2-(5-(anthracen-10-yl)-1-phenyl-1H-
pyrazol-3-yl)-1H-benzo[d]imidazole (5e) 
 
Figure 5.60: Mass spectrum of the 2-(5-(anthracen-10-yl)-1-phenyl-1H-
pyrazol-3-yl)-1H-benzo[d]imidazole (5e) 
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5.1.4 Synthesis of (pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazolederivatives 
(5f-j) 
5.1.4.1 2-(1,5-diphenyl-1H-pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole (5f) 
The physical, chromatographic and spectral characterization of the 
synthesized compound 2-(1,5-diphenyl-1H-pyrazol-3-yl)-1-methyl-1H-
benzo[d]imidazole (5f)are presented in the Table 5.16.  
The IR spectrum of compound (5f)(Figure 5.61), bands at 3523 cm-1   , 
3195 cm-1confirms the presence of NH Stretching , Aromatic CH stretching. 1399 
cm-1  , 1625  cm-1, 888 cm-1, 1324 cm-1band confirms the presence of Aromatic C= 
C Stretching, Aromatic C= N Stretching , Aromatic C-H Bending, Aromatic C-N 
Stretching. 1168 cm-1band confirms the presence of C-O-C Stretching. 
 The 1H NMR spectrum of the compound2-(1,5-diphenyl-1H-pyrazol-3-
yl)-1-methyl-1H-benzo[d]imidazole (5f)(Figure 5.62), benzo[d]imidazole 
pyrazole derivativesaccounts for four protons of benzimidazole moiety resonated 
as multiplet between δ 7.26 – 7.70    ppm. The multiplet between  δ 7.72 – 8.48 
ppm was assigned to four protons of aromatic moiety. The chemical signal at 
δ5.13 ppm can be attributed to the moiety.The  13C NMR spectrum of 2-(1,5-
diphenyl-1H-pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole (5f)(Figure 5.63),the 
chemical signal at δ141.45 and 115.30 ppm can be attributed to the C2 and C6 of 
the benzimidazole moiety. The chemical signal at δ143.38 and 107.98 ppm can be 
attributed to the C2 and C4 of the Pyrazole moiety.The chemical signal at δ 31.24 
ppm can be attributed to the Aliphatic – CH3 moiety. 
The mass spectrum of the compound 22-(1,5-diphenyl-1H-pyrazol-3-yl)-1-
methyl-1H-benzo[d]imidazole (5f) (Figure 5.64), exhibit an ion peak at 350.15m/z 
value which can be designated as the M+ ion peak of the compound 5f and 
indicated formation of the molecule. 
 
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles Page 116 
 
Table 5.16: Physical,chromatographic and spectral characterization of the 2-
(1,5-diphenyl-1H-pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole (5f) 
Compound 
code 
Compound Spectral 
Characterization 
Figure 
 
5f 
 
2-(1,5-diphenyl-1H-pyrazol-3-
yl)-1-methyl-1H-
benzo[d]imidazole 
Mol.Formula: C23H18N4 
Mol. Wt: 350.15 
Yield: 75% 
Mp: 162- 164 0C 
Rf : 0.6 
N
N
N
N
 
IR (KBr) cm-1: 3523 cm-
1 (NH Stretching) ,3195 
cm-1 (Aromatic CH 
stretching),  1399 cm-1  
(Aromatic C= C 
Stretching) , 1625  cm-1 
(Aromatic C= N 
Stretching), 888 cm-1 
(Aromatic C-H Bending), 
1324 cm-1 (Aromatic C-N 
Stretching). 
 
 
 
Figure 
5.61 
1H NMR (500 MHz, 
DMSO) δ (ppm): 7.26 – 
7.70 (m, 4H , 
Benzimidazole ), 7.72 – 
8.48 (m, 4H , Ar-H ). 
 
 
Figure  
5.62 
13C-NMR(400 MHz, 
DMSO-d6) δ  in ppm : δ 
141.45 (Benzimidazole – 
C ) ,115.30 
(Benzimidazole – CH 
),143.38 (Pyrazole – C ), 
107.98 (Pyrazole – CH ),  
126.87(Benzene – CH ), 
133.02 (Benzene – C ), 
31.24 (Aliphatic – CH3).  
 
 
Figure  
5.63 
Mass: m/z: 350.15. 
 
Figure  
5.64 
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Figure 5.61: IR spectrum of the 2-(1,5-diphenyl-1H-pyrazol-3-yl)-1-methyl-
1H-benzo[d]imidazole (5f) 
 
Figure 5.62: 1H NMR spectrum of the 2-(1,5-diphenyl-1H-pyrazol-3-yl)-1-
methyl-1H-benzo[d]imidazole (5f) 
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Figure 5.63: 13C-NMR spectrum of the 2-(1,5-diphenyl-1H-pyrazol-3-yl)-1-
methyl-1H-benzo[d]imidazole (5f) 
 
Figure 5.64: Mass spectrum of the 2-(1,5-diphenyl-1H-pyrazol-3-yl)-1-
methyl-1H-benzo[d]imidazole (5f) 
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5.1.4.2 1-methyl-2-(1-phenyl-5-(pyridin-4-yl)-1H-pyrazol-3-yl)-1H-
benzo[d]imidazole(5g) 
The physical, chromatographic and spectral characterizat ion of the 
synthesized compound 1-methyl-2-(1-phenyl-5-(pyridin-4-yl)-1H-pyrazol-3-yl)-
1H-benzo[d]imidazole (5g)are presented in the Table 5.17.  
The IR spectrum of compound (5g)(Figure 5.65), bands at 3556 cm- , 3140 
cm-1confirms the presence of NH Stretching , Aromatic CH stretching. 1439  cm-1  
, 1589 cm-1, 915 cm-1, 1290 cm-1band confirms the presence of Aromatic C= C 
Stretching, Aromatic C= N Stretching , Aromatic C-H Bending, Aromatic C-N 
Stretching. 1168 cm-1band confirms the presence of C-O-C Stretching. 
 The 1H NMR spectrum of the compound1-methyl-2-(1-phenyl-5-(pyridin-
4-yl)-1H-pyrazol-3-yl)-1H-benzo[d]imidazole (5g)(Figure 5.66), 
benzo[d]imidazole pyrazole derivativesaccounts for four protons of benzimidazole 
moiety resonated as multiplet between δ 7.66 – 7.71     ppm. The multiplet 
between  δ 7.08 – 7.11ppm was assigned to five protons of aromatic moiety. The 
chemical signal at δ 5.17ppm can be attributed to the moiety.The  13C NMR 
spectrum of 1-methyl-2-(1-phenyl-5-(pyridin-4-yl)-1H-pyrazol-3-yl)-1H-
benzo[d]imidazole (5g)(Figure 5.67),the chemical signal at δ 138.37 and 123.01 
ppm can be attributed to the C2 and C6 of the benzimidazole moiety. The chemical 
signal at δ 126.87 and 139.02 ppm can be attributed to the C2 and C6 of the 
Benzene – CH ,  Benzene – C moiety.The chemical signal at δ126.38 and 108.98 
ppm can be attributed to the C2 and C4 of the Pyrazole moiety.The chemical signal 
at δ31.24  ppm can be attributed to the Aliphatic – CH3 moiety. The mass 
spectrum of the compound 1-methyl-2-(1-phenyl-5-(pyridin-4-yl)-1H-pyrazol-3-
yl)-1H-benzo[d]imidazole(5g) (Figure 5.68), exhibit an ion peak at 351.15m/z 
value which can be designated as the M+ ion peak of the compound 5g and 
indicated formation of the molecule. 
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Table 5.17: Physical,chromatographic and spectral characterization of the 1-
methyl-2-(1-phenyl-5-(pyridin-4-yl)-1H-pyrazol-3-yl)-1H-
benzo[d]imidazole(5g) 
Compound 
code 
Compound Spectral 
Characterization 
Figure 
 
5g 
 
1-methyl-2-(1-phenyl-5-(pyridin-
4-yl)-1H-pyrazol-3-yl)-1H-
benzo[d]imidazole 
Mol.Formula: C22H17N5 
Mol. Wt: 351.15 
Yield: 68% 
Mp: 208- 2100C 
Rf : 0.67 
N
N
N
N
N
 
IR (KBr) cm-1: 3556 cm-
1 (NH Stretching) , 3140 
cm-1 (Aromatic CH 
stretching), 1439  cm-1  
(Aromatic C= C 
Stretching) , 1589 cm-1 
(Aromatic C= N 
Stretching), 915 cm-1 
(Aromatic C-H Bending), 
1290 cm-1 (Aromatic C-N 
Stretching). 
 
 
 
Figure 
5.65 
1H NMR (500 MHz, 
DMSO) δ (ppm):  7.66 – 
7.71 (m, 4H , 
Benzimidazole ), 7.08 – 
7.11 (m, 5H , Ar-H ),  ), 
5.17 (s, 1H, ). 
 
 
Figure  
5.66 
13C-NMR(400 MHz, 
DMSO-d6) δ  in ppm : δ 
138.37 (Benzimidazole – 
C ) ,123.01 
(Benzimidazole – CH 
),126.38 (Pyrazole – C ), 
108.98 (Pyrazole – CH ),  
126.87(Benzene – CH ), 
139.02 (Benzene – C ) , 
141.79 (Pyridine–
C),121.45 (Pyridine–CH), 
31.24 (Aliphatic – CH3).  
 
 
Figure  
5.67 
Mass: m/z: 351.15. 
 
Figure  
5.68 
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Figure 5.65: IR spectrum of the 1-methyl-2-(1-phenyl-5-(pyridin-4-yl)-1H-
pyrazol-3-yl)-1H-benzo[d]imidazole(5g) 
 
Figure 5.66: 1H NMR spectrum of the 1-methyl-2-(1-phenyl-5-(pyridin-4-yl)-
1H-pyrazol-3-yl)-1H-benzo[d]imidazole(5g) 
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Figure 5.67: 13C-NMR spectrum of the 1-methyl-2-(1-phenyl-5-(pyridin-4-yl)-
1H-pyrazol-3-yl)-1H-benzo[d]imidazole(5g) 
 
Figure 5.68: Mass spectrum of the 1-methyl-2-(1-phenyl-5-(pyridin-4-yl)-1H-
pyrazol-3-yl)-1H-benzo[d]imidazole(5g) 
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5.1.4.3  2-(5-(3-chloro-4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-1-
methyl-1H-benzo[d]imidazole (5h) 
The physical, chromatographic and spectral characterization of the 
synthesized compound 2-(5-(3-chloro-4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-
yl)-1-methyl-1H-benzo[d]imidazole (5h)are presented in the Table 5.18.  
The IR spectrum of compound (5h)(Figure 5.69), bands at 3484 cm-1, 3398 
cm-1 ,3284 cm-1 confirms the presence of NH2 Stretching ,NH Stretching , 
Aromatic CH stretching. 1585 cm-1  , 1589 cm-1, 879 cm-1, 1383 cm-1band 
confirms the presence of Aromatic C= C Stretching, Aromatic C= N Stretching , 
Aromatic C-H Bending, Aromatic C-N Stretching. The 1H NMR spectrum of the 
compound2-(5-(3-chloro-4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-1-methyl-
1H-benzo -[d]imidazole (5h)(Figure 5.70), benzo[d]imidazole pyrazole 
derivativesaccounts for four protons of benzimidazole moiety resonated as 
multiplet between δ7.47- 8.20ppm. The multiplet between  δ 7.48 – 8.26 ppm was 
assigned to five protons of aromatic moiety. The chemical signal at δ5.13ppm can 
be attributed to the moiety. The  13C NMR spectrum of 2-(5-(3-chloro-4-
methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole (5h) 
(Figure 5.71),the chemical signal at δ138.01 and123.37ppm can be attributed to 
the C2 and C6 of the benzimidazole moiety. The chemical signal at δ 126.87 and 
133.02 ppm can be attributed to the C2 and C6 of the Benzene – CH ,  Benzene – 
C moiety. The chemical signal at δ143.38and 107.98ppm can be attributed to the 
C2 and C4 of the Pyrazole moiety.The chemical signal at δ55.24 ppm can be 
attributed to the Aliphatic – CH3moiety.The mass spectrum of the compound 2-(5-
(3-chloro-4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-1-methyl-1H-
benzo[d]imidazole (5h) (Figure 5.72), exhibit an ion peak at 414.12m/z value 
which can be designated as the M+ ion peak of the compound 5h and indicated 
formation of the molecule. 
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Table 5.18: Physical,chromatographic and spectral characterization of the 2-
(5-(3-chloro-4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-1-methyl-1H-
benzo[d]imidazole (5h) 
Compound 
code 
Compound Spectral 
Characterization 
Figure 
 
5h 
 
2-(5-(3-chloro-4-methoxyphenyl)-
1-phenyl-1H-pyrazol-3-yl)-1-
methyl-1H-benzo[d]imidazole 
Mol.Formula: C24H19ClN4O 
Mol. Wt: 414.12 
Yield: 74% 
Mp: 165- 1690C 
Rf : 0.75 
N
N
N
N
O
Cl
 
IR (KBr) cm-1: 3484 
cm-1 (NH2 Stretching ) , 
3398 cm-1 (NH 
Stretching) , 3284 cm-1 
(Aromatic CH 
stretching),  1585 cm-1  
(Aromatic C= C 
Stretching) , 1589 cm-1 
(Aromatic C= N 
Stretching), 879 cm-1 
(Aromatic C-H 
Bending), 1383 cm-1 
(Aromatic C-N 
Stretching). 
 
 
 
Figure 
5.69 
1H NMR (500 MHz, 
DMSO) δ (ppm): 7.47- 
8.20 (m, 4H , 
Benzimidazole ), 7.48 – 
8.26 (m, 5H , Ar-H ),  
4.76 (s, 2H, Amino 
pyridine ), 5.13 (s, 1H, ). 
 
 
Figure  
5.70 
13C-NMR(400 MHz, 
DMSO-d6) δ  in ppm : δ 
138.01 (Benzimidazole – 
C ) ,123.37 
(Benzimidazole – CH 
),143.38 (Pyrazole – C ), 
107.98 (Pyrazole – CH ),  
126.87(Benzene – CH ), 
133.02 (Benzene – C ) , 
31.24(Aliphatic – CH3), 
55.24(Aliphatic – CH3).  
 
 
Figure  
5.71 
Mass: m/z: 414.12. 
 
Figure  
5.72 
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Figure 5.69: IR spectrum of the 2-(5-(3-chloro-4-methoxyphenyl)-1-phenyl-
1H-pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole (5h) 
 
Figure 5.70: 1H NMR spectrum of the 2-(5-(3-chloro-4-methoxyphenyl)-1-
phenyl-1H-pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole (5h) 
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Figure 5.71: 13C-NMR spectrum of the 2-(5-(3-chloro-4-methoxyphenyl)-1-
phenyl-1H-pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole (5h) 
 
Figure 5.72: Mass spectrum of the 2-(5-(3-chloro-4-methoxyphenyl)-1-
phenyl-1H-pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole (5h) 
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5.1.4.4  2-(5-(3,4-dimethoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-1-
methyl-1H-benzo[d]imidazole (5i) 
The physical, chromatographic and spectral characterization of the 
synthesized compound 2-(5-(3,4-dimethoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-1-
methyl-1H-benzo[d]imidazole(5i)are presented in the Table 5.19. The IR 
spectrum of compound (5i)(Figure 5.73), bands at 3378 cm-1 , 3523 cm-1, 3201 
cm-1confirms the presence of NH2 Stretching,NH Stretching , Aromatic CH 
stretching. 1418 cm-1   , 1589 cm-1, 875 cm-1, 1303 cm-1band confirms the presence 
of Aromatic C= C Stretching, Aromatic C= N Stretching , Aromatic C-H Bending, 
Aromatic C-N Stretching. 1168 cm-1band confirms the presence of C-O-C 
Stretching.The 1H NMR spectrum of the compound2-(5-(3,4-dimethoxyphenyl)-1-
phenyl-1H-pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole(5i) (Figure 5.74), 
benzo[d]imidazole pyrazole derivativesaccounts for four protons of benzimidazole 
moiety resonated as multiplet between δ7.65 – 8.19ppm. The multiplet between  
δ7.39 – 7.54ppm was assigned to five protons of aromatic moiety. The chemical 
signal at δ5.10ppm can be attributed to the moiety. The multiplet between  δ3.63- 
3.72 ppm was assigned to six protons of methoxy (2 –OCH3 ) moiety. The  
13C 
NMR spectrum of 2-(5-(3,4-dimethoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-1-
methyl-1H-benzo[d]imidazole(5i) (Figure 5.75),the chemical signal at δ154.01 
and 123.37ppm can be attributed to the C2 and C6 of the benzimidazole moiety. 
The chemical signal at δ142.38and 107.98ppm can be attributed to the C2 and C4 
of the Pyrazole moiety. The chemical signal at δ 126.87 and 133.02 ppm can be 
attributed to the C2 and C6 of the Benzene – CH ,  Benzene – C moiety. The 
chemical signal at δ56.24ppm can be attributed to the Aliphatic – CH3moiety. The 
mass spectrum of the compound (5i) (Figure 5.76), exhibit an ion peak at 
410.17m/z value which can be designated as the M+ ion peak of the compound 5i 
and indicated formation of the molecule. 
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Table 5.19: Physical,chromatographic and spectral characterization of the 2-
(5-(3,4-dimethoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)-1-methyl-1H-
benzo[d]imidazole (5i) 
Compound 
code 
Compound Spectral 
Characterization 
Figure 
 
5i 
 
2-(5-(3,4-dimethoxyphenyl)-1-
phenyl-1H-pyrazol-3-yl)-1-
methyl-1H-benzo[d]imidazole 
Mol.Formula: C25H22N4O2 
Mol. Wt: 410.17 
Yield: 65% 
Mp: 200- 2030C 
Rf : 0.62 
N
N
N
N
O
O
 
IR (KBr) cm-1: 3378 cm-
1 (NH2 Stretching ) , 3523 
cm-1 (NH Stretching) , 
3201 cm-1 (Aromatic CH 
stretching),  1418 cm-1  
(Aromatic C= C 
Stretching) , 1589 cm-1 
(Aromatic C= N 
Stretching), 875 cm-1 
(Aromatic C-H Bending), 
1303 cm-1 (Aromatic C-N 
Stretching), 1118 cm-1  
(C-Cl Stretching). 
 
 
 
Figure 
5.73 
1H NMR (500 MHz, 
DMSO) δ (ppm): 7.65 – 
8.19 (m, 4H , 
Benzimidazole ), 7.39 – 
7.54 (m, 4H , Ar-H ), 
5.10 (s, 1H, ), 3.63- 3.72 
(m, 6H, 2 –OCH3). 
 
 
Figure  
5.74 
13C-NMR(400 MHz, 
DMSO-d6) δ  in ppm : δ 
154.01 (Benzimidazole – 
C ) ,123.37 
(Benzimidazole – CH 
),142.38 (Pyrazole – C ), 
107.98 (Pyrazole – CH ),  
126.87(Benzene – CH ), 
133.02 (Benzene – C ) , 
31.24(Aliphatic – CH3), 
56.24 (Aliphatic – CH3). 
 
 
Figure  
5.75 
Mass: m/z: 410.17. 
 
Figure  
5.76 
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Figure 5.73: IR spectrum of the 2-(5-(3,4-dimethoxyphenyl)-1-phenyl-1H-
pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole (5i) 
 
Figure 5.74: 1H NMR spectrum of the 2-(5-(3,4-dimethoxyphenyl)-1-phenyl-
1H-pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole (5i) 
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Figure 5.75: 13C-NMR spectrum of the 2-(5-(3,4-dimethoxyphenyl)-1-phenyl-
1H-pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole (5i) 
 
Figure 5.76: Mass spectrum of the 2-(5-(3,4-dimethoxyphenyl)-1-phenyl-1H-
pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole (5i) 
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5.1.4.5 2-(5-(anthracen-10-yl)-1-phenyl-1H-pyrazol-3-yl)-1-methyl-1H-
benzo[d]imidazole (5j) 
The physical, chromatographic and spectral characterization of the 
synthesized compound 2-(5-(anthracen-10-yl)-1-phenyl-1H-pyrazol-3-yl)-1-
methyl-1H-benzo[d]imidazole (5j)are presented in the Table 5.20.  
The IR spectrum of compound (5j)(Figure 5.77), bands at 3362 cm-1,  
3179 cm-1confirms the presence ofNH Stretching , Aromatic CH stretching. 1590 
cm-1   , 1625  cm-1, 873 cm-1, 1246 cm-1band confirms the presence of Aromatic 
C= C Stretching, Aromatic C= N Stretching , Aromatic C-H Bending, Aromatic 
C-N Stretching.  
The 1H NMR spectrum of the compound2-(5-(anthracen-10-yl)-1-phenyl-
1H-pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole (5j)(Figure 5.78), 
benzo[d]imidazole pyrazole derivativesaccounts for four protons of benzimidazole 
moiety resonated as multiplet between δ7.20 – 7.59ppm. The multiplet between  
δ7.60 – 8.20ppm was assigned to five protons of pyrazole moiety. The chemical 
signal at δ6.51ppm can be attributed to the moiety.The  13C NMR spectrum of 2-
(5-(anthracen-10-yl)-1-phenyl-1H-pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole 
(5j)(Figure 5.79),the chemical signal at δ138.37and 123.01ppm can be attributed 
to the C2 and C6 of the benzimidazole moiety. The chemical signal at δ143.38and 
107.98ppm can be attributed to the C2 and C4 of the Pyrazole moiety.The 
chemical signal at δ 126.87 and 133.02 ppm can be attributed to the C2 and C6 of 
the Benzene – CH ,  Benzene – C moiety. The chemical signal at δ31.24ppm can 
be attributed to the Aliphatic – CH3moiety.The mass spectrum of the compound 2-
(5-(anthracen-10-yl)-1-phenyl-1H-pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole 
(5j) (Figure 5.80), exhibit an ion peak at 450.18m/z value which can be designated 
as the M+ ion peak of the compound 5j and indicated formation of the molecule. 
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Table 5.20: Physical,chromatographic and spectral characterization of the 2-
(5-(anthracen-10-yl)-1-phenyl-1H-pyrazol-3-yl)-1-methyl-1H-
benzo[d]imidazole (5j) 
Compound 
code 
Compound Spectral 
Characterization 
Figure 
 
5j 
 
2-(5-(anthracen-10-yl)-1-phenyl-
1H-pyrazol-3-yl)-1-methyl-1H-
benzo[d]imidazole 
Mol.Formula: C31H22N4 
Mol. Wt: 450.18 
Yield: 75% 
Mp: 202- 2050C 
Rf : 0.40 
N
N
N
N
 
IR (KBr) cm-1: 3362 cm-
1 (NH Stretching) ,3179 
cm-1 (Aromatic CH 
stretching),  1590 cm-1  
(Aromatic C= C 
Stretching) , 1625  cm-1 
(Aromatic C= N 
Stretching), 873 cm-1 
(Aromatic C-H 
Bending), 1246 cm-1 
(Aromatic C-N 
Stretching). 
 
 
 
Figure 
5.77 
1H NMR (500 MHz, 
DMSO) δ (ppm): 7.20 – 
7.59  (m, 4H , 
Benzimidazole ), 7.60 – 
8.20  (m, 4H , pyridine ),  
6.51 (s, 1H). 
 
 
Figure  
5.78 
13C-NMR(400 MHz, 
DMSO-d6) δ  in ppm : δ 
138.37 (Benzimidazole – 
C ) ,123.01 
(Benzimidazole – CH 
),143.38 (Pyrazole – C ), 
107.98 (Pyrazole – CH ),  
126.87(Benzene – CH ), 
133.02 (Benzene – C ), 
31.24 (Aliphatic – CH3).  
 
 
Figure  
5.79 
Mass: m/z: 450.18. 
 
Figure  
5.80 
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Figure 5.77: IR spectrum of the 2-(5-(anthracen-10-yl)-1-phenyl-1H-pyrazol-
3-yl)-1-methyl-1H-benzo[d]imidazole (5j) 
 
Figure 5.78: 1H NMR spectrum of the 2-(5-(anthracen-10-yl)-1-phenyl-1H-
pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole (5j) 
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Figure 5.79: 13C-NMR spectrum of the 2-(5-(anthracen-10-yl)-1-phenyl-1H-
pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole (5j) 
 
Figure 5.80: Mass spectrum of the 2-(5-(anthracen-10-yl)-1-phenyl-
1H-pyrazol-3-yl)-1-methyl-1H-benzo[d]imidazole (5j) 
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5.2  In-Vitro Cytotoxicities studies60 
5.2.1 In-vitro cytotoxic evaluation against MCF-7 and CaCo-2 cell line61 
 
Table 5.21: IC50 of the tested compounds against of MCF-7 and CaCo-2 cell 
line - Benzo[d]imidazole pyrimidine derivatives (4a-j) 
S.No Compound 
code 
Substituent 
R 
Substituent 
R1 
Molecular 
Formula 
IC50 ± SD (μM) 
 
MCF-7 CaCo-2 
1 4a H 
 
C17H13N5 8.22  ±  1.48 5.67  ± 1.25 
2 4b H 
N
 
C16H12N6 10.43 ± 1.45 9.56  ±1.33 
3 4c H 
H3CO
Cl  
C19H17N5O2 >30 28.40  ± 248 
4 4d H 
H3CO
OCH3  
C18H14ClN5O 13.05 ±2.07 12.33  ± 1.80 
5 4e H 
 
C25H17N5 
 
>30 ± 2.87 >30 ± 2.98 
6 4f CH3 
 
C18H15N5 
 
>30 ± 2.66 >30 ± 2.43 
7 4g CH3 
N
 
C17H14N6 
 
18.56 ± 2.82 16.23 ± 1.24 
8 4h CH3 
H3CO
Cl  
C19H16ClN5O 
 
>30 ± 2.19 25.50 ± 2.74 
9 4i CH3 
H3CO
OCH3  
C20H19N5O2 
 
25.11 ± 2.44 21.89 ± 2.35 
10 4j CH3 
 
C26H19N5 >30 ± 2.80 >30 ± 2.06 
5-Fluorouracil 7.26 ± 2.30 5.23 ± 2.36 
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Table 5.22: IC50 of the tested compounds against of MCF-7 and CaCo-2 cell 
line - Benzo[d]imidazole pyrazole derivatives (5a-j) 
S.No Compound 
code 
Substituent 
R 
Substituent 
R1 
Molecular 
Formula 
IC50 ± SD (μM) 
 
MCF-7 CaCo-2 
11 5a H 
 
C22H16N4 26.65 ± 2.32 28.45 ± 2.59 
12 5b H 
N
 
C21H15N5 12.79 ± 2.20 9.788 ± 1.48 
13 5c H 
H3CO
Cl  
C23H17ClN4O >30 ± 2.86 >30 ± 2.48 
14 5d H 
H3CO
OCH3  
C24H20N4O2 15.34 ± 2.67 13.27 ± 1.56 
15 5e H 
 
C30H20N4 >30 ± 2.52 >30 ± 2.33 
16 5f CH3 
 
C23H18N4 >30 ± 2.41 >30 ± 2.69 
17 5g CH3 
N
 
C22H17N5 
 
19.04 ± 2.56 17.32 ± 2.27 
18 5h CH3 
H3CO
Cl  
C24H19ClN4O >30 ± 2.38 29.76 ± 2.64 
19 5i CH3 
H3CO
OCH3  
C25H22N4O2 21.73 ± 2.46 18.35 ± 2.54 
20 5j CH3 
 
C31H22N4 
 
>30 ± 2.58 >30 ± 2.62 
5-Fluorouracil 7.26 ± 2.30 5.23 ± 2.36 
 
5.2.2 In-vitro anticancer activity 
 In-vitro anticancer activity was investigated for all synthesised compounds 
to MCF-7 and CaCo-2 in the different doses and found the concentration required 
for the 50 % cell death (IC50).The ability of the test compounds to inhibit cell 
growth was listed in Table 03. The general structure-activity relationship of the 
benzimidazole analogues can be summarized as below: Comparison of the 
cytotoxicity of benzo[d]imidazolyl pyrimidine derivatives and benzo[d]imidazolyl 
Pyrazole derivatives indicates that the importance of substituted benzimidazole 
with pyrimidine derivatives (4a-j ) generally enhance the  cytotoxicity against 
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MCF-7  and CaCo-2 cancer cells. Addition of pyrazole moiety instead of 
pyrimidine moiety with benzimidazole nucleus to give compound (5a-j ) was 
clearly detrimental to the cytotoxicity in both MCF-7  and CaCo-2 cancer cells. It 
should be noted that compound (5a-j ) has a lowest activity than compound.(4a-j ). 
 For compound 4(a-e) (2-position of benzimidazole core was substituted by 
pyrimidine with various aromatic moiety), it indicated that introducing the various 
substituent group to aromatic ring of pyrimidine moiety would not affect their 
efficacy for MCF-7  and CaCo-2 cell lines, but compound 4a,4b,4c,4d, would 
affect their efficacy too much for CaCo-2 cell line: 4a (pyrimidine ring was 
substituted with benzene)  (IC50=5.67μM) was 5.29- fold much stronger than 4e 
and 4f (IC50=>30μM), 4b (pyrimidine ring was substituted with pyridine) 
(IC50=9.56μM) was 3.13- fold stronger than 4e and 4f (IC50=>30μM), 4d 
(pyrimidine ring was substituted with two 3,4-dimethoxy benzene group)  
(IC50=12.33μM) was 2.43-fold much stronger than 4e and 4f (IC50=>30μM), 4c 
(pyrimidine ring was substituted with two 3-chloro4-methoxy benzene group) 
(IC50=28.40μM) was 1.05- fold much stronger than 4e and 4f (IC50=>30μM),  4a 
was also 3.64-fold much stronger than 4e and 4f (IC50=>30μM) against  MCF-7.  
 For compounds 4(f-j) (2-position of 1-methyl-benzimidazole core was 
substituted by pyrimidine with various aromatic moiety), it indicated that 
introducing the various substituent group to aromatic ring of pyrimidine moiety 
not much influence for MCF-7  and CaCo-2 cell lines, but compound 
4g(IC50=16.23μM), 4h(IC50=25.50μM), 4j(IC50=21.89μM) would affect their 
efficacy too much in CaCo-2 cell line compare with MCF-7 cell line. 
For compound 5(a-e) (2-position of benzimidazole core was substituted by 
pyrazole with various aromatic moiety), it indicated that introducing the various 
substituent group to aromatic ring of pyrazole moiety which affect their efficacy 
for MCF-7 and CaCo-2 cell lines. 5b (IC50=9.79μM), 5d (IC50=12.33μM) would 
affect their efficacy too much in CaCo-2 cell line compare with MCF-7 cell line. 
 For compound 5(f-j) (2-position of 1-methyl-benzimidazole core was 
substituted by pyrimidine with various aromatic moiety), it indicated that 
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introducing the various substituent group to aromatic ring of pyrazole moiety not 
much influence for MCF-7  and CaCo-2 cell lines. 5g(IC50=17.32μM), 5i 
(IC50=18.35μM) would affect their efficacy too much in CaCo-2 cell line compare 
with MCF-7 cell line. 
5.2.3 Apoptosis Studies   
 Apoptosis studies were performed with a staining method utilizing 
acridine orange (AO) and ethidium bromide (EB).  
 
 
Figure 5.81: EB/AO method for Caco-2 cells 
White arrows indicate "L" = live cells; "A" = apoptotic cells 
1).control, 2).4 hours, 3).8hours, 4).24 hours 
CaCo-2 cells were treated with 5.67 μM compound 4a for induction of apoptosis. 
The compound 4a induced apoptosis in Caco-2 cells as evaluated by EB/AO 
staining. 
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Figure 5.82: Fold activity of caspase 3 
 
Figure 5.83: Fold activity of caspase 8 
 
 
Figure 5.84: Fold activity of caspase 9 
24 hours Caspase study revealed that compound 4a shows 2 fold activity in 
caspase 3 & 9 pathway, single fold activity in caspase 8 pathway.    
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5.3 Formulation and characterization of nanoparticle62,63 
5.3.1  Preparation of novel benzimidazole derivative [4-(1H-
benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine (4a)]loaded 
chitosannanoaprticles(BZI nano)64 
Synthesised novel benzimidazole derivative [4-(1H-benzo[d]imidazol-2-yl)-6-
phenylpyrimidin-2-amine (4a)] loaded chitosan nanoparticles were prepared using 
ionic gelation method.Optimization of benzimidazole derivative Nanoparticles of 
(CS-NP) on the basis of CS/ TPP ratio was shown in Table  
Table.5.23: Optimization of Nanoparticles of (CS-NP) on the basis of CS/ TPP 
ratio 
S.No 
 
Formulation 
code 
 
CS 
% 
 
TPP 
(%) 
SIZE(nm) PDI 
 
Zeta 
Potential 
(mV) 
 
EE 
(%) 
 
Physical 
appearance 
And 
opacity 
1 BZI 1 nano 0.2 0.2 357.3 ± 
5.7 
0.24 ± 
0.05 
4.89 ± 
0.17 
55.12 
± 3.58 
Opalescent 
suspension 
2 BZI 2 nano 0.4 0.2 297.5 ±6.3 0.27 ± 
0.03 
5.23 ± 
0.24 
61.47 
± 2.46 
Opalescent 
suspension 
3 BZI 3 nano 0.6 0.2 220.2 ± 
4.8 
0.11 ± 
0.02 
5.55 ± 
0.31 
69.2 ± 
2.41 
Opalescent 
suspension 
4 BZI 4 nano 0.2 0.4 421.8 ± 
3.7 
0.32 ± 
0.06 
3.49 ± 
2.41 
64.51 
± 4.39 
Highly 
Opalescent 
suspension 
5 BZI 5 nano 0.4 0.4 376.2 ± 
7.6 
0.37 
±0.08 
3.89 ± 
1.04 
 
56.62 
± 3.45 
Highly 
Opalescent 
suspension 
6 BZI 6 nano 0.6 0.4 343.4 ± 
6.8 
0.35 ± 
0.10 
4.05 ± 
1.82 
63.85 
± 2.74 
Highly 
Opalescent 
suspension 
7 BZI 7 nano 0.2 0.6 436.2 ± 
8.7 
0.37 ± 
0.07 
5.32 ± 
2.64 
60.23 
± 3.51 
Highly 
Opalescent 
suspension 
8 BZI 8 nano 0.4 0.6 359.2 ± 
9.2 
0.41 ± 
0.05 
6.23 ± 
1.53 
58.34 
± 4.65 
Highly 
Opalescent 
suspension 
9 BZI 9 nano 0.6 0.6 362.8 ± 
5.7 
0.39 ± 
0.06 
6.25 ± 
2.61 
 68.52 
± 3.29 
Highly 
Opalescent 
suspension 
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5.3.2  Conditions for formation synthesised novel benzimidazole derivative                                                                                        
[4-(1H-benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-amine (4a)]loaded 
chitosan nanoparticles(BZI nano)65 
5.3.2.1 Effect of Chitosan Concentration 
 When the amount of TPP was kept constant as 0.2% and an rise in 
Chitosan  concentration from 0.2% to 0.6% showed a decrease in the particle size 
with favorable PDI value. When the amount of chitosan exceeded 0.6% of 
Chitosan  a highly opalescent suspension is obtained and it also leads to 
aggregation. Recent studies reported that when the concentration of C hitosan is 
low (0.6%) it forms a low viscosity gelation medium resulting in a decrease  in 
liquid phase dispersion, thus promoting formation of smaller particles. 
5.3.2.2        Effect of Triphenyl phosphate (TPP) concentration 
 The role of TPP (0.2, 0.4 and 0.6%) concentration on particle size 
formation was studied. The increase inTPP concentration showed an increase in 
particle size. The TPP concentration with 0.2 and 0.6 chitosan forms particle 220 
nm at the same time  TPP concentration above 0.4% it results in highly opalescent 
suspension on storage it starts settling of particles. 
5.3.2.3        Effect of Sonication on Particle Size 
 The sonication time in the formation of CS-NP played a crucial role in the 
formation of smaller sizenanoparticles. 
 The smallest nanoparticles (220± 4 nm) were obtained with the sonication 
time of two minutes. While employing ultra-sonication formation of acoustic 
cavitations is the main cause for decreasing particle size. Acoustic cavitations by 
creating a largeshear force on the chitosan molecules breaks the particles in to 
smaller ones. The increase in the sonication time from 30, 60 and 120 seconds 
showed the decreased particle size presented in (Figure 3). The sonication time 
beyond two minutes showed no further decrease in particle size. 
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Figure 5.85:Effect of sonication time on particle size  
 
 
5.3.3 Physicochemical characterization of nanoparticles66 
5.3.3.1Particle Size And Zeta Potential 
The nine formulations were prepared with various concentrations of 
chitosan and TPP. The particle size distribution of prepared CS nanoparticles was 
ranged from 220± 4 to 436±8 nm. With increasing the concentration of CS we 
observed decrease in particle size and increase in zeta value. At 0.2% 
concentration of TPP the cross linking with chitosan is high (0.6%) this result in 
more compact particle structure and the neutralization degree of charged amino 
acid isimproved leading the good net charge of the particles. Due to the compact 
structure and net charge the particles prepared at this concentration have a smaller 
size. 
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Figure 5.86:Particle size of BZI 3 
The zeta potential of the prepared CS nanoparticles was ranged from +3 to 
+6 mV. When increase in the concentration of CS the zeta value increases due to 
the higher degree of protonation of amino group in the CS molecule with the 
strong positive charge which leads to the higher zeta potential.  
The optimum concentration of CS/TPP was identified as 0.6% of CS with 0.2% 
TPP (BZI 3 nano) with size of (220± 4) nm and the zeta potential showed in 
(Figure No.2 and 3)  novel benzimidazole nanoparticle loaded CS-NP (BZI 3 
nano) was 5.55 ± 1 mV which indicates the good colloidal stability of the 
prepared CS NP.  
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Figure 5.87:Zeta potential of BZI 3 
 
5.3.3.2 Transmission electron microscopy TEM images of synthesised novel 
benzimidazole derivative(BZI  nano) 
The TEM images of the prepared novel benzimidazole nanoparticle loaded 
CS-NP (BZI 3 nano) indicate that nanoparticles were roughly spherical in shape 
with size of 200 nm shown in (Figure 5.88).  
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Figure 5.88:TEM images of  synthesised novel benzimidazole derivative 
5.3.3.3 Encapsulation efficiency 
The encapsulation efficiency of 5 Fluorouracil loaded CS-NP were ranged from 
54.7 to 69.2%. The increase in chitosan concentration from 0.2 to 0.6% increases 
in encapsulation was observed at constant TPP concentration of 0.2%. Out of 
these formulations BZI 3 nano was selected as the best formulation based on 
particle size, zeta potential and encapsulation efficiency. The optimized 
formulation was selected for further studies. 
5.3.4.4 In vitro Release67 
A modified dialysis method was used to evaluate the invitro release of novel 
benzimidazole derivative nanoparicle loaded chitosan NPs.Two millilitres of 
nanoparticles suspension (corresponding to 2 mg of benzimidazole derivatives ) 
was placed in a dialysis bag (cellophane membrane, molecular weight cut off 
10,000–12,000, Hi-Media, India) which was tied and placed into 20 ml of 
phosphate buffer (0.1M, pH 7.4) maintained at 37ºC with continuous magnetic 
stirring. At selected time intervals, aliquots were withdrawn from the release 
medium and replaced with the same amount of phosphate buffer. The sample was 
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assayed spectrophotometrically for novel benzimidazole derivative nanoparticle at 
235 nm . 
Table 5.24: Cumulative % Drug Release of synthesised benzimidazole 
derivatives Loaded Nanoparticles  
 
S.No 
 
Time 
(hr) 
BZI 
1 
nano 
BZI 
2 
nano 
BZI 3 
nano 
BZI 4 
nano 
BZI 5 
nano 
BZI 6 
nano 
BZI 7 
nano 
BZI 
8 
nano 
BZI 
9 
nano 
1 0 0 0 0 0 0 0 0 0 0 
2 0.5 27.8 25.4 24.8 28.5 20.8 30.7 29.3 17.6 22.4 
3 1 47.4 48.1 45.2 40.3 43.6 42.4 48.2 36.2 38.6 
4 2 59.3 55.2 49.7 51.7 50.4 47.5 53.6 41.2 43.7 
5 4 63.5 63.6 54.1 58.2 57.3 52.7 59.2 51.5 50.6 
6 6 69.8 72.8 62.6 63.6 62.9 57.3 66.4 58.7 63.5 
7 8 75.7 79.5 74.2 72.1 69.2 68.4 71.8 64.2 69.2 
8 12 79.4 84.8 79.2 76.8 75.1 73.6 77.3 74.2 76.8 
9 16 84.3 89.3 83.1 81.3 79.4 78.7 83.1 79.3 80.3 
10 20 89.2 92.6 89.7 89.3 84.1 86.6 89.4 87.3 88.2 
11 24 98.5 97.3 98.3 99.6 95.7 99.4 96.6 94.5 99.4 
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Time (hrs) 
Figure 5.89:Cumulative % release graph 
 
The cumulative percentage release of optimized novel benzimidazole 
derivative nanoparticle loaded CS-NP (BZI 3  nano) was studied inphosphate 
buffer pH 7.4 and showed in Table No.2 and (Figure 7). The percentage release 
was found to be 98.3 at 24 hrs. The release profile of 5 novel benzimidazole 
derivative nanoparticle loaded CS–NP exhibits a initial release burst release of 
25% in one hour followed by the sustained release of 98% at 24 hrs. The observed 
burst effect was due to the dissociation of drug molecules that were loosely bound 
to the surface of the chitosan nanoparticles. The second part of the release was 
slow and sustained release of encapsulated novel benzimidazole derivative at an 
approximately constant rate from the nanoparticles. 
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5.4In vitro cytotoxicity of nanoparticles68 
5.4.1 In Vitro Cyto Toxicity Study for synthesised benzimidazole derivatives 
Loaded Nanoparticles (BZI 3 nano) 
Table 5.25: IC50 of the 5-Fluorouracil  andsynthesised benzimidazole 
derivatives Loaded Nanoparticles (BZI 3 nano )compounds against of MCF-7 
and CaCo-2 cell 
S.No Compound code 
IC50 ± SD (μM) 
 
MCF-7 
 
CaCo-2 
1 BZI 3 nano 
 
6.26±  1.48 
 
4.21  ± 1.25 
2 4a 
 
8.22  ±  1.48 
 
5.67  ± 1.25 
5-Fluorouracil 7.26 ± 2.30 
 
5.23 ± 2.36 
 
The IC50 of synthesised benzimidazole derivativesLoaded Nanoparticles 
(BZI 3 nano ) increased compare with 5-Fluorouracil (standard) and compound 4a 
against of MCF-7 and CaCo-2 cell compounds against of MCF-7 and CaCo-2 cell 
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5.5Acute Toxicity Study69,70 
 Acute toxicity studies and fixing of dose for the newlyl formulated 
benzimidazole derivative nanoparticle.  
 Acute oral toxicity test was carried out according to the OECD guideline 
No. 423.Male Wistar Albino Rats were kept for overnight fasting prior to drug 
administration. 
 The sighting study of the compound was carried out on the group (3 
numbers) of albino rats of wistar strain of male sex following fixed dose method. 
  Only one animal among the group of three was tested with initial dose 
5mg/kg via orally administration and observe once in 30 min for the first 4 h and 
periodically during the first 24 h for event toxicity or morta lity. Since there was 
no such toxicity or mortality, the other animals in the group were testes with 
initial test dose 5mg/kg and observed for 14 days, the test compound did not 
produce any signs of toxicity or mortality. 
 The procedure of sighting study was repeated at a higher dose of 25mg/kg 
and observed for 14 days, and the test compounds did not produce any signs of 
toxicity or mortality.  
 At 50mg/kg sighting study, the compound produced mortality in more than 
40% of the population with tremors and convulsion. Hence, 5mg/kg was fixed the 
dose strength for the main study.   
5.6  Pharmacological Screening71,72 
 In-vivo studies of Anti-cancer for synthesised novel formulated 
benzimidazole derivative nanoparticle (BZI 3 nano) by DMH induced colon 
cancer.  
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5.6.1    In vivo Methods76 
5.6.1.2 Body Weight Changes77 
Body weight changes on treatment with DMH, 5FU and BZI 3 nano. 
Table 5.26: Body weight changes on treatment with DMH, 5FU and BZI 3 
nano. 
Group/Treatment Initial body 
weight(g) 
Final body 
weight(g) 
Weight 
gain(g) 
Control   165.16 ± 8.93 216.50 ± 7.04 51.34 ± 7.92 
DMH  162.50 ± 7.72 191.83 ± 8.72 29.33 ± 5.24 
DMH+5FU 173.33 ± 7.93 217.60 ± 6.54 44.27 ± 3.04 
*** 
DMH+ BZI 3 
nano 
163.50 ± 6.54 203.33 ± 6.70 39.83 ± 4.54 
** 
Values are mean ± SD, n=6 in each group, statistically significant***p<0.001 
**p<0.01,*p<0.05 when  compared with disease control (DMH treated) group 
(One way ANOVA fallowed by Dunnet‟s test).  
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Figure 5.90:Body weight changes on treatment with DMH, 5FU and BZI 3 
nano. 
Values are mean ± SD, n=6 in each group, statistically significant a***p<0.001, 
b**p<0.01 when compared with disease control (DMH treated) group (One way 
ANOVA fallowed by Dunnet‟s test). 
During the experimental period 30 days, the carcinogen-exposed rats 
(Group II-DMHtreated ) exhibited a significantly (p< 0.05) low gain in body 
weight (Figure 8) and a low growth rate throughout the experimental period as 
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compared to Groups II (DMH+5FU) and IV (DMH+ BZI 3 nano) Oral 
administration of BZI 3 nano at a dose of 5 mg/kg b.w resulted in a significant 
improvement in weight gain relative to treatment with DMH alone. 
5.6.1.3    Determination of Aberrant Crypt Foci (ACF)75 
5.6 .2Aberrant crypt foci scoring - Distribution of altered aberrant crypt foci 
(ACF) category in proximal, distal and total colon of rats exposed to DMH, 
5FU and BZI 3 nano. 
Table 5.27: Aberrant crypt foci scoring - Distribution of altered aberrant 
crypt foci (ACF) category in proximal, distal and total colon of rats exposed 
to DMH, 5FU and BZI 3 nano. 
Group/Treatmen
t 
 
 
No. of 
animal
s 
Total no. 
of AC  
 
Total 
no. of 
ACF  
 
 
Crypt/ACF 
Proximal colon  
Control   6 0 0 0 
DMH  6 21.66 ± 2.47 16.16 ± 3.41 1.34 ±0.70 
DMH+5FU 6 15.33 ± 3.26 10.50 ± 1.19 1.46 ±0.81 
DMH+ BZI 3 nano 6 11.50 ± 1.02 9.33 ± 1.77 1.23 ±0.83 
Distal colon  
 
Control   6 0 0 0 
DMH  6 33.83 ± 2.68 19.16 ± 2.66 1.76 ±0.51 
DMH+5FU 6 24.16 ± 1.68 15.66 ± 3.27 1.54±0.40 
DMH+ BZI 3 nano 6 13.60 ± 1.72 9.50 ± 1.34 1.43±0.72 
Total colon  
 
Control   6 0 0 0 
DMH  6 55.59 ±2.25 35.32±1.64 1.57±0.83 
DMH+5FU 6 39.49 ±1.47 26.16±1.21 1.50±0.81 
DMH+ BZI 3 nano 6 25.10±1.75**
* 
18.83±1.64**
* 
1.33±0.80**
* 
Values are mean ± SD, n=6 in each group, statistically significant***p<0.001 
**p<0.01,*p<0.05 when  compared with disease control (DMH treated) group 
(One way ANOVA fallowed by Dunnet‟s test). 
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Figure 5.91:Aberrant crypt foci scoring  
Values are mean ± SD, n=6 in each group, statistically significant a***p<0.001, 
when compared with disease control (DMH treated) group (One way ANOVA 
fallowed by Dunnet‟s test). 
 ACF formation was observed in all DMH induced groups. The 
majority of ACF appeared in the distal colon of the rats injected with DMH. Oral 
administration of BZI 3 nano at 5 mg/kg b.w. inhibited the formation as well as 
the total number of ACF (Figure 9), as compared to rats injected with DMH 
alone,. No ACF formation was observed in the control (group I - Control). 
 
 
 
 
 
 
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles Page 153 
 
5.6.1.3 Regional distribution of aberrant crypt categories (1, 2, 3, 4 and ≥ 
5) in rats treated with DMH, 5FU and BZI 3 nano. 
Table 5.28 : Regional distribution of aberrant crypt categories (1, 2, 3, 4 and 
≥ 5) in rats treated with DMH, 5FU and BZI 3 nano. 
Group/Treatment   
 
No. 
of 
anim
als 
Number of aberrant crypts per ACF  
 
1 2 3 4 ≥5 
 
Proximal colon  
 
Control   6 0 0 0 0 0 
DMH  6 8.33 ± 
3.61 
6.83 ±2.26 3.16 
±1.72 
2.50 
±1.86 
2.33 
±1.37 
DMH+5FU 6 5.83 ± 
2.33 
4.33 ±3.17 2.83 
±1.68 
1.83 
±1.23 
1.66 
±0.52 
DMH+ BZI 3 nano 6 3.83 ± 
1.67** 
2.83 ±0.17 2.16 
±1.32 
1.33 
±0.87 
1.16 
±0.89 
Distal colon  
 
Control   6 0 0 0 0 0 
DMH  6 15.66 ± 
3.77 
16.50 
±5.62 
12.16 
±1.06 
10.83 
±1.67 
8.16 
±0.63 
DMH+5FU 6 10.16 ± 
4.27 
14.33 
±3.67 
8.50 
±4.4 
8.33 
±2.81 
7.33 
±4.5 
DMH+ BZI 3 nano 6 8.16 ± 
2.82** 
10.16 
±2.12** 
5.16 
±2.89 
5.33 
±2.16 
5.16 
±1.80* 
Total colon  
 
Control   6 0 0 0 0 0 
DMH  6 23.99 
±1.82 
23.33±1.
34 
15.32±
1.38 
13.33±
3.20 
10.49±
2.04 
DMH+5FU 6 15.99 
±2.06 
18.66±2.
16 
11.33±
2.85 
10.16±
2.16 
8.99±1.
67 
DMH+ BZI 3 nano 6 11.99±2.
50 ** 
12.99±2.
80** 
7.32±1.
90 
6.66±1.
64 
6.32±2.
07 
Values are mean±SD, n=6 in each group, statistically significant a 
**p<0.01,b*p<0.05when compared with disease control (DMH treated) group 
(One way ANOVA fallowed by Dunnet‟s test). 
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Figure 5.92:Regional distribution of aberrant crypt categories  
 ACF formation was observed in all DMH induced groups. The 
majority of ACF appeared in the distal colon of the rats injected with DMH. Oral 
administration of BZI 3 nano at 5 mg/kg b.w. inhibited the formation as well as 
the total number of ACF, AC (Figure 9) as compared to rats injected with DMH 
alone. No ACF formation was observed in the control (group I -control). 
5.6.1.4  Apoptosis Measurement in Colonic Mucosa- Effect of DMH, 5FU and 
BZI 3 nano on apoptotic indexes. 
Table5.29: Effect of DMH, 5FU and BZI 3 nano on apoptotic indexes. 
Group/Treatment  
 
Apoptotic 
index  
 
Control   4.16 
DMH  0.80 
DMH+5FU 3.33 ** 
DMH+ BZI 3 nano 3.83 ** 
Values are mean ±SD, n=6 in each group, statistically significant **p<0.01when 
compared with disease control (DMH treated) group (One way ANOVA fallowed 
by Dunnet‟s test). 
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Figure 5.93:Effect of DMH, 5FU and BZI 3 nano on apoptotic indexes. 
Values are mean ±SD, n=6 in each group, statistically significant a**p<0.01,when 
compared with disease control (DMH treated) group (One way ANOVA fallowed 
by Dunnet‟s test). 
 The apoptosis index (AI %) was estimated as the percentage of 
apoptotic cells (i.e., with cellular retraction and condensation, condensed or 
fragmented nuclear chromatin and formation of apoptotic bodies) among the total 
number of counted cells in a whole colonic crypt. The apoptotic index was 
increased in group treated with DMH+ BZI 3 nano compared to DMH treated 
group andDMH + 5FU group.  (Figure 10). 
. 
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5.6.1.5 Haematological Evaluation79 
5.6 .5 Effect of DMH, 5FU and BZI 3 nano on various haematological 
parameters. 
 Table5.30: Effect of DMH, 5FU and BZI 3 nano on various 
haematological parameters. 
Hemotol
ogical 
paramete
rs  
 
Change in hemotological parameters after induction 
 
Control  
 
DMH DMH +5FU DMH + BZI 
3 nano 
Before  
 
After  
 
Before  
 
Afte
r  
 
Befo
re  
 
Afte
r  
 
Befo
re  
 
Afte
r  
 
WBC  
(cells/μL
×103)  
11.16±1.
8 
11.33±2.
4 
11.50± 
1..90 
14.8
3± 
2.40 
11.8
3± 
2.47 
8.66
± 
3.50
** 
11.6
6± 
3.45 
9.50
± 
4.20
** 
RBC  
(cells/μL
×106)  
6.83±0.0
6 
7.50±0.2
6 
6.50±1.0
9 
5.66
± 
1.20  
6.16
± 
1.40 
4.66
± 
0.80
** 
6.50
± 
1.05 
4.83
± 
0.0*
* 
HGB(g/d
L)  
 
11.83±1.
08 
12.16±1.
04 
11.33±2.
32 
9.50
± 
2.56 
11.8
3± 
2.02 
7.50
± 
1.08
* 
11.1
6± 
2.50 
9.83
± 
1.40
** 
PLT  
(cells/μL
×103)  
185.83±
18.78 
187.33±
19.06 
185.50±
15.64 
172.
16± 
1.45 
185.
16± 
15.4
5 
167.
66± 
16.5
0 
185.
83± 
16.2
1 
170.
16± 
15.4
0 
HCT (%)  
 
30.16±1.
21 
32.50±4.
09 
30.66±3.
50 
27.8
3± 
4.65 
30.5
0± 
5.80 
22.5
0± 
4.20 
30.8
3± 
5.40 
28.6
6± 
4.65 
Values are Mean ±S.E.M, n=6 in each group.* P <0.05, ** P <0.01, *** P <0.001 
when compared with disease control group (One way ANOVA followed 
byDunnett‟s test). 
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Various haematological parameters are compared among the groups before and 
after induction of colon cancer.  
5.6.1.6 Individual Organs Weights79 
5.6 .6Effect of DMH, 5FU and BZI 3 nano on relative weight of organs. 
Table5.31: Effect of DMH, 5FU and BZI 3 nano on relative weight of organs. 
Relative wt of 
organs  
(wt of organ/100g)  
 Group/Treatment 
 
Control  
 
DMH DMH+5FU DMH + BZI 3 
nano 
Liver 
 
16.85±0.07 12.29±0.4 14.61±0.06** 13.50±0.18** 
Kidneys 
 
0.93±0.04 0.52±0.02 0.7±0.01** 0.66±0.02** 
 Heart   
 
 
0.49±0.03 0.23±0.02 0.39±0.01 0.32±0.01 
Lungs   
 
0.85±0.01 
 
0.51±0.01 0.74±0.01** 0.69±0.01*** 
 
Pancreas 
 
0.81±0.02 0.57±0.01 0.78±0.005 0.71±0.02 
Spleen 
 
0.39±0.01 0.19±0.01 0.35±0.01** 0.31±0.01*** 
Colon 
 
0.78±0.01 0.56±0.02 0.7±0.01 0.64±0.05 
Stomach 
 
0.80±0.01 0.48±0.01 0.72±0.01 0.65±0.03 
Values are Mean ±S.E.M, n=6 in each group.* P <0.05, ** P <0.01, *** P <0.001 
when compared with disease control group (One way ANOVA followed 
byDunnett‟s test). 
Relative weights of various organs are compared among the groups after induction 
of colon cancer.  
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5.6.1.7       Histopathology of Colon80, 81 
 
 
(1) Control ,(2) DMH Treated,(3) DMH + 5 FU ,(4) DMH + BZI 3 nano 
Figure 5.94:Histopathology of Colon- (1) Topographical view of normal crypt 
(40×). (2) Histological changes in the colonic mucosa on DMH administration 
shows thickened mucosa with densely packed inflammatory cell infiltration 
and a higher degree of hyperplasia (40×). (3) Represents 20 mg/kg b.w., 5FU 
supplemented rat colon showing mucosal thickening and scattered or no 
infiltration of inflammatory cells in the mucosal layer (40×). (4) Represents 5 
mg/kg b.w., BZI 3 nano supplemented rat colon showing mucosal thickening 
in few areas and scattered or no infiltration of inflammatory cells in the 
mucosal layer (40×). 
Pathology of haematoxylin and eosin stained sections of colon slides 
showed that there was a wide range of histology from minor atypia to severe 
dysplasia in DMH treated group than BZI 3 nano treated group. There was no 
change in colonic mucosa of control group rats.  
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6. DISCUSSION 
The novel benzimidazole derivatives were synthesized by 2-acetyl 
benzimidazole  consent to react with various substituted aromatic aldehyde (2a–e) 
to obtain preferred intermediate chalcones (3a–j), these intermediates are undergo 
the cyclocondensation with guanidine hydrochloride and phenyl hydrazine yielded 
benzimidazole derivatives  (4a–j & 5a–j respectively). Melting points of the 
synthesized compounds were determined using melting point apparatus and were 
found uncorrected. The progress of the reaction were monitored by thin layer 
chromatography using precoated sheet silica gel MERCK and was visualized by 
UV lamp. The IR spectra of synthesized compounds were recorded using KBr 
pellets in the range 4000-400cm-1 on the Fourier Transform IR Spectrophotometer 
(Model - Shimadzu –RVS college of pharmaceutical sciences) and frequencies 
were recorded in wave numbers (cm-1). The 1H NMR spectra were recorded by 
BRUKER AV III 500MHz (Indian Institute of Technology, Madras). Chemical 
shifts (δ) are reported in parts per million (ppm) Down filed from internal 
reference tetramethylsilane (TMS). Mass spectrum was recorded by LC-MS 
model –JEOL GC MATE (Indian Institute of Technology, Madras). 
The synthesized compounds were analyzed spectral studies to confirm their 
structure and in-vitro anticancer activity was screened in MCF-7 and CaCo-2. 
Among them the compounds containing benzimidazole with pyrimidine moiety 
(4a, 4b, 4d, 4g, 4i) and compounds containing benzimidazole with pyrazole 
moiety (5b,5d 5g,5i) showed significant activity against MCF-7 and CaCO-2 cell 
line. In particular compound 4a exhibited IC50 8.22μM in MCF-7 , IC50 5.67μM 
CaCO-2 cell line, which can be regarded as promising anticancer potential. 
The compound 4a induced apoptosis in Caco-2 cells as evaluated by EB/AO 
staining.24 hours Caspase study revealed that compound 4a shows 2 fold activity 
in caspase 3 & 9 pathway, single fold activity in caspase 8 pathway.   
In an effort to establish novel benzimidazole derivative with improved 
anticancer activityand achieve the colon target , we report here the formulate  
novel benzimidazole derivative 4-(1H-benzo[d]imidazol-2-yl)-6-phenylpyrimidin-
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2-amine (4a) loaded sustained release nanoparticles with the size of around 220 
nm and to increase the encapsulation efficiency of the drug. The nanoparticles 
were prepared by simple ionic gelation method using various concentrations of 
chitosan and TPP Triphenyl phosphate (TPP) Solution. 
When the amount of TPP was kept constant as 0.2% and an increase in CS 
concentration from 0.2% to 0.6% showed a decrease in the particle size with 
favourable PDI value. When the amount of chitosan exceeded 0.6% of CS a 
highly opalescent suspension is formed and it also leads to aggregation. Recent 
studies reported that when the concentration of CS is low (0.6%) it forms a low 
viscosity gelation medium resulting in a decrease in liquid phase dispersion, thus 
promoting formation of smaller particles.The increase inTPP concentration 
showed an increase in particle size.  
The TPP concentration with 0.2 and 0.6 chitosan forms particle 220 nm at the 
same time  TPP concentration above 0.4% it results in highly opalescent 
suspension on storage it starts settling of particles. 
The prepared nanoparticles were evaluated for particle size, shape, charge, 
encapsulation efficiency, in vitro drug release and in vitro cytotoxicity. The 
optimized synthesised benzimidazole derivatives loaded nanoparticle showed size 
of 220±4 nm with PDI polydispersity index  of 0.11 ±0.07,  Zeta potential of 
+5.55 ±1mv, encapsulation efficiency of 69.2% and the drug release is 98.3% at 
24 hrs.These results demonstrate that the possibility of delivering synthesised 
novel benzimidazole derivative 4-(1H-benzo[d]imidazol-2-yl)-6-phenylpyrimidin-
2-amine (BZI 3 nano) to colorectum with enhanced encapsulation efficiency. 
In vitro cytotoxicity study suggested the safety of the prepared synthesised 
novel benzimidazole derivative 4-(1H-benzo[d]imidazol-2-yl)-6-phenylpyrimidin-
2-amine (BZI 3 nano) loaded chitosan nanoparticles which can be potential carrier 
to deliver hydrophilic drugs to target colorectum.  
In vivo performed to confirm the targeting efficiency of synthesised novel 
benzimidazole derivative 4-(1H-benzo[d]imidazol-2-yl)-6-phenylpyrimidin-2-
amine (BZI 3 nano)  loaded chitosan nanoparticles to treat colorectal cancer. 
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Acute toxicity studies performed on newlyl formulated benzimidazole 
derivative nanoparticle (BZI 3 nano)  (according to OECD guidelines 423). At 
50mg/kg sighting study, the compound produced mortality in more than 40% of 
the population with tremors and convulsion. Hence, from this 1/10th of MTD was 
selected and the effective doses were fixed as 5mg/kg dose strength for the further 
pharmacological studies. 
In vivo study we used DMH as colon cancer inducer and synthesised novel 
benzimidazole derivative nano particle 4-(1H-benzo[d]imidazol-2-yl)-6-
phenylpyrimidin-2-amine (BZI 3 nano) as the test drug.  
Weight loss reflects a common feature of gastrointestinal tumours, and weight 
loss is a frequent cause of concern, the aggressiveness of the disease. As expected 
carcinogen (DMH) treated animals in our study showed decreased weight gain 
compared to other groups. It may be due to reduced food intake. In addition to 
increased hepatic gluconeogenesis and altered glucose metabolism reduces the 
energy sources leading to a significant weight loss in DMH treated animals.  
In this study, colons were examined for ACF 30days after the first injectio n of 
DMH. In our present study increased crypt number was observed in proximal, 
distal and total colons of DMH-treated rats than in treatment group. We also 
identified that the inhibitory effect of BZI 3 nano on the development of ACF was 
more pronounced in the entire period treatment regimen as compared to the other 
treatment groups. Data from ACF incidence indicated that all rats treated with 
DMH developed ACF. The results demonstrated that administration of BZI 3 nano 
may suppress DMH-induced ACF development. BZI 3 nano did not affect the 
number of crypts per ACF but actually suppressed the total number of ACF. 
Besides, the decrease in numbers of ACF suggests that BZI 3 nano may inhibit the 
growth of ACF. The no of ACF in the distal colon were more than the proximal 
colon.  
Pathology of haematoxylin and eosin stained sections of colon slides revealed 
that there was a broad range of histology from minor atypia to severe dysplasia in 
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DMH treated group than BZI 3 nano treated group. There was no change in 
colonic mucosa of control group rats.  
Besides the reduction of ACF, based on the results it also revealed that BZI 3 
nano induces apoptosis the apoptotic index was high in rats treated with DMH and 
BZI 3 nano than rats treated with DMH alone. 
 The results of the present study showed that administration of BZI 3 nano at a 
dose of 5mg/kg body weight during either the initiation, post-initiation or entire 
period phase significantly inhibited DMH-induced colon carcinogenesis in rats. 
Our findings indicate that BZI 3 nano is significantly reduced the number of ACF 
development in the colon. Several studies have suggested the growth features of 
ACF and dysplastic ACF and their location as a measure of the biological efficacy 
of the modifiers of colon carcinogenesis. Thus the data strongly suggest that the 
colon cancer inhibitory effects observed with BZI 3 nano at a dose of 5 mg/kg 
body weight. The inhibitory effect of BZI 3 nano may also due to the induction of 
apoptosis.  
The classical anticancer agents that they require an active transport mechanism 
to enter the cancer cells. This is a major drawback to reach adequate concentration 
of drug inside the cells. To overcome this drawback by various substituted novel 
benzimidazole derivatives were synthesised by using incorporated with different 
heterocycles like pyrimidine, pyrazole and backbone of chalcones. The 
synthesised compounds were characterized and screened for their in-vitro 
anticancer activities and achieve the target drug delivery by nanotechnology. In-
vivo anticancer activities results revealed that the presence substituted 
benzimidazole derivative nanoparticle (BZI 3 nano) could have the anticancer 
potential of the scaffold and selective, good target for drug discovery. 
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7. SUMMARY AND CONCLUSION 
The thesis entitled “SYNTHESIS AND ANTICANCER ACTIVITY OF 
SOME NOVEL BENZIMIDAZOLE NANOPARTICLES” dealswith the rate 
of colorectal cancer incidence is increasing alarmingly in economically 
transitioning countries. The high mortality rate countries may reflect the adoption 
of western lifestyle, food behaviour and physical inactivity. The increased death 
rate added to the huge proportion of colorectal cancer patients in advanced or 
incurable stage shows that treatment is not possible. Many countries undergo rapid 
lifestyle changes that will determine its future disease burden. The incidence of 
colorectal cancer is much lower in India and South Asian countries than in 
Western countries. Consumption of typical vegetarian diet and the regular use of 
spices may be one of the reasons for the low incidence. 
The clinical achievement of related platinum based drugs like cisplatin , as 
anti-cancer agents constitutes the most incredible contribution to the use of metals 
in medicine. However most important problems related with these mettalo-drugs 
include severe toxicity and other side-effects, and main trouble associated with 
resistant. The subsequently most used classes of chemotherapeutic agents in 
cancer therapy include molecules that interfere with intercalators or DNA 
alkylating agents, DNA, like groove binders. However, the activity of various 
anticancer agents is anchored in intercalation, but specificity could be increased 
by addition of definite moiety or substituents on the intercalative aromatic core 
and the classical antitumor agents that they need an active transport mechanism to 
enter the cancer cells. This is a major drawback to reach adequate concentration of 
drug inside the cells.  
To overcome this disadvantage by various substituted novel benzimidazole 
derivatives were synthesised by using incorporated with different heterocycles 
like pyrimidine, pyrazole and backbone of chalcones. The synthesised compounds 
were characterized and screened for their in-vitro anticancer activities and achieve 
the target drug delivery by nanoparticle drug delivery, using biodegradable 
polymers, provides a more effective, less injurious solution to conquer these 
 
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles Page 164 
 
problems.. In-vivo anticancer activities  results revealed that the presence 
substituted benzimidazole derivative nanoparticle (BZI 3 nano) could have the 
anticancer potential of the scaffold and selective, good target for drug discovery, 
which can be regarded as promising anticancer potential. 
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8. IMPACT OF STUDY 
In my research I found that, benzimidazolecomprises a relatively large, 
growing, important pharmacophore and privileged structure in modern drug 
discovery.Nowadays is a moiety of choice which have numerous pharmacological 
properties. Substituted benzimidazole derivatives have found applications in 
diverse therapeutical areas.The literature review revealed that benzimidazole 
derivatives may possess potent anticancer activity and a rational approach for 
design the next generation inhibitors, benzimidazole derivatives. Nanotechnology, 
which are being engineered for the targeted delivery of anticancer drugs. 
Traditional anticancer agents have a drawback that they need an active transport 
mechanism to penetrate the cells.This is a major drawback to reach adequate 
concentration of drug inside the cells.To overcome this disadvantage and 
developed a novel anticancer agent as benzimidazole derivative nano particle, that 
could beselective and goodtarget for drug discovery. Used nanotechnology for 
construct the synthesized benzimidazole derivativeas nano particle for provide the  
customizable, targeted drug delivery vehiclescapable of ferrying large doses of 
chemotherapeutic agentsor therapeutic genes into malignant cells while 
sparinghealthy cells. 
Future studies 
 Benzimidazole derivative nanoparticle explored to benefit modern 
pharmacotherapy and drug discovery. Since only limited scientific studies have 
been carried out so far, a great potential exists to probe the potential therapeutic 
benefit from the Benzimidazole derivativesnano particles used in cancer therapy. 
For reaping such benefit, improving future synthetic research in the cancer therapy 
is essential.  
 
 
 
 
 
                                                                                                          
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles  
 
BIBLIOGRAPHY 
1. Deepak Chowrasia , Chandrabose Karthikeyan , Lokesh Choure , Sahabjada , 
et al  . Synthesis, characterization and anti cancer activity of some fluorinated 
3,6-diaryl-[1,2,4]triazolo[3,4-b][1,3,4] thiadiazoles. Arabian Journal of 
Chemistry. 2013; 7: 418–424. 
2. N. S. Murthy, Aleyamma Mathew, Cancer Epidemiology Prevention and 
Control. current science. 2004; 4; 25 (4): 86. 
3. Chih- Hsiung WU, Chi-chen WU, and Yuan-soon ho. Antitumor of 
combination of Lentinusedodes mycelium extracts with 5-fluorouracil against 
human colon cancer cells xenografted in nude mice. Journal of cancer 
molecules.2007; 3(1): 15-22. 
4. Rebecca Siegel, Ahmedin Jemal. Colorectal Cancer Facts & Figures is a 
publication of the American Cancer Society.American cancer society. 2011: 
1-32. 
5. R. L. Siegel, K. D.Miller, A. Jemal. Cancer statistics - 2015. A Cancer Journal 
for Clinicians. 2015; 65(1): 5–29. 
6. Idress Hamad Attitalla. Anti-colon activity in ethanolic extract of 
Phytolaccaamericanna. Pakistan journal of biological sciences. 2011; 14(19): 
914-915. 
7. Balramsoni, Mahendrasinghranawat. Anil bhandari, Synthesis and in vitro 
antitumor activity of benzimidazole derivatives. International journal of drug 
research and technology. 2012; 2(7): 479-485. 
8. Magdy i. El-zahar1, somaia s. Abd el-karim1, et al  . synthesis, antitumor 
activity and molecular docking study of novel benzofuran-2-yl pyrazole 
pyrimidine derivatives. ActaPoloniaePharmaceutica - Drug Research. 2011; 
68(3): 357-373. 
9. RamanpreetWalia, MD. Hedaitullah, SyedaFarhaNaaz, Khalid Iqbal, et al  . 
Benzimidazole Derivatives – An Overview. International Journal Of Research 
In Pharmacy And Chemistry. 2011; 1:3. 
                                                                                                          
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles  
 
10. A. El Rashedy, Ahmed, Y. Aboul-Enein,  Hassan, et al  .  Benzimidazole 
Derivatives as Potential Anticancer Agents. Mini Reviews in Medicinal 
Chemistry. 2013; 13;3(9): 399-407. 
11. Chavan B B, Chitte P D, Choudhary N P, Albhar KG, et al  . Synthesis and 
biological evaluation of novel benzimidazole derivative with aspirin as potent 
antimicrobial & antifungal. International journal of scientific research and 
reviews. 2012;1(3):22-30. 
12. Celine vidaillac, Jean Guillon, Corinne Arpin, Isabelle Forfar-Bares, et al  . 
Synthesis of Omeprazole Analogues and Evaluation of  These as Potential 
Inhibitors of the Multidrug Efflux Pump NorA of Staphylococcus aureus. 
Antimicrobial Agents And Chemotherapy.  2007; 3: 831–838. 
13. Abbas ahmadi and Babaknahri-niknafs. Synthesis and characterization of 
some benzimidazole derivatives of 1-Bromo-2,4-dinitrobenzene and their 
antifungal activities. Coden ecjhao. 2011;8(S1): S85-S90. 
14. GulugnAyhan-Kılcıgil, CananKus, El_in D. Zdamar, BenayCan-Eke, et al  . 
Synthesis and Antioxidant Capacities of Some New Benzimidazole 
Derivatives. Arch.Pharm. Chem. Life Sci. 2007; 340: 607 – 611. 
15. Ashishkumartewari, Anil Mishra. Synthesis and antiviral activities of N-
substituted-2-substituted-benzimidazole derivatives. Indian journal of 
chemistry.vol. 2006; 45B; Feb :489-493. 
16. Hiroyuki Nakano, TsutomuInoue, NobuhideKawasaki, HidekiMiyataka. 
Synthesis of Benzimidazole Derivatives as Antiallergic Agents with 5-
Lipoxygenase Inhibiting Action. Chem. Pharm. Bull. 1999; 47(11): 1573—
1578. 
17. Singh Gurvinder ,Kaurmanniderjit.  Benzimidazole: The latest information on 
the biological activities. Intentional Research Journal of Pharmacy. 2013; 4: 1. 
18. Sravanthi M, Nagaraju N, Manikanta K, Mogalabi Sk. Synthesis, 
characterization and evaluation of analgesic activity of some 5-nitro 
                                                                                                          
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles  
 
benzimidazolederivatives. Journal of Chemical and Pharmaceutical Research. 
2012; 4(8):3832-3836. 
19. KalyankarTM, Pekamwar SS, Wadher SJ, Tiprale PS. Review on 
Benzimidazole Derivative. International Journal of Chemical and 
Pharmaceutical Sciences.2012; Dec Vol. 3: 4. 
20. KhanFarhan. R., Asnani A. J. Synthesis and Antiulcer, Anti-secretory Activity 
of Some New substituted 2-(Pyrimidinylsulfinyl) Benzamidazoles 
Derivatives. International Journal of Research in Pharmaceutical and 
Biomedical Sciences. 2011; Apr – Jun; Vol. 2 : 2. 
21. Hanan M.Refaat.synthesis and anticancer activity of some novel 2-subtituted       
benzimidazole  derivatives. Eur.J.Med.Chem . 2010; 45: 2949-2956. 
22. Sabitha Alper, O zlem Temiz Arpaci, Esin S ener Aki. some new bi and  
ter-benzimidazole derivatives as topoisomerase I inhibitors. Il Farmaco.2003;  
58: 497-507. 
23. A.selcen Alpan, H.semih gunes, Zeki Topcu . 1H- Benzimidazole derivatives 
as mammalian DNA topoisomerase I inhibitors. Acta Biochemica Polonica,  
2007; 54(3): 561–565. 
24. Christine Le Sann, Anne Baron, John Mann, Hendrik van den berg, et al  .  
New mustard- linked 2-aryl-bis-benzimidazoles with anti-proliferated activity. 
Org.biomol.chem. 2006; 4: 1305-1312. 
25. Junk sun kim, Barbara gatto, Chiang yu, angela Liu. Topoisomerase I 
inhibition and cytotoxicity. J.med.chem.1996; 39(4): 992-998.  
26. A.Selcen Alpan, Selvil zenvir, Istvan zupko. Biological activity of bis-
benzimidazole derivatives on DNA topoisomerse I and Hela, MCF7 and A431 
cells. J.Enzym.Inhib.Med.Ch.2009; 24: 844-849. 
27. Hatem A, Abdel-Azizl, Tamer S, Saleh. Synthesis and in-vitro antitumor 
activity of thiazolo[3,2-a]benzimidazole moiety. Arch.Pharm.Chem.Life.Sci. 
2010; 343: 24-30. 
                                                                                                          
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles  
 
28. M.H.Pourgholami, L.Woon, R.Almajd, J.Akhter.  In vitro and in vivo 
suppression of  growth of hepatocellular carcinoma cells by albendazole. 
Cancer Lett. 2001; 165: 43-49. 
29. Thomas D.Penning , Gui-Dong Zhu , Viraj B.Gandhi , Jianchun Gong , et al  . 
Discovery and SAR of 2(1-prpylpiperidin-4-yl)- 1H Benzimidazole-4-
carboxamide potent of poly (ADP-ribose) polymerase (PARA) for the 
treatment of cancer. Bioorganic & Medicinal Chemistry. 2008, 16(14): 6965-
6975. 
30. Thomas D.Penning , Gui-Dong Zhu , Jianchun Gong, Sheela Thomas, et al  . 
Optimization of phenyl-substituted Benzimidazole  Carboxamide poly (ADP-
ribose) polymerase Inhibitors: Identification of  (S)-2-(2-Fluoro-4-(pyrrolidin-
2-yl)phenyl) -1H-benzimidazole-4-carboxamide (A-966492), a highly potent 
and efficacious Inhibitor . J.Med.Chem. 2010; 53: 3142-3153.  
31. C.R.Calabrese, R.Almassy, S.Barton, M.A.Batey. Anticancer 
chemosensitization and radiosentization by the novel Ploy(ADP-ribose) 
polymerase-1 inhibitors AG14361. J.Natl.Cancer.Inst. 2004; 96: 56-67. 
32. H.E.Bryant, T.Helleday. Ploy(ADP-ribose) polymerase inhibitors as potential  
chemotherapeutic agents. Biochemical Soc.T . 2004; 32: 959-961. 
33. Y.Tong, J.J.Bouska, P.A.Ellis, E.F.Johnson. Synthesis and Evaluation of a 
new  generation of orally efficacious Benzimidazole- Based Ploy(ADP-ribose) 
polymerase-1 (PARP-1) inhibitors as anticancer agents. J.Med.Chem. 2009; 
52: 6803-6813.  
34. Juan C. Stockert, Alfonso Blázquez-Castro, Magdalena Cañete, Richard W. 
Horobin, et al  .   MTT assay for cell viability: Intracellular localization of the 
formazan product is in lipid droplets. Acta Histochem.  2012; December 114 
(8):785–796.  
35. C. Awortwe, P.S. Fasinu ,  B. Rosenkranz . Application of Caco-2 Cell Line 
in Herb-Drug Interaction Studies: Current Approaches and Challenges. J 
Pharm Pharm Sci. 2014; 17(1): 1–19.  
                                                                                                          
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles  
 
36. Tor Lea . Caco-2 Cell Line, The Impact of Food Bioactives on Health. 
Springer link. 2015; 11:103-111. 
37. Tamer S. Saleh, Hatem A. Abdel-Aziz1,  Heba S. A. El-Zahabi. Facile 
Synthesis and In-Vitro Antitumor Activity of Some Pyrazolo[3,4-b]pyridines 
and Pyrazolo[1,5-a]pyrimidines Linked to a Thiazolo[3,2-a]benzimidazole 
Moiety. Arch. Pharm. Chem. Life Sci. 2010; 343: 24–30.  
38. Mansour S. Al-Said, Mahmoud S. Bashandy, Saleh I. Al-qasoumi , Mostafa 
M. Ghorab . Anti-breast cancer activity of some novel 1,2-dihydropyridine, 
thiophene and thiazole derivatives. European Journal of Medicinal Chemistry. 
2011; 46: 137-141.  
39. Liesbeth E Jonges, J Fred Nagelkerke, N Geeske Ensink, Edo A van der 
Velde, et al  . Caspase-3 Activity as a Prognostic Factor in Colorectal 
Carcinoma. Lab Invest. 2001; 81: 681–688. 
40. Rajini sinha, Gloria J. Kim, Shumingnie. Nanotechnology in cancer 
therapeutics: bioconjugated nanoparticles for drug delivery. Molecular cancer 
therapeutics.American association for cancer research. 2006; 5: 1909-1917. 
41. Mostafa M. Ghorab, Mansour S. Alsaid , Mohammed S. Al-Dosari , Marwa 
G. El-Gazzar,  et al  . Design, Synthesis and Anticancer Evaluation of Novel 
Quinazoline-Sulfonamide Hybrids. Molecules. 2016; 21:189.  
42. M. Greenwell , P.K.S.M. Rahman. Medicinal Plants: Their Use in Anticancer 
Treatment. Int J Pharm Sci Res. 2015 ;October 1; 6(10): 4103–4112.  
43. Mohamed Jawed Ahsan. Rationale Design, Synthesis And In Vitro Anticancer 
Activity of New 2,5-Disubstituted-1,3,4-Oxadiazole Analogues.  Chemistry 
Select. 2016; 1; 15: 4713–4720.  
44. Salahuddin  , Mohammad Shaharyar , Avijit Mazumder  , Mohamed Jawed 
Ahsan.  Synthesis, characterization and anticancer evaluation of 2-
(naphthalen-1-ylmethyl/naphthalen- 2-yloxymethyl)-1-[5-(substituted 
phenyl)- [1,3,4]oxadiazol-2-ylmethyl]-1H-benzimidazole. Arabian Journal of 
Chemistry. 2014; 7: 418–424.  
                                                                                                          
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles  
 
45. Azmat ali khan, Amer m. Alanazi, Mumtaz jabeen, Arun chauhan et al  .  
Design, Synthesis and In Vitro Anticancer Evaluation of a Stearic Acid-based 
Ester Conjugate. Anticancer Research. 2013; 33: 2517-2524. 
46. James SE, Burden H, Burgess R, Xie Y, et al  . Anticancer drug- induced 
neurotoxicity and identification of Rho pathway signaling modulators as 
potential neuroprotectants. Neurotoxicol. 2008; 29(4): 605-612.  
47. N. S. Hari Narayana Moorthy, Sergio F. Sousa, Maria J. Ramos, Pedro 
A. Fernande. In Silico–Based Structural Analysis of Arylthiophene 
Derivatives for FTase Inhibitory Activity, hERG, and Other Toxic 
Effects. Journal of Biomolecular Screening. 2011; 16: 9.  
48. T. G. Nithya1, D. Sumalatha. Evaluation Of Invitro Anti-Oxidant And 
Anticancer Activity Of Coriandrum Sativum Against Human Colon 
Cancer Ht- 29 Cell Lines. International Journal of Pharmacy and 
Pharmaceutical Sciences. 2014;  6 : 2.  
49. Mi Hee Park, Ji Eun Hong, Eun Sook Park, Hee Sung Yoon, et al  .  
Anticancer effect of tectochrysin in colon cancer cell via suppression 
of NF-kappaB activity and enhancement of death receptor expression.  
Mol Cancer. 2015; 14: 124. 
50.  Tebbutta N C, Cattellb E. Systemic treatment of colorectal cancer. 
European Journal of Cancer. 2002; 38:1000-1015.  
51. Karanjit Kaur, Kwonho Kim. Studies of chitosan/organic 
acid/Eudragit RS/RL-coated system for colonic delivery. International 
Journal of Pharmaceutics.2009; 366: 140-148.  
52. Sunil A, Agnihotri, Nada Gouda N,  Mallikarjuna. Recent advances on 
chitosan based micro and nanoparticles in drug delivery. Journal of 
Controlled Release. 2004; 100(1) : 5-28. 
53. Emmanuel N K, Sofia A P, Dimitrios N B, George E F. Insight on the 
formation of chitosan nanaoparticles through ionotropic gelation with 
tripoly phosphate. MolecularPharmaceutics.2012; 9(10): 2856-62. 
                                                                                                          
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles  
 
54. Khairia M. Youssef , Azza M. Ezzob, Moushira I. El-Sayed , Amal A. 
Hazzaa ,et al  . Chemopreventive effects of curcumin analogs in DMH-
Induced colon cancer in albino rats model. Future Journal of 
Pharmaceutical Sciences. 2015; 1 : 57-72.  
55. I-Mei Siu, Thomas G. Pretlow, Saeid B. Amini,T , Theresa P. Pretlow. 
Identification of Dysplasia in Human Colonic Aberrant Crypt Foci. 
American Journal of Pathology. 1997; May Vol. 150:5. 
56. Michael J. Wargovich , Vondina R. Brown and Jay Morris. Aberrant 
Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer. 
Cancers . 2010; 2(3) :1705-1716. 
57. Hanan M.Refaat. synthesis and anticancer activity of some novel 2-
subtituted benzimidazole derivatives. Eur.J.Med.Chem . 2010; 45: 
2949-2956. 
58. Christine Le Sann, Anne Baron, John Mann, Hendrik van den berg, 
Mekala Gunaratnam, et al  . New mustard- linked 2-aryl-bis-
benzimidazoles with anti-proliferated activity. Org.biomol.chem. 
2006; 4: 1305-1312. 
59. Junk sun kim, Barbara gatto, Chiang yu, angela Liu. Topoisomerase I 
inhibition and cytotoxicity. J.med.chem.1996; 39(4): 992-998. 
60.  Kamal Ahamed. Synthesis and biological evaluation of 3,5-diaryl 
isoxazoline/isoxazole linked 2,3-dihydroquinazolinone hybrids as 
anticancer agents.Eur J Med Chem. 2011;46:691-703. 
61. Hatem A. Abdel-Aziz1, Tamer S. Saleh, Heba S. A. El-Zahabi. Facile 
Synthesis and In-Vitro Antitumor Activity of Some Pyrazolo[3,4-
b]pyridines and Pyrazolo[1,5-a]pyrimidines Linked to a Thiazolo [3,2-
a] benzimidazole Moiety. Arch. Pharm. Chem. Life Sci. 2010; 343: 
24–30.  
62. Tebbutta N C, Cattellb E. Systemic treatment of colorectal cancer. 
European Journal of Cancer.2002;38:1000-1015. 
                                                                                                          
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles  
 
63. Shu-Jyuan Yang, Ming-Jium Shieh. Colorectal cancer cell detection by 
5-aminolaevulinic acid loaded chitosan nanoparticles. Cancer Letters. 
2009; 273: 210-220. 
64. Guan J, Cheng P, Huang S J, Wu J M.  Optimized Preparation of  
Levofloxacin loaded chitosan nanoparticles by ionotropic gelation. 
Physics Procedia. 2011; 22: 163-169. 
65. Sanjay K, Jain, Anekant Jain, Ganesh N, Jaya Barve. Design and 
development of ligand appended polysaccharidic nanoparticles for the 
delivery of oxaliplatin in colorectal cancer. Nanomedicine, 
Nanotechnology, Biology and Medicine. 2010; 6: 179-190. 
66.  Mohammad pour D N, Eskandari R, Avadi M R, Zolfagharain H, et al  
. Preparation and in vitro characterisation of chitosan nanoparticles 
containing Mesobuthus eupeus Scorpion venom as an antigen delivery 
system. The Journal of Venomous Animals and toxins including 
tropical diseases. 2012;18(1): 44-52. 
67. Zhang Y, Huo M, Zhou J, Zou A, et al  . Solver an add in program for 
modelling and comparison of drug dissolution profiles. AAPS Journal. 
2010; 12(3): 263-71. 
68. Nit in K, Jain , Sanjay K Jian. Development and in vitro 
characterization of galactosylated low molecular weight chitosan 
nanoparticles bearing doxorubicin. AAPS Pharm Sci Tech. 2010; June 
11(2): 686-697.  
69. Lorke, D. A new approach to practical acute toxicity testing. Arch. 
Toxicol. 1983; 54:275-287.  
70. OECD/OCDC, OECD ‘‘Guidelines for Testing of Chemicals’’ 
Revised Draft Guidelines 423; Acute Oral Toxicity.  
71. Venkateshwarlu Eggadi, Swathi Gundamedi, Sharvana Bhava Bandaru 
Sheshagiri .  Evaluation of Anticancer Activity of Annona muricata in 
                                                                                                          
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles  
 
1, 2-Dimethyl Hydrazine Induced Colon Cancer. World Applied 
Sciences Journal. 2014; 32 (3): 444-450. 
72. Roja Pathakota.  Pharmacological evaluation of aegle marmelos for 
anticolon cancer activity in 1, 2 dimethylhydrazine induced colon 
cancer in rats.   World journal of pharmacy and pharmaceutical 
sciences.  2016;  5 (6): 1381-1399. 
73. Martina Perše and Anton Cerar. The dimethylhydrazine induced 
colorectal tumours in rat - experimental colorectal carcinogenesis. 
Radiol Oncol. 2005; 39(1): 61-70.  
74. Ajit B. Patil, Asha S. Jadhav, in-vivo and in-vitro models on colon 
cancer. IJPBS. 2013; JAN-MAR  3(1): 24-31. 
75. M.A.M .Rodrigues, L.A.G.silva, D.M.F.Saladori, J.L.V.de camargo. 
Aberrant crypt foci and colon cancer comparison between a short-and 
medium-term bioassay for colon carcinogenesis using 
dimethylhydrazine in wistar rats. Braz J Med Biol Res. 2002; 35(3): 
351-355. 
76.  Mecklin, J.P, L.B. Svendsen, P. Peltomäki , H.F. Vasen. Hereditary 
nonpolyposis colorectal cancer. Scandinavian Journal of 
Gastroenterology. 1994; 29(8): 673-677.  
77. Aranganathan, S., Selvam, P. Sangeetha, N, Nalini, N. Modulatory 
efficacy of hesperetin (citrus flavanone) on xenobiotic-metabolizing 
enzymes during 1, 2-dimethylhydrazine- induced colon carcinogenesis.  
Chem.–Biol. Interact. 2009;  180: 254–261.  
78. Samaha, H.S, Kelloff , G.J, Steele, V, Rao , C.V, Reddy, B.S. 
Modulation of apoptosis by sulindac, curcumin , phenylethyl-3-
methylcaffeate and 6-phenylhexyl isothiocyanate: apoptotic index as a 
biomarker in colon cancer chemoprevention and promotion. Cancer 
Res. 1997; 57: 1301–1305. 
                                                                                                          
 
Synthesis and anticancer activity of some novel benzimidazole nanoparticles  
 
79.   Roshni, P.S, M. Dhaval , K.G. Ramesh. Anti cancer activity of colon 
specific osmotic drug delivery of acetone extract of Quercus Infectoria 
Olivier, Fagaceae in 1,2-dimethylhydrazine-induced colon cancer in 
rats. Molecular Cytogenetics, 2014;7(1): 14.  
80. Dias, M.C, Spinardi, A.L.T. Rodrigues, M.A. M., De Camargo, J.L.V. 
Teran, E, et al  .  .Lack of chemopreventive effects of ginger on colon 
carcinogenesis induced by 1, 2-dimethylhydrazine in rats. Food and 
chem- toxicol. 2006; 44 (6): 877-884.  
81. Alrawi, S.J, Schiff, M. Carroll, R.E, Dayton, M. Gibbs, et al.  Aberrant 
crypt foci. Anticancer Res. 2006; 26: 107–119. 
Rajendran et al., IJPSR, 2017; Vol. 8(7): 1000-11.                                        E-ISSN: 0975-8232; P-ISSN: 2320-5148 
International Journal of Pharmaceutical Sciences and Research                                                                              1000 
IJPSR (2017), Volume 8, Issue 7                                                                   (Research Article) 
 
Received on 03 January, 2017; received in revised form, 03 May, 2017; accepted, 16 May, 2017; published 01 July, 2017 
SYNTHESIS, CHARACTERIZATION AND IN-VITRO ANTICANCER EVALUATION OF 
NOVEL BENZO[D]IMIDAZOLE DERIVATIVES 
S. S. Rajendran
 1
, G. Geetha 
*2
, R. Venkatanarayanan 
1
 and N. Santhi 
1 
Deparment of Pharmaceutical Chemistry 
1
, RVS College of Pharamceutical Sciences, Sulur, Coimabatore - 
641 402, Tamil Nadu, India. 
Department of Pharmaceutical Chemistry 
2
, PSG College of Pharmacy, Peelamedu, Coimabatore - 641 
004, Tamil Nadu, India. 
 
 
 
ABSTRACT: The novel benzimidazole derivatives were synthesized by 2-
acetyl benzimidazole consent to react with various substituted aromatic 
aldehyde (2a–e) to obtain preferred intermediate chalcones (3a–j), these 
intermediates are undergo the cyclocondensation with guanidine 
hydrochloride and phenyl hydrazine yielded benzimidazole derivatives (4a–j 
and 5a–j respectively). The synthesized compounds were analyzed spectral 
studies to confirm their structure and in-vitro anticancer activity was 
screened in MCF-7 and CaCo-2. Among them the compounds containing 
benzimidazole with pyrimidine moiety (4a, 4b, 4d, 4g, 4i) and compounds 
containing benzimidazole with pyrazole moiety (5b, 5d, 5g, 5i) showed 
significant activity against MCF-7 and CaCO-2 cell line. In particular 
compound 4a exhibited IC50 8.22μM in MCF-7 , IC50 5.67μM CaCO-2 cell 
line. The compound 4a induced apoptosis in Caco-2 cells as evaluated by 
EB/AO staining and 24 hours Caspase study revealed that compound 4a 
shows 2 fold activity in caspase 3 and 9 pathway, single fold activity in 
caspase 8 pathway, which can be regarded as promising anticancer potential. 
INTRODUCTION: The benzimidazole comprises 
a relatively large, growing, important pharmaco-
phore and privileged structure in modern drug 
discovery 
1
. Various substituted benzimidazole 
derivatives have been found to possess potential 
anticancer properties 
2
. Bis and ter - benzimidazole 
derivatives were extraordinarily active compounds 
intrusive with DNA topoisomerase I 
3-4 
and were 
also reported to their cytotoxity against the human 
lympholast cell line 
6
, breast adenocarcinoma and 
skin epidermoid carcinoma 
7
.  
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3- methylthiazolo(3, 2-a)benzimidazole derivatives 
were also reported significant antitumor activity 
against the colon cancer and lower toxicity against 
normal fibroblast 
8
.   
A rational approach for design the next generation 
inhibitors, benzimidazole derivatives, for example, 
Albendazole, a benzimidazole derivative clinically 
used as an anthemintic agent, can also prove in 
both in vitro and in vivo experimental condition    
inhibit the hepatocellular carcinoma proliferation 
9
. 
Cyclic amine containing benzimidazole carbox-
amide 2-(1-propylpiperidin-4-yl)-1H- benzimida-
zole-4- carboxamide 
10
 were vastly more potent as 
poly(ADP-ribose) polymerase inhibitor and also (4-
hydroxyphenyl)benzimidazole-4-carboxamide 2-
(4-oxadiazolyphenyl) derivatives were showed that 
enhance effect in chemotherapy and radiation 
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therapy in-vitro 
11
 and in-vivo 
11
. Tricyclic 
benzimidazole derivative [AG14361], which is 
high – potency PARP-1 inhibitor, has been 
developed and used in-vivo at non-toxic dose to 
enhance the effect of chemotherapy and radiation 
therapy in human cancer cell cultures and 
xenografts 
13, 14
.  
Pyrimidine is a unique molecule possesses wide 
range of biological activity and anticancer property 
like 5-flourouracil 
15, 16
 and pyrazole nucleus are 
also potent medicinal scaffolds and exhibit a full 
spectrum of biological and anticancer activities 
17, 
18
. Both are known to be associated with multiple 
anticancer properties and biological activity. From 
the structural and chemistry point of view, 
literature survey revealed that the utility of 
pyrimidine and pyrazole derivatives are considered 
as useful synthon with benzimidazole derivatives 
could have anticancer potential scaffold. Based on 
all these findings and literature review, the aim of 
present work was focused to synthesis the 
benzimidazole-pyrimidine conjugate and benzimi-
dazole-pyrazole conjugate with backbone scaffold 
of chalcones, in order to investigate there in vitro 
anticancer activities. 
MATERIALS AND METHODS:  
Synthesis Scheme: 
 
 
Synthesis of Benzimidazolyl Chalcones (3a-e): 
Weighed 0.01 molar of 2-acteyl benzimidazole (1a) 
and 10m 30 % potassium hydroxide solution was 
taken in a round bottom flask to this add 0.012 
molar of various aromatic aldehyde (2a-e) namely, 
benzadehyde (2a), pyridine aldehyde (2b), 3-
chloro-4-methoxy benzadehyde (2c), 3,4-
dimethoxy benzadehyde (2d), anthracene aldehyde 
(2e)  separately, with stirring then reflux the 
mixture for 2 hours, cool to room temperature and 
pour in to a beaker containing ice cold water, with 
stirring to get a product. The precipitated chacolnes 
was filtered with ice cold water, washed dried and 
recrystalized from ethanol. The chemical names of 
above synthesized benzimidazoly chalcones as 
follows: (3a-e). 
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 1-(1H-benzo[d]imidazole-2-yl)- 3-phenylprop- 
2-en-1-one 
 1-(1H- benzo[d]imidazole- 2-yl)-3-(pyridine- 4-
yl)prop-2-en-1-one 
 1-(1H- benzo[d]imidazole-2-yl)-3-(3-chloro-4-
methoxyphenyl)prop-2-en-1-one 
 1-(1H-benzo[d]imidazole-2-yl)-3-(3,4-dimetho 
xyphenyl)prop-2-en-1-one 
 3-(anthracen-10-yl)1-(1H-benzo[d]imidazole- 
2-yl)prop-2-en-1-one 
Synthesis of 1-methyl-benzimidazolyl Chalcones 
(3f-j): Weighed 0.01 molar of 1-methyl-2-acteyl 
benzimidazole (1b) and 10m 30% potassium 
hydroxide solution was taken in a round bottom 
fask to this add 0.012 molar of various aromatic 
aldehyde (2a-e) namely, benzadehyde (2a), 
pyridine aldehyde (2b), 3-chloro-4-methoxy 
benzadehyde (2c), 3,4-dimethoxy benzadehyde 
(2d), anthracene aldehyde (2e)  separately, with 
stirring then reflux the mixture for 2 hours, cool to 
room temperature and pour in to a beaker 
containing ice cold water, with stirring to get a 
product. The precipitated chacolnes was filtered 
with ice cold water, washed dried and recrystalized 
from ethanol. The chemical names of above 
synthesized benzimidazoly chalcones as follows: 
(3f-j). 
 1-(1-methyl-1H-benzo[d]imidazole-2-yl)-3-phe 
nylprop-2-en-1-one 
 1-(1-methyl-1H-benzo[d]imidazole-2-yl)-3-(py 
ridine-4-yl)prop-2-en-1-one 
 3-(3-chloro-4-methoxyphenyl) 1-(1-methyl-1H-
benzo[d]imidazole-2-yl)-prop-2-en-1-one 
 3-(3,4-dimethoxyphenyl)-1-(1-methyl-1H-ben 
zo[d]imidazole-2-yl)-prop-2-en-1-one 
 3-(anthracen-10-yl)1-(1-methyl-1H-benzo[d]im 
idazole-2-yl)prop-2-en-1-one 
Synthesis of Benzo[d]imidazol-2-yl Pyrimidine 
Derivatives (4a-e): A mixture of compounds 3(a-e) 
(0.001mol) was condensed with guninidine 
hydrochloride (0.001 mol) in presences of 
potassium hydroxide (0.002 mol) in absolute 
ethanol (5ml) at reflux on a water bath for 3 hours. 
The reaction mixture was cooled at room 
temperature and poured in ice cold water. Solid 
product was filtered and washed with water, dried 
and recrystallized to give 4(a-e), respectively.   
Synthesis of 1-methyl-benzo[d]imidazol-2-yl 
pyrimidine Derivatives (4f-j): A mixture of 
compounds 3(f-j) (0.001mol) was condensed with 
guninidine hydrochloride (0.001 mol) in presences 
of potassium hydroxide (0.002 mol) in absolute 
ethanol (5ml) at reflux on a water bath for 3 hours. 
The reaction mixture was cooled at room 
temperature and poured in ice cold water. Solid 
product was filtered and washed with water, dried 
and recrystallized to give 4(f-j), respectively. 
Synthesis of (pyrazol-3-yl)-benzo[d]imidazole 
Derivatives (5a-e): A mixture of compounds 3(a-e) 
(0.001mol) was condensed with phenyl hydrazine 
(0.001 mol) in presences of potassium hydroxide 
(0.002 mol) in absolute ethanol (5ml) at reflux on a 
water bath for 3 hours. The reaction mixture was 
cooled at room temperature and poured in ice cold 
water. Solid product was filtered and washed with 
water, dried and recrystallized to give 5(a-e), 
respectively.   
Synthesis of (pyrazol-3-yl)-1-methyl-1H-benzo 
[d]imidazole Derivatives (5f-j): A mixture of 
compounds 3(f-j) (0.001 mol) was condensed with 
phenyl hydrazine (0.001 mol) in presences of 
potassium hydroxide (0.002 mol) in absolute 
ethanol (5ml) at reflux on a water bath for 3 hours. 
The reaction mixture was cooled at room 
temperature and poured in ice cold water. Solid 
product was filtered and washed with water, dried 
and recrystallized to give 5(f-j), respectively.   
In-vitro Cytotoxic Evaluation against MCF- and 
Caco-2 Cell Line:  
Cell Culture: MCF-7 (Human breast cancer cell 
line) and Caco-2 (Human colon cancer cell line) 
were obtained from NCCS Pune. It was maintained 
in Roswell Park Memorial Institute (RPMI) 
supplemented with 10% fetal bovine serum (FBS)
 
19, 20
. Approximately 2000 cells/well were seeded in 
96 well pate using culture medium, the viability 
was confirmed. After 24 hrs, the fresh medium with 
the test or standard compound were added at 
respective wells and kept incubation for 72 hrs. 
After incubation the following assays were 
performed. After 72 hrs of the drug treatment the 
fresh medium was changed again for all groups and 
10μl of MTT (5mg/ml stock solution) was added 
and the plates were incubated for an additional 4 
hrs. The medium was discarded and the formazan 
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blue, which was formed in the cells, was dissolved 
with 100μ of DMSO. The optical density was 
measured at 570nm. 
The percentage toxicity was calculated by using 
following formula. Graph pad prism software was 
used to calculate IC50 of the extracts. 
% Toxicity = 1- Treated cells / Untreated cells X 100 
RESULT AND DISCUSSION: Melting points of 
the synthesized compounds were determined using 
melting point apparatus and were found 
uncorrected. The progress of the reaction was 
monitored by thin layer chromatography using pre-
coated sheet silica gel MERCK and was visualized 
by UV lamp. The IR spectra of synthesized 
compounds were recorded using KBr pellets in the 
range 4000-400cm
-1
 on the Fourier Transform IR 
Spectrophotometer (Model - Shimadzu) and 
frequencies were recorded in wave numbers (cm
-1
). 
The 
1
H NMR spectra were recorded by BRUKER 
AV III 500MHz (Indian Institute of Technology, 
Madras). Chemical shifts (δ) are reported in parts 
per million (ppm). Down fied from internal 
reference tetramethylsilane (TMS). Mass spectrum 
was recorded by LC-MS model - JEOL GC MATE 
(Indian Institute of Technology, Madras). 
Spectral Discussion: 
4-(1H-benzo[d]imidazol-2-yl)-6-phenylpyrimidin 
-2-amine (4a): Rf = 0.75, MP = 146 °C, IR (KBr) 
cm
-1
: 3378 cm
-1
 (NH2 Stretching), 3523 cm
-1 
(NH 
Stretching), 3201 cm
-1
 (Aromatic CH Stretching), 
1453 cm
-1 
 (Aromatic C=C Stretching), 1589 cm
-1
 
(Aromatic C=N Stretching), 988 cm
-1 
(Aromatic C-
H Stretching), 1303 cm
-1 
(Aromatic C-N 
Stretching). 
1
H NMR (500 MHz, DMSO) δ (ppm): 
7.48 - 8.20 (m, 4H, Benzimidazole), 7.21 - 7.47 (m, 
5H, Ar-H), 4.17 (s, 2H, Amino pyridine), 5.13 (s, 
1H). 
13
C-NMR (400 MHz, DMSO-d6) δ (ppm): δ 
154.79 (Benzimidazole-C), 124.02 (Benzimidazole 
- CH), 126.87 (Benzene - CH), 133.02 (Benzene - 
C), 163.79 (Pyrimidine - C), 95.45 (Pyrimidine - 
CH). Mass: m/z: 287.32. 
4- (1H-benzo[d]imidazol- 2- yl)- 6- (pyridin-4-yl) 
pyrimidin-2-amine (4b): Rf = 0.65, MP = 156 °C, 
IR (KBr) cm
-1
: 3412 cm
-1
 (NH2 Stretching), 3556 
cm
-1 
(NH Stretching), 3140 cm
-1
 (Aromatic CH 
Stretching), 1439 cm
-1 
 (Aromatic C=C Stretching), 
1589 cm
-1
 (Aromatic C=N Stretching), 915 cm
-1 
(Aromatic C-H Stretching), 1290 cm
-1 
(Aromatic 
C-N Stretching). 
1
H NMR (500 MHz, DMSO) δ 
(ppm): 7.71 – 8.16 (m, 4H, Benzimidazole), 7.08 - 
7.11 (m, 5H, Ar-H), 4.27 (s, 2H, Amino pyridine), 
5.17 (s, 1H). 
13
C-NMR (400 MHz, DMSO-d6) δ 
(ppm): δ 154.95 (Benzimidazole-C), 121.81 
(Benzimidazole - CH), 126.87, 163.79 (Pyrimidine 
- C), 95.45 (Pyrimidine - CH), 146.04 (Pyridine-C), 
121.81(Pyridine-CH). Mass: m/z: 288.31. 
4-(1H-benzo[d]imidazol- 2-yl)- 6- (3- chloro-4-
methoxyphenyl)pyrimidin-2-amine (4c): Rf = 
0.40, MP = 216 °C, IR (KBr) cm
-1
: 3378 cm
-1 
(NH2 
Stretching) , 3523 cm
-1 
(NH Stretching), 3201 cm
-1
 
(Aromatic CH stretching), 1418 cm
-1 
(Aromatic C 
= C Stretching), 1589 cm
-1
 (Aromatic C = N 
Stretching), 875 cm
-1
 (Aromatic C-H Bending), 
1303 cm
-1
 (Aromatic C-N Stretching), 1118 cm
-1
 
(C-Cl Stretching). 
1
H NMR (500 MHz, DMSO) δ 
(ppm): 7.48 - 8.26 (m, 4H, Benzimidazole), 6.94 - 
7.40 (m, 4H, Ar-H), 4.09 (s, 2H, Amino pyridine), 
5.13 (s, 1H,), 3.46- 3.62 (m, 6H, 2 - OCH3). 
13
C-
NMR (400 MHz, DMSO-d6) δ in ppm: δ 154.04 
(Benzimidazole - C), 124.02 (Benzimidazole - 
CH), 126.87 (Benzene - CH), 133.02 (Benzene - 
C), 163.95 (Pyrimidine - C), 93.45 (Pyrimidine -
CH) Mass: m/z: 351.79 
4-(1H-benzo[d]imidazol-2-yl)- 6- (3,4- dimethoxy 
phenyl)pyrimidin-2-amine(4c): Rf = 0.80, MP = 
140 °C, IR (KBr) cm
-1
: 3484 cm
-1 
(NH2 Stretching), 
3398 cm
-1 
(NH Stretching), 3284 cm
-1
 (Aromatic 
CH stretching), 1585 cm
-1 
(Aromatic C=C 
Stretching) , 1589 cm
-1
 (Aromatic C=N Stretching), 
879 cm
-1
 (Aromatic C-H Bending), 1383 cm
-1
 
(Aromatic C-N Stretching). 
1
H NMR (500 MHz, 
DMSO) δ (ppm): 7.21 - 7.47 (m, 4H, 
Benzimidazole), 7.48 - 8.20 (m, 5H, Ar-H), 4.17 (s, 
2H, Amino pyridine), 5.13 (s, 1H). 
13
C-NMR (400 
MHz, DMSO-d6) δ in ppm: δ 154.81 (Benzimi-
dazole - C), 115.27 (Benzimidazole - CH), 163.81 
(Pyrimidine - C), 95.62 (Pyrimidine - CH) Mass: 
m/z: 347.37. 
4-(anthracen-10-yl)- 6- (1H-benzo[d]imidazol- 2-
yl)pyrimidin-2-amine (4e): Rf = 0.70, MP = 190 
°C, IR (KBr) cm
-1
: 3313 cm
-1 
(NH2 Stretching), 
3370 cm
-1 
(NH Stretching), 3100 cm
-1
 (Aromatic 
CH stretching), 1428 cm
-1 
(Aromatic C=C 
Stretching), 1534 cm
-1
 (Aromatic C=N Stretching), 
860 cm
-1
 (Aromatic C-H Bending), 1370 cm
-1
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(Aromatic C-N Stretching), 1118 cm
-1
 (C-Cl 
Stretching). 
1H NMR (500 MHz, DMSO) δ (ppm): 
7.46 - 7.87 (m, 4H, Benzimidazole), 7.25 - 7.49 (m, 
10H, Ar-H), 4.17 (s, 2H, Amino pyridine), 5.10 (s, 
1H). 
13
C-NMR (400 MHz, DMSO-d6) δ in ppm: δ 
154.44 (Benzimidazole - C), 123.02 (Benzimida 
zole - CH), 163.32 (Pyrimidine - C), 95.70 
(Pyrimidine - CH). Mass: m/z: 387.15 
4-(1-methyl-1H-benzo[d]imidazol-2-yl)-6-phenyl 
pyrimidin-2-amine (4f): Rf = 0.75, MP = 152 °C, 
IR (KBr) cm
-1
: 3378 cm
-1 
(NH2 Stretching), 3523 
cm
-1 
(NH Stretching), 3201 cm
-1
 (Aromatic CH 
stretching), 1453 cm
-1 
(Aromatic C= C Stretching), 
1589 cm
-1
 (Aromatic C= N Stretching), 988 cm
-1
 
(Aromatic C-H Bending), 1303 cm
-1
 (Aromatic C-
N Stretching). 
1H NMR (500 MHz, DMSO) δ 
(ppm): 7.48 - 8.21 (m, 4H, Benzimidazole), 7.19 - 
7.47 (m, 5H, Ar-H), 4.17 (s, 2H, Amino pyridine), 
4.90 (s, 1H). 
13
C-NMR (400 MHz, DMSO-d6) δ in 
ppm: δ 154.79 (Benzimidazole - C), 123.02 
(Benzimidazole - CH), 119.87(Benzene - CH), 
133.02 (Benzene - C), 163.79 (Pyrimidine -C), 
95.17 (Pyrimidine - CH), 32.04 (Aliphatic - CH3) 
78.89 (Aliphatic - CH) Mass: m/z: 301.13. 
4-(1-methyl-1H-benzo[d]imidazol-2-yl)-6-(pyrid 
ine-4-yl)pyrimidin-2-amine (4g): Rf = 0.65, MP = 
154 °C, IR (KBr) cm
-1
: 3410 cm
-1 
(NH2 Stretching), 
3556 cm
-1 
(NH Stretching), 3140 cm
-1
 (Aromatic 
CH stretching), 1439 cm
-1 
(Aromatic C=C 
Stretching) , 1589 cm
-1
 (Aromatic C=N Stretching), 
915 cm
-1
 (Aromatic C-H Bending), 1290 cm
-1
 
(Aromatic C-N Stretching). 
1
H NMR (500 MHz, 
DMSO) δ (ppm): 7.66 - 7.71 (m, 4H, 
Benzimidazole), 7.08 - 7.11 (m, 5H, Ar-H), 4.27 (s, 
2H, Amino pyridine), 5.17 (s, 1H). 
13
C-NMR (400 
MHz, DMSO-d6) δ in ppm: δ 154.90 
(Benzimidazole - C), 123.71 (Benzimidazole - 
CH), 163.36 (Pyrimidine - C), 95.17 (Pyrimidine -
CH) 31.04 (Aliphatic - CH3). Mass: m/z: 302.13. 
4-(3-chloro-4-methoxyphenyl)- 6-(1- methyl- 1H-
benzo[d]imidazol- 2-yl)pyrimidin- 2- amine (4h): 
Rf = 0.82, MP = 204 °C, IR (KBr) cm
-1
: 3484 cm
-1 
(NH2 Stretching), 3398 cm
-1 
(NH Stretching), 3284 
cm
-1
 (Aromatic CH stretching), 1585 cm
-1  
(Aromatic C=C Stretching), 1589 cm
-1
 (Aromatic 
C=N Stretching), 879 cm
-1
 (Aromatic C-H 
Bending), 1383 cm
-1
 (Aromatic C-N Stretching). 
1H NMR (500 MHz, DMSO) δ (ppm): 7.47 - 8.20 
(m, 4H, Benzimidazole), 7.48 - 8.26 (m, 5H, Ar-H), 
4.76 (s, 2H, Amino pyridine), 5.13 (s, 1H). 
13
C-
NMR (400 MHz, DMSO-d6) δ in ppm: δ 154.04 
(Benzimidazole - C), 124.02 (Benzimidazole - 
CH), 126.87 (Benzene -NCH), 133.02 (Benzene - 
C), 163.95 (Pyrimidine - C), 93.45 (Pyrimidine -
CH), 55.71 (Aliphatic - CH3). 31.89 (Aliphatic - 
CH3). Mass: m/z: 365.15. 
4-(3,4-dimethoxyphenyl)-6- (1-methyl-1H- benzo 
[d]imidazol-2-yl)pyrimidin-2-amine (4i): Rf = 
0.68, MP = 202 °C, IR (KBr) cm
-1
: 3378 cm
-1 
(NH2 
Stretching ), 3523 cm
-1 
(NH Stretching), 3201 cm
-1
 
(Aromatic CH stretching), 1418 cm
-1  
(Aromatic C= 
C Stretching), 1589 cm
-1
 (Aromatic C=N 
Stretching), 875 cm
-1
 (Aromatic C-H Bending), 
1303 cm
-1
 (Aromatic C-N Stretching), 1118 cm
-1
  
(C-Cl Stretching). 
1H NMR (500 MHz, DMSO) δ 
(ppm): 7.65 - 8.19 (m, 4H, Benzimidazole), 7.39 - 
7.54 (m, 4H, Ar-H), 4.46 (s, 2H, Amino pyridine), 
5.10 (s, 1H), 3.63- 3.72 (m, 6H, 2 - OCH3).
 13
C-
NMR (400 MHz, DMSO-d6) δ in ppm: δ 154.81 
(Benzimidazole - C), 115.27 (Benzimidazole - 
CH), 163.81 (Pyrimidine - C), 95.62 (Pyrimidine -
CH), 56.71 (Aliphatic - CH3). 31.89 (Aliphatic - 
CH3). Mass: m/z: 361.15 
4-(anthracen-10-yl)- 6- (1- methyl- 1H- benzo[d] 
imidazol-2-yl)pyrimidin-2-amine (4j): Rf = 0.60, 
MP = 208 °C, IR (KBr) cm
-1
: 3313 cm
-1 
(NH2 
Stretching), 3375 cm
-1 
(NH Stretching), 3099 cm
-1
 
(Aromatic CH stretching), 1428 cm
-1  
(Aromatic C= 
C Stretching), 1534 cm
-1
 (Aromatic C=N 
Stretching), 860 cm
-1
 (Aromatic C-H Bending), 
1370 cm
-1
 (Aromatic C-N Stretching), 1118 cm
-1
  
(C-Cl Stretching). 
1H NMR (500 MHz, DMSO) δ 
(ppm): 7.46 - 7.87 (m, 4H, Benzimidazole), 7.25 - 
7.49 (m, 10H, Ar-H), 4.17 (s, 2H, Amino pyridine), 
5.10 (s, 1H). 
13
C-NMR (400 MHz, DMSO-d6) δ in 
ppm: δ 154.44 (Benzimidazole - C), 123.02 (Benzi-
midazole - CH), 163.32 (Pyrimidine - C), 95.70 
(Pyrimidine - CH), 31.90 (Aliphatic - CH3). Mass: 
m/z: 401.46. 
2-(1,5- diphenyl- 1H-pyrazol-3-yl)- 1H-benzo[d] 
imidazole (5a): Rf = 0.7, MP = 168 °C, IR (KBr) 
cm
-1
: 3520 cm
-1 
(NH Stretching), 3100 cm
-1
 
(Aromatic CH stretching), 1505 cm
-1 
(Aromatic 
C=C Stretching), 1534 cm
-1
 (Aromatic C=N 
Stretching), 880 cm
-1
 (Aromatic C-H Bending), 
1303 cm
-1
 (Aromatic C-N Stretching), 1168 cm
-1
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(C-O-C Stretching). 
1
H NMR (500 MHz, DMSO) δ 
(ppm): 7.75 - 7.77 (m, 4H, Benzimidazole), 6.96 - 
7.51 (m, 10H, Ar-H), 5.22 (s, 1H,), 4.02- 4.06 (m, 
6H, 2 - OCH3).
 13
C-NMR (400 MHz, DMSO-d6) δ 
in ppm: δ 138.37 (Benzimidazole - C), 123.01 
(Benzimidazole - CH), 143.38 (Pyrazole - C), 
107.98 (Pyrazole - CH), 126.87(Benzene - CH), 
133.02 (Benzene - C), 163.79 (Pyrimidine - C), 
95.45 (Pyrimidine - CH). Mass: m/z: 336.14. 
2-(1-phenyl-5-(pyridin-4-yl)- 1H-pyrazol- 3-yl)-1 
H-benzo[d]imidazole (5b): Rf = 0.62, MP = 176 
°C, IR (KBr) cm
-1
: 3523 cm
-1 
(NH Stretching), 
3094 cm
-1
 (Aromatic CH stretching), 1505 cm
-1 
(Aromatic C= C Stretching), 1534 cm
-1
 (Aromatic 
C=N Stretching), 880 cm
-1
 (Aromatic C-H 
Bending), 1303 cm
-1
 (Aromatic C-N Stretching), 
1168 cm
-1
 (C-O-C Stretching). 
1
H NMR (500 MHz, 
DMSO) δ (ppm): 7.75 - 7.77 (m, 4H, 
Benzimidazole), 6.96 - 7.51 (m, 10H, Ar-H), 5.22 
(s, 1H,), 4.02- 4.06 (m, 6H, 2 - OCH3). 
13
C-NMR 
(400 MHz, DMSO-d6) δ in ppm: δ 138.37 
(Benzimidazole - C), 123.01 (Benzimidazole - 
CH), 126.38 (Pyrazole - C), 108.98 (Pyrazole - 
CH), 126.87(Benzene - CH), 139.02 (Benzene - C), 
149.79 (Pyridine - C), 121.45 (Pyridine - CH). 
Mass: m/z: 337.13. 
2-(5-(3-chloro-4-methoxyphenyl)- 1- phenyl- 1H-
pyrazol-3-yl)-1H-benzo[d]imidazole (5c): Rf = 
0.55, MP = 192 °C, IR (KBr) cm
-1
: 3484 cm
-1 
(NH 
Stretching), 3100 cm
-1 
(NH Stretching), 3284 cm
-1
 
(Aromatic CH stretching), 1585 cm
-1 
(Aromatic 
C=C Stretching), 1589 cm
-1
 (Aromatic C=N 
Stretching), 879 cm
-1
 (Aromatic C-H Bending), 
1383 cm
-1
 (Aromatic C-N Stretching). 
1
H NMR 
(500 MHz, DMSO) δ (ppm): 7.21 - 7.47 (m, 4H, 
Benzimidazole), 7.48 - 8.20 (m, 5H, Ar-H), 5.13 (s, 
1H). 
13
C-NMR (400 MHz, DMSO-d6) δ in ppm: δ 
154.01 (Benzimidazole - C), 123.37 (Benzimi-
dazole - CH), 143.38 (Pyrazole - C), 107.98 
(Pyrazole - CH), 126.87(Benzene - CH), 133.02 
(Benzene - C), 55.40 (Aliphatic - CH3). Mass: m/z: 
400.11. 
2-(5-(3,4-dimethoxyphenyl)- 1- phenyl- 1H-pyra- 
zol-3-yl)-1H-benzo[d]imidazole (5d): Rf = 0.45, 
MP = 182 °C, IR (KBr) cm
-1
: 3391 cm
-1 
(NH 
Stretching), 3099 cm
-1
 (Aromatic CH stretching),  
1453 cm
-1  
(Aromatic C=C Stretching), 1623 cm
-1
 
(Aromatic C=N Stretching), 759 cm
-1
 (Aromatic C-
H Bending), 1505 cm
-1
 (Aromatic C-N Stretching). 
1H NMR (500 MHz, DMSO) δ (ppm): 7.11 - 7.33 
(m, 4H, Benzimidazole), 7.34 - 7.42 (m, 13H, Ar-
H), 5.11 (s, 1H). 
13
C-NMR (400 MHz, DMSO-d6) δ 
in ppm: δ 154.01 (Benzimidazole - C), 123.37 
(Benzimidazole - CH), 142.38 (Pyrazole - C), 
107.98 (Pyrazole - CH), 126.87(Benzene - CH), 
133.02 (Benzene - C), 56.24 (Aliphatic - CH3). 
Mass: m/z: 396.16 
2-(5-(anthracen-10-yl)- 1- phenyl-1H-pyrazol- 3-
yl)-1H-benzo[d]imidazole (5e): Rf = 0.70, MP = 
162 °C, IR (KBr) cm
-1
: 3370 cm
-1 
(NH Stretching), 
3100 cm
-1
 (Aromatic CH stretching), 1428 cm
-1 
(Aromatic C=C Stretching), 1534 cm
-1
 (Aromatic 
C=N Stretching), 860 cm
-1
 (Aromatic C-H 
Bending), 1370 cm
-1
 (Aromatic C-N Stretching), 
1118 cm
-1
  (C-Cl Stretching). 
1
H NMR (500 MHz, 
DMSO) δ (ppm): 7.46 - 7.87 (m, 4H, Benzi-
midazole), 7.25 - 7.49 (m, 10H, Ar-H), 5.10 (s, 
1H). 
13
C-NMR (400 MHz, DMSO-d6) δ in ppm: δ 
138.37 (Benzimidazole - C), 123.01 (Benzimi-
dazole - CH), 143.38 (Pyrazole - C), 107.98 
(Pyrazole - CH), 126.87(Benzene - CH), 133.02 
(Benzene - C). Mass: m/z: 436.17. 
2-(1,5-diphenyl-1H-pyrazol-3-yl)- 1- methyl- 1H-
benzo[d]imidazole (5f): Rf = 0.6, MP = 164 °C, IR 
(KBr) cm
-1
: 3523 cm
-1 
(NH Stretching), 3195 cm
-1
 
(Aromatic CH stretching), 1399 cm
-1 
(Aromatic 
C=C Stretching), 1625 cm
-1
 (Aromatic C=N 
Stretching), 888 cm
-1
 (Aromatic C-H Bending), 
1324 cm
-1
 (Aromatic C-N Stretching). 
1
H NMR 
(500 MHz, DMSO) δ (ppm): 7.26 - 7.70 (m, 4H, 
Benzimidazole), 7.72 - 8.48 (m, 4H, Ar-H). 
13
C-
NMR (400 MHz, DMSO-d6) δ in ppm: δ 141.45 
(Benzimidazole - C), 115.30 (Benzimidazole - 
CH), 143.38 (Pyrazole - C), 107.98 (Pyrazole - 
CH), 126.87 (Benzene - CH), 133.02 (Benzene - 
C), 31.24 (Aliphatic - CH3). Mass: m/z: 350.15. 
1-methyl- 2- (1-phenyl-5- (pyridin-4-yl)- 1H-
pyra zol-3-yl)-1H-benzo[d]imidazole (5g): Rf = 
0.67, MP = 210 °C, IR (KBr) cm
-1
: 3556 cm
-1 
(NH 
Stretching), 3140 cm
-1
 (Aromatic CH stretching), 
1439  cm
-1 
(Aromatic C= C Stretching, 1589 cm
-1
 
(Aromatic C= N Stretching), 915 cm
-1
 (Aromatic 
C-H Bending), 1290 cm
-1
 (Aromatic C-N 
Stretching). 
1H NMR (500 MHz, DMSO) δ (ppm): 
7.66 - 7.71 (m, 4H , Benzimidazole), 7.08 - 7.11 
(m, 5H , Ar-H), 5.17 (s, 1H). 
13
C-NMR (400 MHz, 
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DMSO-d6) δ  in ppm: δ 138.37 (Benzimidazole - 
C), 123.01 (Benzimidazole - CH), 126.38 (Pyrazole 
- C), 108.98 (Pyrazole - CH), 126.87(Benzene - 
CH), 139.02 (Benzene - C), 141.79 (Pyridine -C), 
121.45 (Pyridine - CH), 31.24 (Aliphatic - CH3). 
Mass: m/z: 351.15. 
2-(5-(3-chloro-4-methoxyphenyl)- 1 -phenyl- 1H-
pyrazol-3-yl)- 1- methyl- 1H- benzo[d] imidazole 
(5h): Rf = 0.75, MP = 169 °C, IR (KBr) cm
-1
: 3484 
cm
-1 
(NH2 Stretching), 3398 cm
-1 
(NH Stretching), 
3284 cm
-1
 (Aromatic CH stretching), 1585 cm
-1  
(Aromatic C=C Stretching), 1589 cm
-1
 (Aromatic 
C=N Stretching), 879 cm
-1
 (Aromatic C-H 
Bending), 1383 cm
-1
 (Aromatic C-N Stretching). 
1
H NMR (500 MHz, DMSO) δ (ppm): 7.47- 8.20 
(m, 4H, Benzimidazole), 7.48 - 8.26 (m, 5H, Ar-H), 
4.76 (s, 2H, Amino pyridine), 5.13 (s, 1H). 
13
C-
NMR (400 MHz, DMSO-d6) δ in ppm: δ 138.01 
(Benzimidazole - C), 123.37 (Benzimidazole - 
CH), 143.38 (Pyrazole - C), 107.98 (Pyrazole - 
CH), 126.87(Benzene - CH), 133.02 (Benzene - C), 
31.24 (Aliphatic - CH3), 55.24(Aliphatic - CH3). 
Mass: m/z: 414.12. 
2-(5-(3,4-dimethoxyphenyl)-1-phenyl-1H-pyrazo 
l-3-yl)-1-methyl-1H-benzo[d]imidazole (5i): Rf = 
0.62, MP = 203 °C, IR (KBr) cm
-1
: 3378 cm
-1 
(NH2 
Stretching), 3523 cm
-1 
(NH Stretching), 3201 cm
-1
 
(Aromatic CH stretching), 1418 cm
-1 
(Aromatic 
C=C Stretching), 1589 cm
-1
 (Aromatic C=N 
Stretching), 875 cm
-1
 (Aromatic C-H Bending), 
1303 cm
-1
 (Aromatic C-N Stretching), 1118 cm
-1
  
(C-Cl Stretching). 
1H NMR (500 MHz, DMSO) δ 
(ppm): 7.65 - 8.19 (m, 4H, Benzimidazole), 7.39 - 
7.54 (m, 4H, Ar-H), 5.10 (s, 1H), 3.63- 3.72 (m, 
6H, 2 - OCH3). 
13
C-NMR (400 MHz, DMSO-d6) δ 
in ppm: δ 154.01 (Benzimidazole - C), 123.37 
(Benzimidazole - CH), 142.38 (Pyrazole - C), 
107.98 (Pyrazole - CH), 126.87(Benzene - CH), 
133.02 (Benzene - C), 31.24(Aliphatic - CH3), 
56.24 (Aliphatic - CH3). Mass: m/z: 410.17. 
2-(5-(anthracen-10-yl)-1- phenyl- 1H-pyrazol- 3-
yl)-1-methyl-1H-benzo[d]imidazole (5j): Rf = 0.4 
MP = 205 °C, IR (KBr) cm
-1
: 3362 cm
-1 
(NH 
Stretching), 3179 cm
-1
 (Aromatic CH stretching),  
1590 cm
-1  
(Aromatic C=C Stretching), 1625 cm
-1
 
(Aromatic C=N Stretching), 873 cm
-1
 (Aromatic C-
H Bending), 1246 cm
-1
 (Aromatic C-N Stretching). 
1H NMR (500 MHz, DMSO) δ (ppm): 7.20 - 7.59 
(m, 4H, Benzimidazole), 7.60 - 8.20 (m, 4H, 
pyridine), 6.51 (s, 1H). 
13
C-NMR (400 MHz, 
DMSO-d6) δ in ppm: δ 138.37 (Benzimidazole - 
C), 123.01 (Benzimidazole - CH), 143.38 (Pyrazole 
- C), 107.98 (Pyrazole - CH), 126.87(Benzene - 
CH), 133.02 (Benzene - C), 31.24 (Aliphatic - 
CH3). Mass: m/z: 450.18. 
In-vitro Anticancer Activity: In-vitro anticancer 
activity was investigated for all synthesised 
compounds to MCF-7 and CaCo-2 in the different 
doses and found the concentration required for the 
50% cell death (IC50). The ability of the test 
compounds to inhibit cell growth was listed in 
Table 3. The general structure-activity relationship 
of the benzimidazole analogues can be summarized 
as below: Comparison of the cytotoxicity of benzo 
[d]imidazolyl pyrimidine derivatives and benzo 
[d]imidazolyl Pyrazole derivatives indicates that 
the importances of substituted benzimidazole with 
pyrimidine derivatives (4a-j) generally enhance the 
cytotoxicity against MCF-7 and CaCo-2 cancer 
cells. Addition of pyrazole moiety instead of 
pyrimidine moiety with benzimidazole nucleus to 
give compound (5a-j) was clearly detrimental to the 
cytotoxicity in both MCF-7 and CaCo-2 cancer 
cells. It should be noted that compound (5a-j) has a 
lowest activity than compound (4a-j). 
For compound 4(a-e) (2-position of benzimidazole 
core was substituted by pyrimidine with various 
aromatic moiety), it indicated that introducing the 
various substituent group to aromatic ring of 
pyrimidine moiety would not affect their efficacy 
for MCF-7 and CaCo-2 cell lines, but compound 
4a, 4b, 4c, 4d would affect their efficacy too much 
for CaCo-2 cell line: 4a (pyrimidine ring was 
substituted with benzene) (IC50 = 5.67μM) was 
5.29-fold much stronger than 4e and 4f (IC50 => 
30μM), 4b (pyrimidine ring was substituted with 
pyridine) (IC50 = 9.56μM) was 3.13-fold stronger 
than 4e and 4f (IC50 => 30μM), 4d (pyrimidine ring 
was substituted with two 3,4-dimethoxy benzene 
group) (IC50 = 12.33μM) was 2.43-fold much 
stronger than 4e and 4f (IC50 => 30μM), 4c 
(pyrimidine ring was substituted with two 3-
chloro4-methoxy benzene group) (IC50 = 28.40μM) 
was 1.05-fold much stronger than 4e and 4f (IC50 
=> 30μM),  4a was also 3.64-fold much stronger 
than 4e and 4f (IC50 => 30μM) against  MCF-7.  
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For compounds 4(f-j) (2-position of 1-methyl-
benzimidazole core was substituted by pyrimidine 
with various aromatic moiety), it indicated that 
introducing the various substituent group to 
aromatic ring of pyrimidine moiety not much 
influence for MCF-7 and CaCo-2 cell lines, but 
compound 4g(IC50 = 16.23μM), 4h(IC50 = 
25.50μM), 4j(IC50 = 21.89μM) would affect their 
efficacy too much in CaCo-2 cell line compare with 
MCF-7 cell line. 
For compound 5(a-e) (2-position of benzimidazole 
core was substituted by pyrazole with various 
aromatic moiety), it indicated that introducing the 
various substituent group to aromatic ring of 
pyrazole moiety which affect their efficacy for 
MCF-7 and CaCo-2 cell lines. 5b (IC50 = 9.79μM), 
5d (IC50 = 12.33μM) would affect their efficacy too 
much in CaCo-2 cell line compare with MCF-7 cell 
line. 
For compound 5(f-j) (2-position of 1-methyl-
benzimidazole core was substituted by pyrimidine 
with various aromatic moiety), it indicated that 
introducing the various substituent group to 
aromatic ring of pyrazole moiety not much 
influence for MCF-7 and CaCo-2 cell lines. 5g 
(IC50 = 17.32μM), 5i (IC50 = 18.35μM) would affect 
their efficacy too much in CaCo-2 cell line 
compare with MCF-7 cell line. 
TABLE 1: IC50 OF THE TESTED COMPOUNDS AGAINST OF MCF-7 AND CACO-2 CELL LINE - BENZO [D] 
IMIDAZOLE PYRIMIDINE DERIVATIVES 
S. No Compound  
code 
Substituent R Substituent R1 Molecular 
Formula 
IC50 ± SD ( μM) 
MCF-7 CaCo-2 
1 4a H 
 
C17H13N5 8.22  ±  1.48 5.67  ± 1.25 
2 4b H 
N
 
C16H12N6 10.43 ± 1.45 9.56  ±1.33 
3 4c H 
H3CO
Cl  
C19H17N5O2 >30 28.40  ± 248 
4 4d H 
H3CO
OCH3  
C18H14ClN5O 13.05 ±2.07 12.33  ± 1.80 
5 4e H 
 
C25H17N5 
 
>30 ± 2.87 >30 ± 2.98 
6 4f CH3 
 
C18H15N5 
 
>30 ± 2.66 >30 ± 2.43 
7 4g CH3 
N
 
C17H14N6 
 
18.56 ± 2.82 16.23 ± 1.24 
8 4h CH3 
H3CO
Cl  
C19H16ClN5O 
 
>30 ± 2.19 25.50 ± 2.74 
9 4i CH3 
H3CO
OCH3  
C20H19N5O2 
 
25.11 ± 2.44 21.89 ± 2.35 
10 4j CH3 
 
C26H19N5 >30 ± 2.80 >30 ± 2.06 
5-Fluorouracil 7.26 ± 2.30 5.23 ± 2.36 
TABLE 2: IC50 OF THE TESTED COMPOUNDS AGAINST OF MCF-7 AND CACO-2 CELL LINE - BENZO [D] 
IMIDAZOLE PYRAZOLE DERIVATIVES 
S. No Compound  
code 
Substituent R Substituent R1 Molecular Formula IC50 ± SD ( μM) 
MCF-7 CaCo-2 
11 5a H 
 
C22H16N4 26.65 ± 2.32 28.45 ± 2.59 
12 5b H 
N
 
C21H15N5 12.79 ± 2.20 9.788 ± 1.48 
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13 5c H 
H3CO
Cl  
C23H17ClN4O >30 ± 2.86 >30 ± 2.48 
14 5d H 
H3CO
OCH3  
C24H20N4O2 15.34 ± 2.67 13.27 ± 1.56 
15 5e H 
 
C30H20N4 >30 ± 2.52 >30 ± 2.33 
16 5f CH3 
 
C23H18N4 >30 ± 2.41 >30 ± 2.69 
17 5g CH3 
N
 
C22H17N5 
 
19.04 ± 2.56 17.32 ± 2.27 
18 5h CH3 
H3CO
Cl  
C24H19ClN4O >30 ± 2.38 29.76 ± 2.64 
19 5i CH3 
H3CO
OCH3  
C25H22N4O2 21.73 ± 2.46 18.35 ± 2.54 
20 5j CH3 
 
C31H22N4 
 
>30 ± 2.58 >30 ± 2.62 
5-Fluorouracil 7.26 ± 2.30 5.23 ± 2.36 
 
Apoptosis Studies: Apoptosis studies were 
performed with a staining method utilizing acridine 
orange (AO) and ethidium bromide (EB). CaCo-2 
cells were incubated in the absence or presence of 
the test compound 4a and the indicated synthesized 
compounds at their respective IC50 concentration at 
37 °C and 5% CO2 for 48 hr. After 48 hr, cells were 
stained with AO/EB solution (100 μg/mL AO, 
100μg/mL EB). Then the cells were observed under 
a fluorescence microscope. 
  
                           (a) Control                 (b) 4 hour 
  
                                                       (c) 8 hour                                                        (d) 24 hour 
FIG. 1: EB/AO METHOD FOR CACO-2 CELLS 
White arrows indicate "L" = live cells; "A" = apoptotic cells; CaCo-2 cells were treated with 5.67μM compound 4a for induction 
of apoptosis. The compound 4a induced apoptosis in Caco-2 cells as evaluated by EB/AO staining. 
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FIG. 2: FOLD ACTIVITY OF CASPASE 3 
 
FIG. 3: FOLD ACTIVITY OF CASPASE 8 
 
FIG. 3: FOLD ACTIVITY OF CASPASE 9 
24 hours Caspase study revealed that compound 4a 
shows 2 fold activities in caspase 3 and 9 pathway, 
single fold activity in caspase 8 pathways.    
CONCLUSION: To conclude, various substituted 
novel benzimidazole derivatives were synthesised 
by using incorporated with different heterocycles 
like pyrimidine, pyrazole and backbone of 
chalcones. The synthesised compounds were 
screened for their in vitro anticancer activities 
results revealed that the presence substituted 
benzimidazole derivative could have the anticancer 
potential of the scaffold.  
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